Patent Publication Number: US-2023133671-A1

Title: Setd2 inhibitors and related methods and uses, including combination therapies

Description:
BACKGROUND OF THE INVENTION 
     Field of the Invention 
     The present disclosure provides SETD2 protein inhibitors, and methods, compositions, and kits for treating diseases, disorders, or conditions in a subject with a SETD2 protein inhibitor. In some embodiments, the methods, compositions, and kits for treating diseases, disorders, or conditions further comprise a second therapeutic agent, wherein the second therapeutic agent comprises one or more glucocorticoid receptor agonists, one or more immunomodulatory drugs, one or more proteasome inhibitors, one or more Bcl-2 inhibitors, one or more pleiotropic pathway modulators, one or more XPO1 inhibitors, one or more histone deacetylase inhibitors, or one or more EZH2 inhibitors, or a combination thereof. 
     Background 
     The selective addition of methyl groups to specific amino acid sites on histones is controlled by the action of a family of enzymes known as histone methyltransferases (HMTs). The level of expression of a particular gene is influenced by the presence or absence of one or more methyl groups at a relevant histone site. The specific effect of a methyl group at a particular histone site persists until the methyl group is removed by a histone demethylase, or until the modified histone is replaced through nucleosome turnover. In a like manner, other enzyme classes can decorate DNA and histones with other chemical species, and still other enzymes can remove these species to provide control of gene expression. 
     SETD2 is a human histone methyltransferase located at the cytogenic band p21.31 of chromosome 3 (3p21.31). The acronym “SETD2” stands for Suppressor of variegation, Enhancer of zeste, and Trithorax domain containing 2. The SETD2 protein comprises three conserved functional domains: (1) the triplicate AWS-SET-PostSET domain; (2) a WW domain; and (3) a Set2-Rbp1 interacting (“SRI”) domain. These three functional domains define the biological function of SETD2. See, Li, J. et al.,  Oncotarget  7:50719-50734 (2016). SETD2 is believed to be the single human gene responsible for the trimethylation of lysine 36 (Lys-36) of histone H3 (H3K36me3) using dimethylated Lys-36 (H3K36me2) as substrate. Edmunds, J. W. et al.,  The EMBO Journal  27:406-420 (2008). 
     Human SETD2 has been shown to have tumor suppressor functionality. Li, J. et al.,  Oncotarget  7:50719-50734 (2016). For example, inactivation of human SETD2 has been reported in renal cell carcinoma (RCC). Larkin, J., et al.,  Nature Reviews  9:147-155 (2012). Also, expression levels of SETD2 in breast cancer samples have been reported as significantly lower than in adjacent non-cancerous tissue (ANCT) samples. Newbold, R. F. and Mokbel, K.,  Anticancer Research  30: 3309-3311 (2010). Additionally, biallelic mutations and loss-of-function point mutations in SETD2 were reported in patients with acute leukemia. Zhu, X. et al.,  Nature Genetics  46: 287-293 (2014). Mutations in SETD2 have also been reported in pediatric high-grade gliomas. Fontebasso, A. M. et al.,  Acta Neuropathol.  125: 659-669 (2013). 
     BRIEF SUMMARY OF THE INVENTION 
     The present disclosure generally provides SETD2 protein inhibitors, and methods, compositions, and kits for treating diseases, disorders, or conditions in a subject with a SETD2 protein inhibitor and, optionally, a second therapeutic agent, wherein the second therapeutic agent comprises glucocorticoid receptor agonists, immunomodulatory drugs, proteasome inhibitors, Bcl-2 inhibitors, pleiotropic pathway modulators, XPO1 inhibitors, histone deacetylase inhibitors, or EZH2 inhibitors, or a combination thereof. 
     In one aspect, the present disclosure provides methods of treating diseases, disorders, or conditions, e.g., cancer, in a subject in need thereof with: 
     (1) a therapeutically effective amount of a substituted indole represented by any one of Formulae I, II, II-A, III, III-A, IV, IV-A, IV-B, IV-C, IV-D, V, V-A, V-B, VI, VII, VII-A, VII-B, VII-C, VII-D, VII-E, VII-F, VII-G, VII-H, VIII, VIII-A, or VIII-B, or a compound of Table 1, or a compound of Table 1B, below, and the pharmaceutically acceptable salts and solvates thereof, collectively referred to herein as a “Compounds of the Disclosure;” and 
     (2) a therapeutically effective amount of a second therapeutic agent, 
     wherein the second therapeutic agent comprises one or more glucocorticoid receptor agonists, one or more immunomodulatory drugs, one or more proteasome inhibitors, one or more Bcl-2 inhibitors, one or more pleiotropic pathway modulators, one or more XPO1 inhibitors, one or more histone deacetylase inhibitors, or one or more EZH2 inhibitors, or a combination thereof. 
     In another aspect, the present disclosure provides a Compound of the Disclosure for use in treating cancer, e.g., multiple myeloma, in a subject in need thereof, wherein the Compound of the Disclosure is to be administered to the subject in combination with a Second Therapeutic Agent. 
     In another aspect, the present disclosure provides a Compound of the Disclosure for use in the manufacture of a medicament for treating cancer in a mammal, wherein the Compound of the Disclosure is to be administered to the subject in combination with a Second Therapeutic Agent. 
     In another aspect, the present disclosure provides a kit comprising a Compound of the Disclosure and a Second Therapeutic Agent. 
     In another aspect, the present disclosure provides a Compound of the Disclosure, i.e., substituted indole represented by any one of Formulae I, II, II-A, III, III-A, IV, IV-A, IV-B, IV-C, IV-D, V, V-A, V-B, VI, VII, VII-A, VII-B, VII-C, VII-D, VII-E, VII-F, VII-G, VII-H, VIII, VIII-A, or VIII-B, or a compound of Table 1, or a compound of Table 1B. 
     In another aspect, the present disclosure provides a pharmaceutical composition comprising a Compound of the Disclosure and a pharmaceutically acceptable carrier. 
     In one aspect, the present disclosure provides methods of treating diseases, disorders, or conditions, e.g., cancer, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a Compound of the Disclosure. 
     In another aspect, the present disclosure provides a Compound of the Disclosure for use in treating cancer, e.g., multiple myeloma, in a subject in need thereof. 
     In another aspect, the present disclosure provides a Compound of the Disclosure for use in the manufacture of a medicament for treating cancer in a subject. 
     Additional embodiments and advantages of the disclosure will be set forth, in part, in the description that follows, and will flow from the description, or can be learned by practice of the disclosure. The embodiments and advantages of the disclosure will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. 
     It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only, and are not restrictive of the invention as claimed. 
    
    
     
       BRIEF DESCRIPTION OF DRAWINGS 
         FIG.  1    is a line graph showing the anti-proliferative activity of Cpd. No. 15, tazemetostat (Taz), and lenalidomide (Len), and combinations thereof, in KMS-11 cells over the course of a 14-day co-treatment study. 
         FIG.  2    is a bar graph showing the anti-proliferative activity of Cpd. No. 15, tazemetostat (Taz), and lenalidomide (Len), and combinations thereof, in KMS-11 cells at day 14 of a co-treatment study. 
         FIG.  3    is a line graph showing the synergistic anti-proliferative activity of Cpd. No. 15 in combination with pomalidomide in KMS-11 cells in 7-day co-treatment study. 
         FIG.  4    is a table showing the Loewe Excess Model analysis of the Cpd. No. 15 plus pomalidomide combination in KMS-11 cells in 7-day co-treatment study. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     I. Compounds of the Disclosure 
     Certain Compounds of the Disclosure are disclosed in PCT/US2019/046569 as SETD2 inhibitors. PCT/US2019/046569 is fully incorporated by reference herein in its entirety. Certain other Compounds of the Disclosure are an embodiment of the disclosure as set forth herein. 
     In one embodiment, Compounds of the Disclosure are compounds having Formula I: 
     
       
         
         
             
             
         
       
     
     wherein: 
     R 1a  is selected from the group consisting of halogen, alkyl, alkoxy, cycloalkyl, (hydroxy)alkyl, and (cycloalkyl)alkyl; 
     Q 1  is selected from the group consisting of —C(R 1b )═ and —N═; 
     Q 2  is selected from the group consisting of —C(R 1c )═ and —N═; 
     Q 3  is selected from the group consisting of —C(R 1d )═ and —N═; 
     provided that at least one of Q 1 , Q 2 , or Q 3  is —C(R 1b )═, —C(R 1c )═, or —C(R 1d )═, respectively; 
     R 1b , R 1c  and R 1d  are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, (hydroxy)alkyl, and alkoxy; 
     R 1e  is selected from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, (hydroxy)alkyl, and (cycloalkyl)alkyl; 
        is a single or double bond; 
     G 1  is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, optionally substituted cycloalkyl, (aryl)alkyl, (heteroaryl)alkyl, (heterocyclo)alkyl, (amino)(aryl)alkyl, (heteroaryl)(aryl)alkyl, (heteroaryl)(heterocyclo)alkyl, (heteroaryl)(carboxamido)alkyl, (heteroaryl)(cycloalkyl)alkyl, (aryl)(alkoxycarbonyl)alkyl, (cycloalkyl)alkyl, (heteroaryl)(amino)alkyl, (cycloalkyl)(alkoxycarbonyl)alkyl, (heteroaryl)(alkoxycarbonyl)alkyl, (heterocyclo)(cycloalkyl)alkyl, (aryl)(cycloalkyl)alkyl, (aryl)(hydroxy)alkyl, (cycloalkyl)(hydroxy)alkyl, (hydroxy)alkyl, optionally substituted alkyl, (aryl)(haloalkyl)alkyl, (cycloalkyl)(haloalkyl)alkyl, (hydroxy)(haloalkyl)alkyl, and (alkoxycarbonyl)(haloalkyl)alkyl; and 
     G 2  is selected from the group consisting of hydrogen and alkyl; or 
     G 1  and G 2  taken together with the nitrogen atom to which they are attached form an optionally substituted heterocyclo, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, the compound having Formula I is not N-(1-(1-(L-alanyl)piperidin-4-yl)ethyl)-7-methyl-1H-indole-2-carboxamide, N-((1r,4r)-4-(3-aminopropanamido)cyclohexyl)-7-methyl-1H-indole-2-carboxamide, or N-((1r,4r)-4-aminocyclohexyl)-7-methyl-1H-indole-2-carboxamide. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula I, wherein: 
     R 1a  is selected from the group consisting of halogen, C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 3 -C 8  cycloalkyl, (hydroxy)C 1-6  alkyl, and (C 3 -C 6  cycloalkyl)C 1-6  alkyl; 
     R 1b , R 1c , and R 1d  are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 6  alkyl, C 2 -C 6  alkenyl, (hydroxy)C 1 -C 6  alkyl, and C 1 -C 6  alkoxy; 
     R 1e  is selected from the group consisting of hydrogen and C 1 -C 6  alkyl; 
     G 1  is selected from the group consisting of optionally substituted C 6 -C 10  aryl, optionally substituted 5- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocyclo, optionally substituted C 3 -C 8  cycloalkyl, (C 6 -C 10  aryl)C 1 -C 6  alkyl, (5- to 10-membered heteroaryl)C 1 -C 6  alkyl, (3- to 10-membered heterocyclo)C 1 -C 6  alkyl, (amino)(C 6 -C 10  aryl)C 1 -C 6  alkyl, (5- to 14-membered heteroaryl)(C 6 -C 10  aryl)C 1 -C 6  alkyl, (5- to 10-membered heteroaryl)(3- to 10-membered heterocyclo)C 1 -C 6  alkyl, (5- to 10-membered heteroaryl)(carboxamido)C 1 -C 6  alkyl, (5- to 10-membered heteroaryl)(C 3 -C 6  cycloalkyl)C 1 -C 6  alkyl, (C 6 -C 10  aryl)(alkoxycarbonyl)C 1 -C 6  alkyl, (C 3 -C 6  cycloalkyl)C 1 -C 6  alkyl, (5- to 10-membered heteroaryl)(amino)C 1 -C 6  alkyl, (C 3 -C 6  cycloalkyl)(alkoxycarbonyl)C 1 -C 6  alkyl, (5- to 14-membered heteroaryl)(alkoxycarbonyl)C 1 -C 6  alkyl, (3- to 14-membered heterocyclo)(C 3 -C 6  cycloalkyl)C 1 -C 6  alkyl, (C 6-10  aryl)(C 3 -C 8  cycloalkyl)C 1 -C 6  alkyl, (C 6 -C 10  aryl)(hydroxy)C 1 -C 6  alkyl, (C 3 -C 6  cycloalkyl)(hydroxy)C 1 -C 6  alkyl, (hydroxy)C 1 -C 6  alkyl, optionally substituted C 1 -C 6  alkyl, (C 6 -C 10  aryl)(C 1 -C 6  haloalkyl)C 1 -C 6  alkyl, (C 3 -C 6  cycloalkyl)(C 1 -C 6  haloalkyl)C 1 -C 6  alkyl, (hydroxy)(C 1 -C 6  haloalkyl)C 1 -C 6  alkyl; and (alkoxycarbonyl)(C 1 -C 6  haloalkyl)C 1 -C 6  alkyl; and 
     G 2  is selected from the group consisting of hydrogen and C 1 -C 6  alkyl; or 
     G 1  and G 2  taken together with the nitrogen atom to which they are attached form a 5- to 10-membered optionally substituted heterocyclo, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula I, wherein: 
     R 1a  is selected from the group consisting of halogen, C 1 -C 3  alkyl, C 1 -C 3  alkoxy, C 3 -C 6  cycloalkyl, (hydroxy)C 1 -C 4  alkyl, and (C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl; 
     R 1b , R 1c , and R 1d  are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 3  alkyl, C 2 -C 4  alkenyl, (hydroxy)C 1 -C 4  alkyl, and C 1 -C 3  alkoxy; 
     R 1e  is selected from the group consisting of hydrogen and C 1 -C 3  alkyl; 
     G 1  is selected from the group consisting of optionally substituted C 6 -C 10  aryl, optionally substituted 5- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocyclo, optionally substituted C 3 -C 8  cycloalkyl, (C 6 -C 10  aryl)C 1 -C 4  alkyl, (5- to 10-membered heteroaryl)C 1 -C 6  alkyl, (3- to 10-membered heterocyclo)C 1 -C 4  alkyl, (amino)(C 6 -C 10  aryl)C 1 -C 6  alkyl, (5- to 14-membered heteroaryl)(C 6 -C 10  aryl)C 1 -C 4  alkyl, (5- to 10-membered heteroaryl)(3- to 10-membered heterocyclo)C 1 -C 4  alkyl, (5- to 10-membered heteroaryl)(carboxamido)C 1 -C 4  alkyl, (5- to 10-membered heteroaryl)(C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl, (C 6 -C 10  aryl)(alkoxycarbonyl)C 1 -C 4  alkyl, (C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl, (5- to 10-membered heteroaryl)(amino)C 1 -C 4  alkyl, (C 3 -C 6  cycloalkyl)(alkoxycarbonyl)C 1 -C 4  alkyl, (5- to 14-membered heteroaryl)(alkoxycarbonyl)C 1 -C 4  alkyl, (3- to 14-membered heterocyclo)(C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl, (C 6-10  aryl)(C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl, (C 6 -C 10  aryl)(hydroxy)C 1 -C 4  alkyl, (C 3 -C 6  cycloalkyl)(hydroxy)C 1 -C 4  alkyl, (hydroxy)C 1 -C 4  alkyl, optionally substituted C 1 -C 4  alkyl, (C 6 -C 10  aryl)(C 1 -C 4  haloalkyl)C 1 -C 4  alkyl, (C 3 -C 6  cycloalkyl)(C 1 -C 4  haloalkyl)C 1 -C 4  alkyl, (hydroxy)(C 1 -C 4  haloalkyl)C 1 -C 4  alkyl, and (alkoxycarbonyl)(C 1 -C 4  haloalkyl)C 1 -C 4  alkyl; and 
     G 2  is selected from the group consisting of hydrogen and C 1 -C 4  alkyl; or 
     G 1  and G 2  taken together with the nitrogen atom to which they are attached form a 5- to 10-membered optionally substituted heterocyclo, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula I, wherein   is a double bond, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula I, wherein Q 1  and Q 2  are —C(H)═, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula I, wherein Q 3  is —C(R 1d )═; and R 1d  is selected from the group consisting of hydrogen and halo, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula I, wherein R 1e  is hydrogen, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula I, wherein R 1a  is C 1 -C 3  alkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula I, wherein G 2  is hydrogen, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula II: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof, wherein R 1d  and G 1  are as defined in connection with Formula I. 
     In another embodiment, Compounds of the Disclosure are compounds having Formulae I or II, wherein R 1d  is selected from the group consisting of hydrogen and fluoro, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula II-A: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof, wherein G 1  is as defined in connection with Formula II. 
     In another embodiment, Compounds of the Disclosure are compounds having Formulae I, II, or II-A, wherein G 1  is selected from the group consisting of optionally substituted C 6 -C 10  aryl, optionally substituted 5- to 9-membered heteroaryl, optionally substituted 3- to 10-membered heterocyclo, optionally substituted C 6 -C 8  cycloalkyl, (5- to 9-membered heteroaryl)C 1 -C 6  alkyl, (5- to 9-membered heteroaryl)(C 6-10  aryl)C 1 -C 4  alkyl, (5- to 9-membered heteroaryl heteroaryl)(C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl, and (C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III: 
     
       
         
         
             
             
         
       
     
     wherein: 
     A 1  is selected from the group consisting of —N═ and —C(R 2a )═; 
     R 2a  is selected from the group consisting of hydrogen, alkyl, halogen, and haloalkyl; 
     R 2b  is selected from the group consisting of optionally substituted alkyl, optionally substituted heterocyclo, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, (carboxamido)alkyl, —OR 10c , amino, (heterocyclo)alkyl, (amino)alkyl, (hydroxy)alkyl, carboxamido, (heteroaryl)alkyl, —S(═O)R 9b , —S(═O) 2 R 9b , and —C(═O)R 9c ; 
     A 2  is selected from the group consisting of —N═ and —C(R 2c )═; 
     R 2c  is selected from the group consisting of hydrogen, alkyl, halogen, and haloalkyl; 
     R 2d  is selected from the group consisting of hydrogen, alkyl, halogen, cyano, and haloalkyl; 
     R 2e  is selected from the group consisting of hydrogen, alkyl, halogen, and haloalkyl; 
     R 9b  is selected from the group consisting of amino, alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclo, and optionally substituted heteroaryl; 
     R 9c  is selected from the group consisting of amino, alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclo, and optionally substituted heteroaryl; and 
     R 10c  is selected from the group consisting of alkyl, (hydroxy)alkyl, and (amino)alkyl; and 
     R 1d  is as defined in connection with Formula I, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III-A: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 2a , R 2b , R 2c , R 2d , and R 2e  are as defined in connection with Formula III, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein: 
     R 2a  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, halogen, and C 1 -C 4  haloalkyl; 
     R 2b  is selected from the group consisting of: 
     (A) unsubstituted 4- to 10-membered heterocyclo; 
     (B) substituted 4- to 10-membered heterocyclo having one, two, three, or four substituents independently selected from the group consisting of (i) —N(R 3a )C(═O)R 4a ; (ii) —NR 5a R 5b ; (iii) unsubstituted 4- to 10-membered heterocyclo; (iv) substituted 4- to 10-membered heterocyclo having one, two, or three substituents independently selected from the group consisting of hydroxy, —NR 5c R 5d , C 1 -C 4  alkyl, C 1 -C 6  alkoxy, —C(R 6a )(R 6b )C(═O)NR 5e R 5f , —C(═O)R 4b , (hydroxy)C 1 -C 4  alkyl, and halo; (v) unsubstituted C 3 -C 6  cycloalkyl; (vi) (hydroxy)C 1 -C 4  alkyl; (vii) C 1 -C 6  alkyl; (viii) —C(═O)NR 5g R 5h ; (ix) halo; (x) —C(═O)R 4c ; (xi) C 1 -C 6  haloalkyl; (xii) hydroxy; (xiii) (amino)C 1 -C 4  alkyl; (xiv) (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (xv) -S(═O) 2 R 9a ; (xvi) (3- to 8-membered heterocyclo)C 1 -C 4  alkyl; (xvii) C 1 -C 6  alkoxy; (xviii) (C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl; (xix) (C 6-10  aryl)C 1 -C 4  alkyl; and (xxii) —OR 10b ; 
     (C) unsubstituted C 3 -C 8  cycloalkyl; 
     (D) substituted C 3 -C 8  cycloalkyl having one, two, three, or four substituents independently selected from the group consisting of (i)unsubstituted 4- to 10-membered heterocyclo; (ii) substituted 4- to 10-membered heterocyclo having one or two substituents, independently selected from the group consisting of amino and C 1 -C 4  alkyl; (iii) unsubstituted 5- or 6-membered heteroaryl; (iv) substituted 5- or 6-membered heteroaryl having one, two, or three substituents independently selected from the group consisting of halo, C 1 -C 4  alkyl, (3- to 8-membered heterocyclo)alkyl, hydroxy, and amino; (v) —NR 5i R 5j ; (vi) cyano; (vii) —N(R 3d )C(═O)R 4f ; (viii) hydroxy; and (ix) C 1 -C 4  alkyl; 
     (E) unsubstituted 5- to 10-membered heteroaryl; 
     (F) substituted 5- to 10-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of (i) halo; (ii) C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (hydroxy)C 1 -C 4  alkyl; C 3 -C 6  cycloalkyl; (amino)C 1 -C 4  alkyl; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one, two, three, or four substituents independently selected from the group consisting of —NR 5g R 5h ; unsubstituted 4- to 14-membered heterocyclo; substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; —NR 5q R 5r ; and (ix) (3- to 8-membered heterocyclo)C 1 -C 4  alkyl; 
     (G) unsubstituted C 6 -C 10  aryl; 
     (H) substituted C 6 -C 10  aryl, having one, two, three, or four substituents independently selected from the group consisting of (i) halo; (ii) C 1 -C 4  alkyl; (iii) —CH— 2 N(H)S(═O) 2 R 8 ; (iv) (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; (v) —OR 10a ; (vi) —N(R 3b )C(═O)R 4b ; (vii) (amino)C 1 -C 4  alkyl; and (viii) (hydroxy)C 1 -C 4  alkyl; 
     (I) (carboxamido)C 1 -C 4  alkyl; 
     (J) —OR 10c ; 
     (K) —NR 5o R 5p ; 
     (L) (3- to 8-membered heterocyclo)C 1 -C 4  alkyl; 
     (M) (amino)C 1 -C 4  alkyl; 
     (N) (hydroxy)C 1 -C 4  alkyl; 
     (O) —C(═O)NR 5s R 5t ; 
     (P) (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; and 
     (Q) —S(═O) 2 R 9b ; 
     R 2c  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, halogen, and C 1 -C 4  haloalkyl; 
     R 2d  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, halogen, cyano, and C 1 -C 4  haloalkyl; 
     R 2e is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, halogen, and C 1 -C 4  haloalkyl; 
     R 3a , R 3b , R 3c , and R 3d  are each independently selected from the group consisting of hydrogen, C 1 -C 4  alkyl, optionally substituted C 3 -C 6  cycloalkyl, and optionally substituted 4- to 14-membered heterocyclo; 
     R 4a , R 4b , R 4c , R 4d , R 4e , and R 4f  are each independently selected from the group consisting of C 1 -C 6  alkyl; C 1 -C 6  haloalkyl; C 3 -C 6  cycloalkyl; C 1 -C 6  alkoxy; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (C 6-10  aryl)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (hydroxy)C 1 -C 4  alkyl; (cyano)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted C 6 -C 10  aryl; substituted C 6 -C 10  aryl, having one, two, three, or four substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; and substituted 5- or 6-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; 
     R 5a  and R 5b  are independently selected from the group consisting of hydrogen; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; (hydroxy)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; 
     R 5c  and R 5d  are independently selected from the group consisting of hydrogen; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; (hydroxy)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; or 
     R 5c  and R 5d  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 5e  and R 5f  are independently selected from the group consisting of hydrogen; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; (hydroxy)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; or 
     R 5e  and R 5f  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 5g  and R 5h  are independently selected from the group consisting of hydrogen; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; (hydroxy)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; or 
     R 5g  and R 5h  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 5i  and R 5j  are independently selected from the group consisting of hydrogen; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; (hydroxy)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; or 
     R 5i  and R 5j  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 5k  and R 5l  are independently selected from the group consisting of hydrogen; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; (hydroxy)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; or 
     R 5k  and R 5l  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 5m  and R 5n  are independently selected from the group consisting of hydrogen; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; (hydroxy)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; or 
     R 5m  and R 5n  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 5o  and R 5p  are independently selected from the group consisting of hydrogen; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; (hydroxy)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; or 
     R 5o  and R 5p  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 5q  and R 5r  are independently selected from the group consisting of hydrogen; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; (hydroxy)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; 
     R 5s  and R 5t  are independently selected from the group consisting of hydrogen; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; (hydroxy)C 1 -C 4  alkyl; (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; 
     R 6a , R 6b , R 6c , and R 6d  are each independently selected from the group consisting of hydrogen and C 1 -C 4  alkyl; 
     R 8  is C 1 -C 6  alkyl; 
     R 9a  is selected from the group consisting of C 1 -C 6  alkyl; unsubstituted C 3 -C 8  cycloalkyl; and substituted C 3 -C 8  cycloalkyl having one or two substituents independently selected from the group consisting of halo, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; 
     R 9b  is selected from the group consisting of C 1 -C 6  alkyl and amino; 
     R 10a  is selected from the group consisting of alkyl, (hydroxy)C 1 -C 4  alkyl, and (amino)C 1 -C 4  alkyl; 
     R 10b  is (amino)C 1 -C 4  alkyl; and 
     R 10c  is (amino)C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is an optionally substituted 3- to 10-membered heterocycle linked to the rest of the molecule through a nitrogen atom, e.g., R 2b  is: 
     
       
         
         
             
             
         
       
     
     and the like. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein: 
     R 2b  is selected from the group consisting of: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     R a1  is selected from the group consisting of —N(R 3a )C(═O)R 4a ; —NR 5a R 5b ; unsubstituted 4- to 10-membered heterocyclo; substituted 4- to 10-membered heterocyclo having one, two, or three substituents independently selected from the group consisting of hydroxy, —NR 5 cR 5d , C 1 -C 4  alkyl, C 1 -C 6  alkoxy, —C(R 6a )(R 6b )C(═O)NR 5e R 5f , —C(═O)R 4b , (hydroxy)C 1 -C 4  alkyl, and halo; 
     R a2  and R a3  are each hydrogen; or 
     R a2  and R a3  taken together with the carbon atom to which they are attached form a C(═O) group; 
     R a4  is selected from the group consisting of hydrogen, halo, and hydroxy; 
     R a5  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and C 3 -C 6  cycloalkyl; 
     R b1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and C 3 -C 6  cycloalkyl; 
     R c1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, C 3 -C 6  cycloalkyl, and —C(═O)R 4c ; 
     R c2  and R c3  are each independently selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and C 1 -C 4  haloalkyl; or 
     R c2  and R c3  taken together with the carbon atom to which they are attached form a C(═O) group; 
     R c4  is selected from the group consisting of hydrogen and C 1 -C 4  alkyl; 
     m is 1 or 2; 
     R d1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and —C(═O)R 4c , 
     R d2  and R d3  are each independently selected from the group consisting of hydrogen and fluoro; 
     R e1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, C 3 -C 6  cycloalkyl, and —C(═O)R 4c ; 
     R f1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, C 3 -C 6  cycloalkyl, and —C(═O)R 4c , 
     R g1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, —C(═O)R 4c , C 1 -C 4  haloalkyl, (C 1 -C 4  alkoxy)C 1 -C 4  alkyl 
     R h1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, C 3 -C 6  cycloalkyl, and —C(═O)R 4c ; 
     R h2  is selected from the group consisting of hydrogen and C 1 -C 4  alkyl; 
     R h3  and R h4  are each independently selected from the group consisting of hydrogen and C 1 -C 4  alkyl; or 
     R h3  and R h4  taken together with the carbon atom to which they are attached form a C(═O) group; 
     R i1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, C 3 -C 6  cycloalkyl, (hydroxy)C 1 -C 4  alkyl, —N(R 3a )C(═O)R 4a , and (amino)C 1 -C 4  alkyl; 
     Z 1  is selected from the group consisting of —CH 2 — and —O—; 
     R j1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, C 3 -C 6  cycloalkyl, and —C(═O)R 4c ; 
     R k1  is selected from the group consisting of C 1 -C 4  alkyl, unsubstituted 4- to 14-membered heterocyclo and —NR 5a R 5b ; 
     R k2  is selected from the group consisting of hydrogen, hydroxy, and C 1 -C 4  alkyl; 
     r is 0, 1, or 2; 
     Z 2  is selected from the group consisting of —O— and —N(R m3 )—; 
     R m3  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and C 1 -C 4  haloalkyl; 
     R n3  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and —C(═O)R 4c ; 
     R o1  is selected from the group consisting of hydroxy, (hydroxy)C 1 -C 4  alkyl, (amino)C 1 -C 4  alkyl, (C 1 -C 4  alkoxy)C 1 -C 4  alkyl, C 1 -C 4  alkoxy, —NR 5a R 5b , unsubstituted 4- to 14-membered heterocyclo, substituted 4- to 14-membered heterocyclo having one, two, or three substituents independently selected from the group consisting of halo, C 1 -C 4  alkyl and C 1 -C 4  alkoxy; 
     R o2  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and (C 1 -C 4  alkoxy)C 1 -C 4  alkyl 
     R o3  is selected from the group consisting of hydrogen, fluoro, and C 1 -C 4  alkyl; 
     R p1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and —C(═O)R 4c ; 
     Z 3  is selected from the group consisting of —O— and —N(R q1 )—; 
     R q1  is selected from the group consisting of hydrogen and C 1 -C 4  alkyl; 
     R r1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and —C(═O)R 4c ; 
     R s1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and —C(═O)R 4c ; 
     R t1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and —C(═O)R 4c ; 
     R u1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and —C(═O)R 4c ; 
     R v1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and —C(═O)R 4c ; 
     R s1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and —C(═O)R 4c ; 
     R x1  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and —C(═O)R 4c ; 
     R y1  is selected from the group consisting of hydrogen and C 1 -C 4  alkyl; and 
     R z1  is selected from the group consisting of hydrogen and C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein: 
     R 2b  is selected from the group consisting of: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -1, R 2b -1A, R 2b -1B, R 2b -1C, or R 2b -1D, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R a1  is —N(R 3a )C(═O)R 4a . In another embodiment, R a1  is —NR 5a R 5b . In another embodiment, R a1  is —NR 5a R 5b  and R 5a  and R 5b  are independently selected from the group consisting of hydrogen and C 1 -C 4  alkyl. In another embodiment, R a1  is optionally substituted 4- to 10-membered heterocyclo. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -2, R 2b -2A, or R 2b -2b, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R b1  is C 1 -C 4  alkyl. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -3, R 2b -3A, or R 2b -3B, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R c1  is selected from the group consisting of C 1 -C 4  alkyl, C 3 -C 6  cycloalkyl, and —C(═O)R 4c . In another embodiment, R c2  and R c3  are each hydrogen. In another embodiment, R c2  and R c3  taken together with the carbon atom to which they are attached form a C(═O) group. In another embodiment, R c4  is hydrogen. In another embodiment, m is 1. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -4, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R d1  is C(═O)R 4c . In another embodiment, R d2  and R d3  are each hydrogen or fluoro. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -5, R 2b -5A, or R 2b -5B, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R e1  is —C(═O)R 4c . 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -6, R 2b -6A, or R 2b -6B, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R f1  is C(═O)R 4c . 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -7, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R g1  is C(═O)R 4c . 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -8, R 2b -8A, R 2b -8B, R 2b -8C, or R 2b -8D, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R h1  is —C(═O)R 4c . In another embodiment, R h2  is selected from the group consisting of hydrogen and C 1 -C 3  alkyl. In another embodiment, R h3  is hydrogen. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -9, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is selected from the group consisting of R 2b -10, R 2b -10A, R 2b -10B, R 2b -10C, and R 2b -10d, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is selected from the group consisting of R 2b -11, R 2b -11A and R 2b -11B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -12, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R j1  is —C(═O)R 4c . 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is selected from the group consisting of R 2b -13, R 2b -13A, R 2b -13B, R 2b -13C, R 2b -13D, R 2b -13E, and R 2b -13F, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -14, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -15, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is selected from the group consisting of R 2b -16, R 2b -16A and R 2b -16B, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R n3  is —C(═O)R 4c . 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -17, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -18, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -19, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -20, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is selected from the group consisting of R 2b -21, R 2b -21A and R 2b -21B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III, wherein R 2b  is selected from the group consisting of R 2b -22, R 2b -22A and R 2b -22B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -23, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -24, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -25, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is selected from the group consisting of R 2b -26, R 2b -26A and R 2b -26B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is selected from the group consisting of R 2b -27, R 2b -27A and R 2b -27B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is selected from the group consisting of R 2b -28, R 2b -28A and R 2b -28B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -29, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is R 2b -30, R 2b -30A, or R 2b -30B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2b  is any one or more of the R 11a  groups provided in connection with Formula IV, see below, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 4c  is C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2d  is selected from the group consisting of hydrogen, fluoro, and chloro, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2d  is hydrogen, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III in any of the above described embodiments, wherein A 1  and A 2  are —C(H)═; R 2e  is hydrogen; and R 2d  is selected from the group consisting of hydrogen and halogen, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula III or Formula III-A, wherein R 2d  is fluoro, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV: 
     
       
         
         
             
             
         
       
     
     wherein: 
     Z 4  is selected from the group consisting of —O—, —C(R 28a )(R 28b )—, and —N(R 23 )—; or Z 4  is absent; 
     Z 5  is selected from the group consisting of —CH 2 — and —CH 2 CH 2 —; 
     R 11a  is selected from the group consisting of optionally substituted alkyl, optionally substituted heterocyclo, optionally substituted heteroaryl, and —N(R 12b )C(═O)R 13c ; 
     R 12b  is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and heterocyclo; 
     R 13c  is selected from the group consisting of alkyl, haloalkyl, alkoxy, (alkoxy)alkyl, (hydroxy)alkyl, (cyano)alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycle, amino, (amino)alkyl, (C 3 -C 6  cycloalkyl)oxy, and (4- to 8-membered heterocyclo)oxy; 
     R 23  is selected from the group consisting of hydrogen and C 1 -C 4  alkyl; 
     R 28a  and R 28b  are independently selected from the group consisting of hydrogen, alkyl, and halo; and 
     R 1d  is as defined in connection with Formula I, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV, wherein Z 4  is selected from the group consisting of —O— and —CH 2 —; or Z 4  is absent, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV, wherein: 
     Z 4  is selected from the group consisting of —O— and —CH 2 —; or Z 4  is absent; 
     Z 5  is selected from the group consisting of —CH 2 — and —CH 2 CH 2 —; 
     R 13c  is selected from the group consisting of alkyl, haloalkyl, alkoxy, (alkoxy)alkyl, (hydroxy)alkyl, (cyano)alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycle, and 
     R 1d  is as defined in connection with Formula I, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV-A: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof, wherein R 1d , R 11a  and Z 4  are as defined in connection with Formula IV. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV-B: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof, wherein R 1d , R 11a  and Z 4  are as defined in connection with Formula IV. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV-C: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof, wherein R 1d , R 11a  and Z 4  are as defined in connection with Formula IV. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV-D: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof, wherein R 1d , R 11a  and Z 4  are as defined in connection with Formula IV. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein: 
     R 11a  is selected from the group consisting of: (A) unsubstituted 4- to 14-membered heterocyclo; (B) substituted 4- to 14-membered heterocyclo having one, two or three substituents independently selected from the group consisting of —N(R 12a )C(═O)R 13a ; —C(═O)R 13b ; C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (hydroxy)C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; amino; hydroxy; —N(R 12a )S(═O) 2 R 24 ; —S(═O) 2 R 24 ; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two sub stituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (C) unsubstituted 5- to 10-membered heteroaryl; (D) substituted 5- or 6-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo, C 1 -C 4  alkyl, and (amino)alkyl; (E) C 1 -C 6  alkyl; and (F) —N(R 12b )C(═O)R 13c ; 
     R 12a  and R 12b  are each independently selected from the group consisting of hydrogen, C 1 -C 4  alkyl, (C 1 -C 4  alkoxy)C 1 -C 4  alkyl, and (hydroxy)C 1 -C 4  alkyl; 
     R 13a , R 13b , and R 13c  are each independently selected from the group consisting of C 1 -C 6  alkyl; C 1 -C 6  haloalkyl; unsubstituted C 3 -C 6  cycloalkyl; C 1 -C 6  alkoxy; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (hydroxy)C 1 -C 4  alkyl; (cyano)alkyl; unsubstituted C 6 -C 10  aryl; substituted C 6 -C 10  aryl, having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; amino; (amino)alkyl; (C 3 -C 6  cycloalkyl)oxy; and (4- to 8-membered heterocyclo)oxy; and 
     R 24  is selected from the group consisting of C 1 -C 4  alkyl and (hydroxy)C 1 -C 4  alkyl. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV, IV-A, IV-B, IV-C, or IV-D, wherein Z 4  is —C(R 28a )(R 28b )—; and R 28a  and R 28b  are independently selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and fluoro, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV, IV-A, IV-B, IV-C, or IV-D, wherein Z 4  is —C(R 28a )(R 28b )—; R 28a  is hydrogen; and R 28b  is selected from the group consisting of C 1 -C 4  alkyl and fluoro, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV, IV-A, IV-B, IV-C, or IV-D, wherein Z 4  is —C(R 28a )(R 28b )—; and R 28a  and R 28b  are independently C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula IV, IV-A, IV-B, IV-C, or IV-D, wherein Z 4  is selected from the group consisting of —O—, —CH 2 —, and —N(R 23 ), or Z 4  is absent, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein Z 4  is —CH 2 —, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is an optionally substituted 3- to 10-membered heterocycle linked to the rest of the molecule through a nitrogen atom, e.g., R 11a  is 
     
       
         
         
             
             
         
       
     
     and the like. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is a substituted 4- to 14-membered heterocyclo selected from the group consisting of: 
     
       
         
         
             
             
         
       
     
     R 12a  is selected from the group consisting of hydrogen, C 1 -C 3  alkyl, (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; and (hydroxy)C 1 -C 4  alkyl; 
     R 13a  is selected from the group consisting of C 1 -C 4  alkyl; amino; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (hydroxy)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; 
     R 13b  is selected from the group consisting of C 1 -C 4  alkyl; amino; C 1 -C 4  haloalkyl; C 1 -C 4  alkoxy; (hydroxy)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (amino)alkyl; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (C 3 -C 6  cycloalkyl)oxy; and (4- to 8-membered heterocyclo)oxy; 
     R 21  is selected from the group consisting of hydrogen, —C(═O)R 13b , C 1 -C 4  alkyl, C 1 -C 4  haloalkyl, unsubstituted 4- to 14-membered heterocyclo, and —S(═O) 2 R 24 ; 
     R 22  is C 1 -C 4  alkyl; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two sub stituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; 
     R 24  is selected from the group consisting of C 1 -C 4  alkyl and (hydroxy)C 1 -C 4  alkyl; 
     R 25  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and C 1 -C 4  haloalkyl; 
     R 25b  and R 25c  are independently selected from the group consisting of C 1 -C 4  alkyl and C 1 -C 4  haloalkyl; 
     R 26  is selected from the group consisting of unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; and 
     R 21a  and R 25a  taken together with the atoms to which they are attached form an optionally substituted 4- to 8-membered heterocyclo, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     wherein: 
     R 27a  and R 27b  are each independently selected from the group consisting of hydrogen, C 1 -C 4  alkyl, C 1 -C 4  haloalkyl, (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; and (hydroxy)C 1 -C 4  alkyl; 
     R 27c  is selected from the group consisting of hydrogen; —C(═O)R 13b ; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; and —S(═O) 2 R 24 ; 
     R 27d  is selected from the group consisting of hydrogen; C 1 -C 4  alkyl; and C 1 -C 4  haloalkyl; 
     R 13b  is selected from the group consisting of C 1 -C 4  alkyl; aminoC 1 -C 4  haloalkyl; C 1 -C 4  alkoxy; (hydroxy)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (amino)alkyl; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (C 3 -C 6  cycloalkyl)oxy; and (4- to 8-membered heterocyclo)oxy; and 
     R 24  is selected from the group consisting of C 1 -C 4  alkyl and (hydroxy)C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of unsubstituted 4- to 14-membered heterocyclo; substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of —N(R 12a )C(═O)R 13a , —C(═O)R 13b , and C 1 -C 4  alkyl; unsubstituted 5- to 10-membered heteroaryl; and substituted 5- or 6-membered heteroaryl having one or two substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is a substituted 4- to 14-membered heterocyclo is selected from the group consisting of: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R 12 a is selected from the group consisting of hydrogen and C 1 -C 3  alkyl; R 13a  is C 1 -C 4  alkyl; and R 13b  is C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R 12a  is selected from the group consisting of hydrogen and methyl; R 13a  is methyl; and R 13b  is methyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is any one or more of the R 2b  groups provided in connection with Formula III, see above, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein: 
     R 11a  is selected from the group consisting of: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     and R a1 , R a2 , R a3 , R a4 , R a5 , R b1 , R c1 , R c2 , R c3 , R c4 , m, R d1 , R d2 , R d3 , R e1 , R f1 , R g1 , R h1 , R h2 , R h3 , R h4 , R i1 , Z 1 , R j1 , R k1 , R k2 , r, Z 2 , R n3 , R o1 , R o2 , R o3 , R p1 , Z 3 , R r1 , R s1 , R t1 , R u1 , R v1 , R w1 , R x1 , R y1 , and R z1  are as defined in connection with Formula III; or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein: 
     R 11a  is selected from the group consisting of: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     and R a1 , R a5 , R b1 , R c1 , R f1 , R h1 , R h2 , R h3 , R k1 , R n3 , R s1 , R t1 , R w1 , R x1 , and R y1  are as defined in connection with Formula III; or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -1, R 11a -1A, R 11a -1B, R 11a -1C, or R 11a -1D, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R a1  is —N(R 3a )C(═O)R 4a . In another embodiment, R a1  is —NR 5a R 5b . In another embodiment, R a1  is —NR 5a R 5b  and R 5a  and R 5b  are independently selected from the group consisting of hydrogen and C 1 -C 4  alkyl. In another embodiment, R a1  is optionally substituted 4- to 10-membered heterocyclo. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -2, R 11a -2A or R 11a -2b, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R b1  is C 1 -C 4  alkyl. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -3, R 11a -3A, or R 11a -3B, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R c1  is selected from the group consisting of C 1 -C 4  alkyl, C 3 -C 6  cycloalkyl, and —C(═O)R 4c . In another embodiment, R c2  and R c3  are each hydrogen. In another embodiment, R c2  and R c3  taken together with the carbon atom to which they are attached form a C(═O) group. In another embodiment, R c4  is hydrogen. In another embodiment, m is 1. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -4, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R d1  is C(═O)R 4c . In another embodiment, R d2  and R d3  are each hydrogen or fluoro. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -5, R 11a -5A, or R 11a -5B, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R e1  is —C(═O)R 4c . 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -6, R 11a -6A, or R 11a -6B, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R f1  is C(═O)R 4c . 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -7, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R g1  is C(═O)R 4c . 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -8, R 11a -8A, R 11a -8B, R 11a -8C or R 11a -8D, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R h1  is —C(═O)R 4c . In another embodiment, R h2  is selected from the group consisting of hydrogen and C 1 -C 3  alkyl. In another embodiment, R h3  is hydrogen. 
     In another embodiment, Compounds of the Disclosure are compounds any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -9, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of R 11a -10, R 11a -10A, R 11a -10B, R 11a -10C, and R 11a -10d, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of R 11a -11, R 11a -11A and R 11a -11B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -12, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R j1  is —C(═O)R 4c . 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of R 11a -13, R 11a -13A, R 11a -13B, R 11a -13C, R 11a -13D, R 11a -13E, and R 11a -13F, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -14, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -15, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of R 11a -16, R 11a -16A and R 11a -16B, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R n3  is —C(═O)R 4c . 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -17, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -18, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -19, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -20, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of R 11a -21, R 11a -21A and R 11a -21B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of R 11a -22, R 11a -22A and R 11a -22B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -23, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -24, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -25, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of R 11a -26, R 11a -26A and R 11a -26B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of R 11a -27, R 11a -27A and R 11a -27B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is selected from the group consisting of R 11a -28, R 11a -28A and R 11a -28B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -29, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV, IV-A, IV-B, IV-C, or IV-D, wherein R 11a  is R 11a -30, R 11a -30A, or R 11a -30B, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV-A, IV-B, IV-C, or IV-D, wherein: 
     Z 4  is —CH 2 —; 
     R 11a  is selected from the group consisting of: 
     
       
         
         
             
             
         
       
     
     R 12a  is selected from the group consisting of hydrogen and C 1 -C 3  alkyl; 
     R 21  is —C(═O)R 13b ; 
     R 27c  is —C(═O)R 13b ; 
     R 13b  is selected from the group consisting of C 1 -C 4  alkyl and (hydroxy)C 1 -C 4  alkyl; 
     R 24  is C 1 -C 4  alkyl; 
     R 25  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and C 1 -C 4  haloalkyl; and 
     R 25b  and R 25c  are independently selected from the group consisting of C 1 -C 4  alkyl and C 1 -C 4  haloalkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV-A, IV-B, IV-C, or IV-D, wherein: 
     Z 4  is —CH 2 —; and 
     R 11a  is selected from the group consisting of: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV-A, IV-B, IV-C, or IV-D, wherein: 
     Z 4  is —CH 2 —; and 
     R 11a  is selected from the group consisting of: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae IV-A, IV-B, IV-C, or IV-D, wherein: 
     Z 4  is —CH 2 —; 
     R 11a  is: 
     
       
         
         
             
             
         
       
     
     and R 27a  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, C 1 -C 4  haloalkyl, (C 1 -C 4  alkoxy)C 1 -C 4  alkyl, and (hydroxy)C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, R 27a  is methyl. 
     In another embodiment, Compounds of the Disclosure are compounds Formula V: 
     
       
         
         
             
             
         
       
     
     wherein: 
     R 14a  is selected from the group consisting of optionally substituted alkyl and optionally substituted heteroaryl; 
     R 14b  is selected from the group consisting of optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted heterocyclo, optionally substituted cycloalkyl, and carboxamido; and 
     p is 0, 1, 2, or 3; or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula V-A: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 14a , R 14d , and p are as defined in connection with Formula V, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula V-B: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 14a , R 14d , and p are as defined in connection with Formula V, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae V, V-A, or V-B, wherein: 
     R 14a  is selected from the group consisting of (A) unsubstituted 5- to 10-membered heteroaryl; (B) substituted 5- or 10-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of (i) halo; (ii) C 1 -C 4  alkyl; (iii) C 1 -C 4  alkoxy; (iv) (3- to 8-membered heterocyclo)C 1 -C 4  alkyl; (v) (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; (vi) —C(═O)NR 15a R 15b ; (vii) unsubstituted 5- to 10-membered heteroaryl; (viii) substituted 5- or 10-membered heteroaryl having one, two, or three substituents independently selected from the group consisting of halo, C 1 -C 4  alkyl, (3- to 8-membered heterocyclo)C 1 -C 4  alkyl, 5- to 9-membered heteroaryl, and —NR 15e R 15f ; (ix) —OR 16  (x) unsubstituted C 3 -C 6  cycloalkyl; (xi) substituted C 3 -C 6  cycloalkyl having one, two, three, or four substituents independently selected from the group consisting of C 1 -C 4  alkyl and —N(R 17a )C(═O)R 18a ; (xii) cyano; (xiii) unsubstituted 4- to 14-membered heterocyclo; (xiv) substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of C 1 -C 4  alkyl, (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; (xv) (carboxy)C 1 -C 4  alkyl; (xvi) (carboxamido)C 1 -C 4  alkyl; and (xvii) carboxy; and (C) C 1 -C 6  alkyl; 
     R 14b  is selected from the group consisting of: (A) unsubstituted 5- to 10-membered heteroaryl; (B) substituted 5- or 10-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo, C 1 -C 4  alkyl, and (C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl; (C) unsubstituted C 6 -C 10  aryl; (D) substituted C 6 -C 10  aryl, having one, two, three, or four substituents independently selected from the group consisting of halo, C 1 -C 4  alkyl, and (3- to 8-membered heterocyclo)C 1 -C 4  alkyl; (E) unsubstituted 4- to 14-membered heterocyclo; (F) substituted 4- to 14-membered heterocyclo having one, two, three, or four substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; (G) —C(═O)NR 15c R 15d ; (H) unsubstituted C 3 -C 6  cycloalkyl; and (I) C 1 -C 6  alkyl; 
     p is 0, 1, 2, or 3; 
     R 15a  and R 15b  are independently selected from the group consisting of: (A) hydrogen; (B) C 1 -C 6  alkyl; (C) C 1 -C 6  haloalkyl; (D) (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (E) (hydroxy)C 1 -C 4  alkyl; (F) (cyano)alkyl; (G) unsubstituted C 6 -C 10  aryl; (H) substituted C 6 -C 10  aryl, having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (I) unsubstituted 5- or 6-membered heteroaryl; (J) substituted 5- or 6-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (K) unsubstituted 4- to 14-membered heterocyclo; (L) substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (M) unsubstituted C 3 -C 8  cycloalkyl; and (N) substituted C 3 -C 8  cycloalkyl having one, two, three, or four substituents independently selected from the group consisting of C 1 -C 6  alkyl and —NR 15g R 15h ; or 
     R 15a  and R 15b  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 15c  and R 15d  are independently selected from the group consisting of: (A) hydrogen; (B) C 1 -C 6  alkyl; (C) C 1 -C 6  haloalkyl; (D) (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (E) (hydroxy)C 1 -C 4  alkyl; (F) (cyano)alkyl; (G) unsubstituted C 6 -C 10  aryl; (H) substituted C 6 -C 10  aryl, having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (I) unsubstituted 5- or 6-membered heteroaryl; (J) substituted 5- or 6-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (K) unsubstituted 4- to 14-membered heterocyclo; (L) substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (M) unsubstituted C 3 -C 8  cycloalkyl; and (N) substituted C 3 -C 8  cycloalkyl having one, two, three, or four substituents independently selected from the group consisting of C 1 -C 6  alkyl and —NR 15g R 15h ; or 
     R 15c  and R 15d  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 15e  and R 15f  are independently selected from the group consisting of: (A) hydrogen; (B) C 1 -C 6  alkyl; (C) C 1 -C 6  haloalkyl; (D) (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (E) (hydroxy)C 1 -C 4  alkyl; (F) (cyano)alkyl; (G) unsubstituted C 6 -C 10  aryl; (H) substituted C 6 -C 10  aryl, having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (I) unsubstituted 5- or 6-membered heteroaryl; (J) substituted 5- or 6-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (K) unsubstituted 4- to 14-membered heterocyclo; (L) substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (M) unsubstituted C 3 -C 8  cycloalkyl; and (N) substituted C 3 -C 8  cycloalkyl having one, two, three, or four substituents independently selected from the group consisting of C 1 -C 6  alkyl and —NR 15g R 15h ; or 
     R 15e  and R 15f  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 15g  and R 15h  are independently selected from the group consisting of: (A) hydrogen; (B) C 1 -C 6  alkyl; (C) C 1 -C 6  haloalkyl; (D) C 1 -C 6  alkoxy; (E) (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (F) (hydroxy)C 1 -C 4  alkyl; (G) (cyano)alkyl; (H) unsubstituted C 6 -C 10  aryl; (I) substituted C 6 -C 10  aryl, having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (J) unsubstituted 5- or 6-membered heteroaryl; (K) substituted 5- or 6-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (L) unsubstituted 4- to 14-membered heterocyclo; (M) substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (N) unsubstituted C 3 -C 8  cycloalkyl; and (O) substituted C 3 -C 8  cycloalkyl having one, two, three, or four substituents independently selected from the group consisting of C 1 -C 6  alkyl and —NR 15g R 15h ; or 
     R 15g  and R 15g  taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 14-membered heterocyclo; 
     R 16  is (amino)(hydroxy)C 1 -C 4  alkyl; 
     R 17  is selected from the group consisting of hydrogen and C 1 -C 4  alkyl; 
     R 18a  is selected from the group consisting of: (A) C 1 -C 6  alkyl; (B) C 1 -C 6  haloalkyl; (C) C 1 -C 6  alkoxy; (D) (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (E) (hydroxy)C 1 -C 4  alkyl; (F) (cyano)alkyl; (G) unsubstituted C 6 -C 10  aryl; (H) substituted C 6 -C 10  aryl, having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (I) unsubstituted 5- or 6-membered heteroaryl; (J) substituted 5- or 6-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (K) unsubstituted 4- to 14-membered heterocyclo; (L) substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (M) unsubstituted C 3 -C 8  cycloalkyl; and (N) substituted C 3 -C 8  cycloalkyl having one, two, three, or four substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl, 
     or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae V, V-A, or V-B, wherein R 14a  is selected from the group consisting of unsubstituted 5- to 10-membered heteroaryl; and substituted 5- or 10-membered heteroaryl having one, two, or three substituents independently selected from the group consisting of C 1 -C 4  alkyl; C 1 -C 4  alkoxy; (3- to 8-membered heterocyclo)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; —C(═O)NR 15a R 15b ; unsubstituted 5- to 10-membered heteroaryl; substituted 5- or 10-membered heteroaryl having one, two, or three substituents independently selected from the group consisting of halo, C 1 -C 4  alkyl, (3- to 8-membered heterocyclo)C 1 -C 4  alkyl, 5- to 9-membered heteroaryl, and —NR 15e R 15f ; unsubstituted C 3 -C 6  cycloalkyl; and substituted C 3 -C 6  cycloalkyl having one, two, or three substituents independently selected from the group consisting of C 1 -C 4  alkyl and —N(R 17a )C(═O)R 18a , or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae V, V-A, or V-B, wherein R 14a  is a substituted pyridyl having one, two, or three substituents independently selected from the group consisting of C 1 -C 4  alkyl; C 1 -C 4  alkoxy; (3- to 8-membered heterocyclo)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl)C 1 -C 4  alkyl; —C(═O)NR 15a R 15b ; unsubstituted 5- to 10-membered heteroaryl; substituted 5- to 10-membered heteroaryl having one, two, or three substituents independently selected from the group consisting of halo, C 1 -C 4  alkyl, (3- to 8-membered heterocyclo)C 1 -C 4  alkyl, 5- to 9-membered heteroaryl, and —NR 15e R 15f ; unsubstituted C 3 -C 6  cycloalkyl; and substituted C 3 -C 6  cycloalkyl having one, two, or three substituents independently selected from the group consisting of C 1 -C 4  alkyl and —N(R 17a )C(═O)R 18a , or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae V, V-A, or V-B, wherein R 14b  is selected from the group consisting of unsubstituted 5- to 10-membered heteroaryl; substituted 5- to 10-membered heteroaryl having one or two sub stituents independently selected from the group consisting of C 1 -C 4  alkyl and (C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl; unsubstituted C 6 -C 10  aryl; substituted C 6 -C 10  aryl, having one or two substituents independently selected from the group consisting of C 1 -C 4  alkyl and (3- to 8-membered heterocyclo)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of hydroxy, amino, and C 1 -C 4  alkyl; and unsubstituted C 3 -C 6  cycloalkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae V, V-A, or V-B, wherein R 14b  is selected from the group consisting of unsubstituted 5- or 6-membered heteroaryl; substituted 5- or 6-membered heteroaryl having one or two sub stituents independently selected from the group consisting of C 1 -C 4  alkyl and (C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl; unsubstituted phenyl; substituted phenyl, having one or two substituents independently selected from the group consisting of C 1 -C 4  alkyl and (3- to 8-membered heterocyclo)C 1 -C 4  alkyl; and unsubstituted C 3 -C 6  cycloalkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae V, V-A, or V-B, wherein p is 0, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae V, V-A, or V-B, wherein p is 1, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VI: 
     
       
         
         
             
             
         
       
     
     wherein: 
     R 19  is selected from the group consisting of unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; 
     R 20  is selected from the group consisting of hydrogen, halo, and C 1 -C 4  alkyl; and 
     q is 1, 2, or 3, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VI, wherein q is 1. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VII: 
     
       
         
         
             
             
         
       
     
     wherein: 
     R 11b  is selected from the group consisting of C 1 -C 4  alkyl, halo, and C 1 -C 4  haloalkyl; and 
     R 1d  and R 11a  are as defined in connection with Formula IV, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VII-A: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 11a , and R 11b  are as defined in connection with Formula VII, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VII-B: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 11a , and R 11b  are as defined in connection with Formula VII, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VII-C: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 11a , and R 11b  are as defined in connection with Formula VII, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VII-D: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 11a , and R 11b  are as defined in connection with Formula VII, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VII-E: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 11a , and R 11b  are as defined in connection with Formula VII, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VII-F: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 11a , and R 11b  are as defined in connection with Formula VII, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VII-G: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 11a , and R 11b  are as defined in connection with Formula VII, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VII-H: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 11a , and R 11b  are as defined in connection with Formula VII, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VIII: 
     
       
         
         
             
             
         
       
     
     wherein: 
     R 30  is selected from the group consisting of hydrogen; C 1 -C 6  alkyl; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two sub stituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; —C(═O)R 13b , and —S(═O) 2 R 24 ; 
     R 13b  is selected from the group consisting of C 1 -C 4  alkyl; amino; C 1 -C 4  haloalkyl; C 1 -C 4  alkoxy; (hydroxy)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (amino)alkyl; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (C 3 -C 6  cycloalkyl)oxy; and (4- to 8-membered heterocyclo)oxy; 
     R 24  is selected from the group consisting of C 1 -C 4  alkyl and (hydroxy)C 1 -C 4  alkyl; 
     u is 0, 1, 2, or 3; and 
     R 1d  is as defined in connection with Formula I, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VIII-A: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 30 , and u are as defined in connection with Formula VIII, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds having Formula VIII-B: 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 30 , and u are as defined in connection with Formula VIII, or a pharmaceutically acceptable salt or solvate thereof. 
     In another embodiment, Compounds of the Disclosure are compounds of Table 1, and the pharmaceutically acceptable salts or solvates thereof. The chemical names of the compounds of Table 1 were generated by Chemdraw® Professional version 17.0.0.206. Mass spectroscopy and biological data of representative Compounds of the Disclosure are provided in Table 1B and/or PCT/US2019/046569. In another embodiment, Compounds of the Disclosure are compounds of Table 1B, and the pharmaceutically acceptable salts or solvates thereof. The biological data in Table 1B were generated following the protocols described in EXAMPLES 11 and 12 of PCT/US2019/046569. 
     In another embodiment, Compounds of the Disclosure are selected from the group consisting of Cpd. Nos. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 824, 828, 839, 870, 922, 930, 942, 995, 1007, 1025, 1043, 1044, 1045, 1048, 1051, 1055, 1070, 1078, 1083, 1097, 1117, 1138, 1180, 1184, and 1192, and the pharmaceutically acceptable salts or solvates thereof. In another embodiment, Compounds of the Disclosure are selected from the group consisting of Cpd. Nos. 15, 922, 930, 942, 1055, 1070, 1117, 1180, 1184, and 1192, and the pharmaceutically acceptable salts or solvates thereof In another embodiment, Compounds of the Disclosure are selected from the group consisting of Cpd. Nos. 1228, 1229, 1230, 1231, 1232, 1233, 1234 and 1235, and the pharmaceutically acceptable salts or solvates thereof. 
     In another embodiment, Compounds of the Disclosure are selected from the group consisting of Cpd. Nos. 15, 942, 1184, and 1232, and the pharmaceutically acceptable salts or solvates thereof. 
     In a non-limiting embodiment, the Compound of the Disclosure is Cpd. No. 15. 
     In a non-limiting embodiment, the Compound of the Disclosure is Cpd. No. 1228. In a non-limiting embodiment, the Compound of the Disclosure is Cpd. No. 1229. In a non-limiting embodiment, the Compound of the Disclosure is Cpd. No. 1230. In a non-limiting embodiment, the Compound of the Disclosure is Cpd. No. 1231. In a non-limiting embodiment, the Compound of the Disclosure is Cpd. No. 1232. In a non-limiting embodiment, the Compound of the Disclosure is Cpd. No. 1233. In a non-limiting embodiment, the Compound of the Disclosure is Cpd. No. 1234. In a non-limiting embodiment, the Compound of the Disclosure is Cpd. No. 1235. In a non-limiting embodiment, the Compound of the Disclosure is a pharmaceutically acceptable salt or solvate of Cpd. No. 15. In a non-limiting embodiment, the Compound of the Disclosure is a pharmaceutically acceptable salt or solvate of Cpd. No. 1228. In a non-limiting embodiment, the Compound of the Disclosure is a pharmaceutically acceptable salt or solvate of Cpd. No. 1229. In a non-limiting embodiment, the Compound of the Disclosure is a pharmaceutically acceptable salt or solvate of Cpd. No. 1230. In a non-limiting embodiment, the Compound of the Disclosure is a pharmaceutically acceptable salt or solvate of Cpd. No. 1231. In a non-limiting embodiment, the Compound of the Disclosure is a pharmaceutically acceptable salt or solvate of Cpd. No. 1232. In a non-limiting embodiment, the Compound of the Disclosure is a pharmaceutically acceptable salt or solvate of Cpd. No. 1233. In a non-limiting embodiment, the Compound of the Disclosure is a pharmaceutically acceptable salt or solvate of Cpd. No. 1234. In a non-limiting embodiment, the Compound of the Disclosure is a pharmaceutically acceptable salt or solvate of Cpd. No. 1235 
     
       
         
           
               
               
             
               
                 TABLE 1 
               
               
                   
               
               
                 Cpd. 
                   
               
               
                 No. 
                 Chemical Name 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 1 
                 4-fluoro-N-(3-fluoro-5-(3-(N-methylacetamido)pyrrolidin-1-yl)phenyl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 2 
                 4-fluoro-N-(3-fluoro-5-(3-(2-methyl-3-oxohexahydroimidazo[1,5-a]pyrazin- 
               
               
                   
                 7(1H)-yl)pyrrolidin-1-yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 3 
                 N-(3-(3-(dimethylamino)-2-oxopyrrolidin-1-yl)-5-fluorophenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 4 
                 N-(3-(3-(4-(2-(dimethylamino)-2-oxoethyl)piperazin-1-yl)pyrrolidin-1-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 5 
                 N-(3-(8-acetyl-2,8-diazaspiro[4.5]decan-2-yl)-5-fluorophenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 6 
                 N-(3-(3-(4-(2-amino-2-oxoethyl)piperazin-1-yl)pyrrolidin-1-yl)-5-fluorophenyl)- 
               
               
                   
                 4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 7 
                 N-(3-(4-acetylpiperazin-1-yl)-5-fluorophenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 8 
                 N-(3-(3-(1,1-dioxidothiomorpholino)pyrrolidin-1-yl)-5-fluorophenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 9 
                 N-(3-(3-(4-acetylpiperazin-1-yl)pyrrolidin-1-yl)-5-fluorophenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 10 
                 N-(3-(4-cyclopropyl-3-oxopiperazin-1-yl)-5-fluorophenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 11 
                 4-fluoro-N-(3-fluoro-5-(3-morpholinopyrrolidin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 12 
                 4-fluoro-N-(3-fluoro-5-(4-(2-methoxyacetyl)piperazin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 13 
                 N-(3-(4-acetylhexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)-5-fluorophenyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 14 
                 N-(3-(1-acetylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-5-fluorophenyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 15 
                 N-((1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 16 
                 4-fluoro-N-(3-fluoro-5-(3-(2-(hydroxymethyl)morpholino)pyrrolidin-1- 
               
               
                   
                 yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 17 
                 4-fluoro-N-(3-fluoro-5-(3-(4-methyl-3-oxopiperazin-1-yl)pyrrolidin-1-yl)phenyl)- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 18 
                 4-fluoro-N-(3-fluoro-5-(2-oxo-[1,3′-bipyrrolidin]-1′-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 19 
                 N-(3-(7-acetyl-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluorophenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 20 
                 4-fluoro-N-(3-fluoro-5-(4-methyl-3-oxopiperazin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 21 
                 4-fluoro-N-(3-fluoro-5-(4-methyl-5-oxo-1,4-diazepan-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 22 
                 N-(3-chloro-5-(3-morpholinopyrrolidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 23 
                 N-(3-(1-acetyl-4-methylpiperidin-4-yl)-5-fluorophenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 24 
                 4-fluoro-N-(3-fluoro-5-(2-(2-hydroxyethyl)morpholino)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 25 
                 N-(3-(4-(dimethylcarbamoyl)piperazin-1-yl)-5-fluorophenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 26 
                 4-fluoro-N-(3-fluoro-5-((7S,8aS)-3-oxooctahydroindolizin-7-yl)phenyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 27 
                 4-fluoro-7-methyl-N-(3-(6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 28 
                 N-(3-(6,6-difluoro-2,8-diazaspiro[4.5]decan-2-yl)-5-fluorophenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 29 
                 N-(3-(3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)pyrrolidin-1-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 30 
                 N-(3-(2-acetyl-2,8-diazaspiro[4.5]decan-8-yl)-5-fluorophenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 31 
                 N-(3-(4-acetylpiperazin-1-yl)-5-chlorophenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 32 
                 N-(3-(4-acetyl-3-methylpiperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 34 
                 N-(3-(4-acetylpiperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 35 
                 4-fluoro-N-(3-fluoro-5-((1s,4s)-4-morpholinocyclohexyl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 36 
                 4-fluoro-7-methyl-N-(3-(4-propionylpiperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 37 
                 4-fluoro-7-methyl-N-(3-(3-oxooctahydroindolizin-7-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 38 
                 4-fluoro-7-methyl-N-(3-(3-(N-methylacetamido)pyrrolidin-1-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 39 
                 N-(3-(3-(4-(dimethylglycyl)piperazin-1-yl)pyrrolidin-1-yl)-5-fluorophenyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 40 
                 N-(3-(7-(2,2-difluoroethyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluorophenyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 41 
                 N-(3-(7-(2,2-difluoroethyl)-2,7-diazaspiro[3.5]nonan-2-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 42 
                 4-fluoro-7-methyl-N-(3-(3-(N-methylacetamido)piperidin-1-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 43 
                 N-(3-(4-(dimethylalanyl)piperazin-1-yl)-5-fluorophenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 44 
                 4-fluoro-N-(3-(4-(2-methoxyacetyl)piperazin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 45 
                 N-(3-(1-acetylpiperidin-4-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 46 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 47 
                 4-fluoro-N-(3-fluoro-5-(3-((2-fluoroethyl)(methyl)amino)pyrrolidin-1-yl)phenyl)- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 48 
                 4-fluoro-N-(3-fluoro-5-(2-(hydroxymethyl)morpholino)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 49 
                 4-fluoro-7-methyl-N-(3-(4-nicotinoylpiperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 50 
                 4-fluoro-N-(3-(2-(2-hydroxyethyl)morpholino)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 51 
                 4-fluoro-7-methyl-N-(3-((7R,8aR)-3-oxooctahydroindolizin-7-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 52 
                 N-(3-(4-acetylpiperazin-1-yl)-2-fluorophenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 53 
                 N-(3-(3-(dimethylamino)pyrrolidin-1-yl)-5-fluorophenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 54 
                 4-fluoro-7-methyl-N-(3-(2-methyl-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)- 
               
               
                   
                 yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 55 
                 N-(3-(4-(dimethylcarbamoyl)piperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 56 
                 N-(3-(1-acetylpyrrolidin-3-yl)-5-fluorophenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 57 
                 N-(3-(2-oxa-7-azaspiro[3.5]nonan-7-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 58 
                 4-fluoro-7-methyl-N-(3-(4-methyl-3-oxopiperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 59 
                 N-(3-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 60 
                 N-(3-(1,3,4-oxadiazol-2-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 61 
                 N-(3-((3S,4S)-3-(dimethylamino)-4-hydroxypyrrolidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 62 
                 N-(3-(4-(dimethylglycyl)piperazin-1-yl)-5-fluorophenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 63 
                 N-(3-(3-(dimethylamino)-4-fluoropyrrolidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 64 
                 4-fluoro-7-methyl-N-(3-(pyrimidin-5-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 65 
                 4-fluoro-7-methyl-N-(3-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 66 
                 4-fluoro-7-methyl-N-(3-(2-oxooxazolidin-3-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 68 
                 N-(3-((1r,4r)-4-(dimethylamino)cyclohexyl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 69 
                 N-(3-((1s,4s)-4-(dimethylamino)cyclohexyl)-5-fluorophenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 70 
                 N-(3-(4-(dimethylglycyl)-3-methylpiperazin-1-yl)-5-fluorophenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 71 
                 N-(3-(4-acetyl-3-ethylpiperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 72 
                 4-fluoro-N-(3-(4-(2-hydroxyacetyl)piperazin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 73 
                 N-(3-(1-acetylpyrrolidin-3-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 74 
                 4-fluoro-7-methyl-N-(3-(3-morpholinopyrrolidin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 75 
                 4-fluoro-N-(3-(4-(3-methoxypropanoyl)piperazin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 76 
                 4-fluoro-7-methyl-N-(3-(4-morpholinopiperidin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 77 
                 N-(3-(4-acetyl-3-(trifluoromethyl)piperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 78 
                 4-fluoro-7-methyl-N-(3-(4-(N-methylacetamido)piperidin-1-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 79 
                 N-(3-(4-acetylpiperazin-1-yl)-4-fluorophenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 80 
                 N-(3-(4-(dimethylamino)piperidin-1-yl)-5-fluorophenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 81 
                 4-fluoro-N-(3-(5-(methoxymethyl)-1,3,4-thiadiazol-2-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 82 
                 4-fluoro-N-(7-fluoroisoquinolin-5-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 83 
                 methyl 2-(3-(4-fluoro-7-methyl-1H-indole-2-carboxamido)phenyl)-2,8- 
               
               
                   
                 diazaspiro[4.5]decane-8-carboxylate 
               
               
                 84 
                 N-(3-(4-acetylpiperazin-1-yl)phenyl)-7-bromo-4-fluoro-1H-indole-2-carboxamide 
               
               
                 85 
                 4-fluoro-7-methyl-N-(2-(1-methyl-1H-pyrazol-4-yl)-1-(3-methylpyridin-2- 
               
               
                   
                 yl)ethyl)-1H-indole-2-carboxamide 
               
               
                 86 
                 N-(3-(1,8-diazaspiro[4.5]decan-8-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 87 
                 4-fluoro-N-(3-(4-hydroxy-4-methylpiperidin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 88 
                 N-(3-(4-ethyl-3-oxopiperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 89 
                 4-fluoro-N-(3-fluoro-5-(1′-methyl-5′-oxo-[1,3′-bipyrrolidin]-3-yl)phenyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 90 
                 4-fluoro-7-methyl-N-(3-((7S,8aS)-3-oxooctahydroindolizin-7-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 91 
                 N-(3-chloro-5-(4-methylpiperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 92 
                 4-fluoro-N-(3-(4-(2-fluoroacetyl)piperazin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 93 
                 N-(3-(4-(cyclopropanecarbonyl)piperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 94 
                 (R)-N-(3-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 95 
                 N-(3-(4-oxa-1,9-diazaspiro[5.5]undecan-9-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 96 
                 4-fluoro-N-(3-fluoro-5-((7R,8aS)-3-oxooctahydroindolizin-7-yl)phenyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 97 
                 N-(3-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 98 
                 4-fluoro-7-methyl-N-(3-(2-methyl-2,7-diazaspiro[3.5]nonan-7-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 99 
                 N-(3-(4-(dimethylamino)-3-methylpiperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 100 
                 N-(3-(4-cyclopropyl-3-oxopiperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 101 
                 4-fluoro-7-methyl-N-(3-(tetrahydro-2H-pyran-4-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 102 
                 (S)-N-(3-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 103 
                 N-(3-(4,4-bis(hydroxymethyl)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 104 
                 N-(3-(1-acetyl-1,8-diazaspiro[4.5]decan-8-yl)-5-fluorophenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 105 
                 4-fluoro-N-(3-fluoro-5-((3aS,6aS)-1-methylhexahydropyrrolo[3,4-b]pyrrol- 
               
               
                   
                 5(1H)-yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 106 
                 N-(3-chloro-5-((1s,4s)-4-(dimethylamino)cyclohexyl)phenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 107 
                 4-fluoro-N-(3-(5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 108 
                 4-fluoro-7-methyl-N-(3-(oxazol-5-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 109 
                 4-fluoro-N-(3-(7-(2-methoxyethyl)-2,7-diazaspiro[3.5]nonan-2-yl)phenyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 110 
                 4-fluoro-7-methyl-N-(3-(2-(2,2,2-trifluoroethyl)-2,7-diazaspiro[3.5]nonan-7- 
               
               
                   
                 yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 111 
                 N-(3-((3R,4S)-4-(dimethylamino)-3-methylpiperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 112 
                 methyl 2-(3-(4-fluoro-7-methyl-1H-indole-2-carboxamido)phenyl)-2,7- 
               
               
                   
                 diazaspiro[3.5]nonane-7-carboxylate 
               
               
                 113 
                 N-(3-(4-(dimethylamino)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 114 
                 4-fluoro-N-(3-fluoro-5-((8aR)-3-oxooctahydroindolizin-7-yl)phenyl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 115 
                 4-fluoro-N-(3-(2-(hydroxymethyl)morpholino)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 116 
                 4-fluoro-7-methyl-N-(3-(pyridin-4-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 117 
                 N-(3-(4-((dimethylamino)methyl)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 118 
                 4-fluoro-7-methyl-N-(3-(2-oxopyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 119 
                 N-(3-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)phenyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 120 
                 N-(3-chloro-5-(3-(dimethylamino)pyrrolidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 121 
                 methyl 4-(3-(4-fluoro-7-methyl-1H-indole-2-carboxamido)phenyl)piperazine-1- 
               
               
                   
                 carboxylate 
               
               
                 122 
                 4-fluoro-N-(3-fluoro-5-((3aR,6aR)-1-methylhexahydropyrrolo[3,4-b]pyrrol- 
               
               
                   
                 5(1H)-yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 123 
                 N-(3-(1-acetylpiperidin-3-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 124 
                 4-fluoro-7-methyl-N-(3-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 125 
                 N-(3-(1,1-dioxidoisothiazolidin-2-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 126 
                 4-fluoro-N-(3-(4-hydroxypiperidin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 127 
                 methyl 8-(3-(4-fluoro-7-methyl-1H-indole-2-carboxamido)phenyl)-2,8- 
               
               
                   
                 diazaspiro[4.5]decane-2-carboxylate 
               
               
                 128 
                 4-fluoro-7-methyl-N-(3-(3-(methylamino)pyrrolidin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 129 
                 4-fluoro-7-methyl-N-(3-(2-methylmorpholino)phenyl)-1H-indole-2-carboxamide 
               
               
                 130 
                 4-fluoro-N-(3-(3-((2-fluoroethyl)(methyl)amino)pyrrolidin-1-yl)phenyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 131 
                 4-fluoro-7-methyl-N-((1S,3R)-3-(pyrimidin-5-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 132 
                 N-(3-(5-((dimethylamino)methyl)-1,3,4-thiadiazol-2-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 133 
                 4-fluoro-N-(3-(2-(methoxymethyl)morpholino)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 134 
                 4-fluoro-N-(isoquinolin-5-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 135 
                 4-fluoro-7-methyl-N-(3-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 136 
                 4-fluoro-7-methyl-N-(4′-(methylsulfonamidomethyl)-[1,1′-biphenyl]-3-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 137 
                 4-fluoro-7-methyl-N-(3-(pyridin-3-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 138 
                 4-fluoro-7-methyl-N-(3-(4-(1-methylpiperidine-3-carbonyl)piperazin-1- 
               
               
                   
                 yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 139 
                 4-fluoro-7-methyl-N-(3-(4-(methylcarbamoyl)piperazin-1-yl)phenyl)-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 140 
                 N-(3-(1-(dimethylglycyl)pyrrolidin-3-yl)-5-fluorophenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 141 
                 N-(2-(1-(cyclopropylmethyl)-1H-pyrazol-4-yl)-1-(3-methylpyridin-2-yl)ethyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 142 
                 N-(3-(1-(2,2-difluoroethyl)-1,8-diazaspiro[4.5]decan-8-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 143 
                 N-(3-(2-cyclopropylmorpholino)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 144 
                 4-fluoro-7-methyl-N-(3-(4-(methylamino)piperidin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 145 
                 N-(3-chloro-5-(pyrimidin-5-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 146 
                 4-fluoro-7-methyl-N-(3-(4-(tetrahydrofuran-3-yl)piperazin-1-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 147 
                 4-fluoro-7-methyl-N-(3-(3-oxopiperazin-1-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 148 
                 4-fluoro-N-(3-(3-((2-hydroxyethyl)(methyl)amino)pyrrolidin-1-yl)phenyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 149 
                 4-fluoro-N-(3-(4-(3-hydroxypropanoyl)piperazin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 150 
                 N-(3-(4-(3-aminopropyl)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 151 
                 4-fluoro-7-methyl-N-(3-(1-methyl-1H-pyrazol-4-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 152 
                 4-fluoro-7-methyl-N-(3-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 153 
                 N-(3-(3-(4,4-difluoropiperidin-1-yl)pyrrolidin-1-yl)phenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 154 
                 N-(3-((3R,4R)-3-(dimethylamino)-4-hydroxypyrrolidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 155 
                 4-fluoro-N-(3-(4-(3-methoxyazetidin-1-yl)piperidin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 156 
                 4-fluoro-N-(3-(3-((2-methoxyethyl)(methyl)amino)pyrrolidin-1-yl)phenyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 157 
                 4-fluoro-7-methyl-N-(3-(4-(pyridin-3-ylamino)piperidin-1-yl)phenyl)-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 159 
                 4-fluoro-N-(3-fluoro-5-(3-methyl-3-morpholinopyrrolidin-1-yl)phenyl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 160 
                 4-fluoro-7-methyl-N-(3-(1-methyl-2-oxopiperidin-4-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 161 
                 N-((5-((1H-imidazol-1-yl)methyl)-3-methylpyridin-2-yl)(cyclopropyl)methyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 162 
                 N-(3-(1H-1,2,4-triazol-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 163 
                 N-(3-(8-acetyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 164 
                 4-fluoro-7-methyl-N-(3-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 165 
                 4-fluoro-7-methyl-N-(3-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)- 
               
               
                   
                 yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 166 
                 4-fluoro-7-methyl-N-(3-((7S,8aR)-3-oxooctahydroindolizin-7-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 167 
                 N-(3-(2-((dimethylamino)methyl)morpholino)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 168 
                 4-fluoro-7-methyl-N-(3-(1-methylpiperidin-4-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 169 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 170 
                 N-(3-(4-(2-cyanoacetyl)piperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 171 
                 4-fluoro-7-methyl-N-(3-(1-methyl-1H-imidazol-2-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 172 
                 4-fluoro-7-methyl-N-(3-(1-methyloctahydro-5H-pyrrolo[3,2-c]pyridin-5- 
               
               
                   
                 yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 173 
                 N-(3-(4,4-bis(methoxymethyl)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 174 
                 4-fluoro-N-(3-(3-(3-hydroxyazetidin-1-yl)pyrrolidin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 175 
                 N-(2-(1-(cyclopropylmethyl)-1H-pyrazol-4-yl)-1-(3-methylpyridin-2-yl)ethyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 176 
                 4-fluoro-7-methyl-N-(3-(4-(methylsulfonyl)piperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 177 
                 4-fluoro-7-methyl-N-(3-(5-oxopyrrolidin-3-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 178 
                 N-(3-(3-(azetidin-1-yl)pyrrolidin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 179 
                 N-(3-(2,7-diazaspiro[3.5]nonan-7-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 180 
                 4-fluoro-7-methyl-N-(3-(4-(pyrrolidin-1-yl)piperidin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 181 
                 4-fluoro-7-methyl-N-(3-(3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)- 
               
               
                   
                 yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 182 
                 4-fluoro-7-methyl-N-(3-(1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6- 
               
               
                   
                 yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 183 
                 4-fluoro-N-(3-fluoro-5-(4-methyl-3-oxo-1,4-diazepan-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 184 
                 N-(3-(2,7-diazaspiro[3.5]nonan-2-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 185 
                 N-(5-(4-acetylpiperazin-1-yl)-2-fluorophenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 186 
                 N-(3-((3R,4S)-4-(dimethylamino)-3-fluoropiperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 187 
                 N-(3-(4-(dimethylamino)piperidin-1-yl)-5-methylphenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 188 
                 N-(3-chloro-5-(4-(3-morpholinopropyl)piperidin-1-yl)phenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 189 
                 N-(3-(2,8-diazaspiro[4.5]decan-2-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 190 
                 N-(3-chloro-5-(4-(dimethylamino)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 191 
                 4-fluoro-7-methyl-N-(3-(3-methyl-2-oxoimidazolidin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 192 
                 N-(3-(4-aminopiperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 193 
                 N-(3-(4-acetyl-3-isobutylpiperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 194 
                 4-fluoro-7-methyl-N-(3-morpholinophenyl)-1H-indole-2-carboxamide 
               
               
                 195 
                 N-(3-(4-(dimethylamino)-1-hydroxycyclohexyl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 196 
                 4-fluoro-N-(3-(isoxazol-5-yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 197 
                 4-fluoro-7-methyl-N-(3-(1-methyl-1H-imidazol-5-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 198 
                 4-fluoro-N-(3-(4-methoxypiperidin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 199 
                 N-(3-(4-(cyclopropylmethyl)piperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 200 
                 4-fluoro-7-methyl-N-(3-(5-oxo-1,4-diazepan-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 201 
                 4-fluoro-N-(3-(4-isopropyl-3-oxopiperazin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 202 
                 N-(3-((3S,4R)-4-(dimethylamino)-3-methylpiperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 203 
                 N-(3-(2-((ethylamino)methyl)morpholino)phenyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 204 
                 4-fluoro-N-(3-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 205 
                 4-fluoro-N-(3-(4-isopropyl-3-methylpiperazin-1-yl)phenyl)-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 206 
                 N-(3-(2-(2,2-difluoroethyl)-2,8-diazaspiro[4.5]decan-8-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 207 
                 4-fluoro-7-methyl-N-(3-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 208 
                 N-(3-(4-(dimethylglycyl)piperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 209 
                 4-fluoro-7-methyl-N-(3-(3-oxomorpholino)phenyl)-1H-indole-2-carboxamide 
               
               
                 210 
                 4-fluoro-N-(3-(4-((2-hydroxyethyl)amino)piperidin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 211 
                 4-fluoro-7-methyl-N-((1R,3S)-3-morpholinocyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 212 
                 4-fluoro-7-methyl-N-(3-(1-methyl-1,8-diazaspiro[4.5]decan-8-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 213 
                 N-(1-((1r,4r)-4-(dimethylamino)cyclohexyl)-1H-indazol-4-yl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 214 
                 N-(3-((3R,5R)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 215 
                 4-fluoro-7-methyl-N-(3-(pyrrolo[1,2-a]pyrazin-7-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 216 
                 4-fluoro-7-methyl-N-(3-(3-methylmorpholino)phenyl)-1H-indole-2-carboxamide 
               
               
                 217 
                 N-(3-((1R,3R)-3-(dimethylamino)cyclopentyl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 218 
                 N-(3-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 219 
                 4-fluoro-N-(3-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)phenyl)-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 220 
                 4-fluoro-N-(3-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 221 
                 N-(3-(1H-imidazol-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 222 
                 N-(3-(4-(dimethylamino)-4-methylpiperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 223 
                 4-fluoro-N-(3-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 224 
                 4-fluoro-7-methyl-N-(3-(oxetan-3-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 225 
                 4-fluoro-7-methyl-N-(3-(4-(propylamino)piperidin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 226 
                 N-(3-(1-(dimethylglycyl)pyrrolidin-3-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 227 
                 N-(3-(4-(bis(2-hydroxyethyl)amino)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 228 
                 N-(4′-((1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-3-yl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 229 
                 4-fluoro-7-methyl-N-(3-(4-methyl-3-(trifluoromethyl)piperazin-1-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 230 
                 4-fluoro-N-(3-fluoro-5-(1′-methyl-2′-oxo-[1,3′-bipyrrolidin]-3-yl)phenyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 231 
                 4-fluoro-N-(4′-(2-hydroxyethoxy)-[1,1′-biphenyl]-3-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 232 
                 4-fluoro-7-methyl-N-(5-(4-methylpiperazin-1-yl)imidazo[1,5-a]pyridin-7-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 233 
                 N-(3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 234 
                 4-fluoro-7-methyl-N-(3-(4-methylpiperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 235 
                 4-fluoro-7-methyl-N-(3-(pyrazolo[1,5-a]pyridin-4-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 236 
                 N-(3-(4-cyclopropylpiperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 237 
                 4-fluoro-7-methyl-N-(3-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 238 
                 4-fluoro-7-methyl-N-(quinolin-5-yl)-1H-indole-2-carboxamide 
               
               
                 239 
                 4-fluoro-7-methyl-N-(3-(1-methyl-1H-pyrazol-5-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 240 
                 N-(3-(4-(2-aminoethoxy)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 241 
                 N-(3-(2,8-diazaspiro[4.5]decan-8-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 242 
                 N-(3-(4-acetylpiperazin-1-yl)-5-(trifluoromethyl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 243 
                 4-fluoro-N-(3-(4-isopropylpiperazin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 244 
                 4-fluoro-7-methyl-N-(3-(2-(4-methylpiperazin-1-yl)ethyl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 245 
                 4-fluoro-7-methyl-N-(3-(1-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)- 
               
               
                   
                 yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 246 
                 N-(3-(4-(3-aminopropyl)piperidin-1-yl)-5-chlorophenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 247 
                 4-fluoro-7-methyl-N-(1-(1-methylpiperidin-4-yl)-1H-indazol-4-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 248 
                 N-(3-(4-acetyl-1,4-diazepan-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 249 
                 N-(3-(1,2,4-oxadiazol-3-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 250 
                 N-(3-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)phenyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 251 
                 N-(3-(4-(dimethylamino)bicyclo[4.1.0]heptan-1-yl)phenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 252 
                 N-(3-(1H-pyrazol-4-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 253 
                 N-(3-(4-(dimethylamino)-4-(methoxymethyl)piperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 254 
                 N-(3-(4-((dimethylamino)methyl)-4-hydroxypiperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 255 
                 N-(3-(1-cyano-4-(dimethylamino)cyclohexyl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 256 
                 N-(3-(2-(dimethylamino)-2-oxoethyl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 257 
                 N-(3-(6-acetyl-3,6-diazabicyclo[3.1.1]heptan-3-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 258 
                 4-fluoro-7-methyl-N-(1-(3-methyl-5-(2-(4-methylpiperazin-1-yl)ethyl)pyridin-2- 
               
               
                   
                 yl)-2-phenylethyl)-1H-indole-2-carboxamide 
               
               
                 259 
                 N-(3-(8-(2,2-difluoroethyl)-2,8-diazaspiro[4.5]decan-2-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 260 
                 tert-butyl 4-(3-(4-fluoro-7-methyl-1H-indole-2-carboxamido)phenyl)piperazine- 
               
               
                   
                 1-carboxylate 
               
               
                 261 
                 4-fluoro-7-methyl-N-(3-(oxazol-2-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 262 
                 4-fluoro-N-(3-(4-methoxy-4-methylpiperidin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 263 
                 N-(3′-acetamido-[1,1′-biphenyl]-3-yl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 264 
                 N-(3-((1S,3S)-3-(dimethylamino)cyclopentyl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 265 
                 4-fluoro-N-(3-(3-(hydroxymethyl)morpholino)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 266 
                 N-(3′-((dimethylamino)methyl)-[1,1′-biphenyl]-3-yl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 267 
                 N-(3-(1-acetyl-4-carbamoylpiperidin-4-yl)-5-fluorophenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 268 
                 4-fluoro-N-(3-(4-hydroxy-1′-methyl-[4,4′-bipiperidin]-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 269 
                 N-(cyclopropyl(4-methoxy-3-methylpyridin-2-yl)methyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 270 
                 4-fluoro-7-methyl-N-(4-methyl-3-(4-methylpiperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 271 
                 N-(3-(4-acetylpiperazin-1-yl)-5-fluorophenyl)-4-fluoro-1H-indole-2-carboxamide 
               
               
                 272 
                 4-fluoro-N-(3-(imidazo[1,2-a]pyridin-5-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 273 
                 N-(cyclopropyl(3-methyl-5-((2-oxo-2,3-dihydro-1H-imidazol-1- 
               
               
                   
                 yl)methyl)pyridin-2-yl)methyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 274 
                 N-(3-(4-(dimethylamino)piperidin-1-yl)-5-(fluoromethyl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 275 
                 N-(3-chloro-5-(4-(3-morpholinopropyl)piperidin-1-yl)phenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 276 
                 N-(3-(3-((dimethylamino)methyl)-1H-1,2,4-triazol-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 277 
                 4-fluoro-N-(3-(2-(hydroxymethyl)-4-methylpiperazin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 278 
                 4-fluoro-N-(3-(imidazo[1,5-a]pyridin-6-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 279 
                 4-fluoro-7-methyl-N-(3-(4-methyl-1,4-diazepan-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 280 
                 4-fluoro-N-(3-(4-isopropyl-2-methylpiperazin-1-yl)phenyl)-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 281 
                 N-(3-(4H-1,2,4-triazol-4-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 282 
                 N-(3-(3-(dimethylamino)cyclopentyl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 283 
                 4-fluoro-7-methyl-N-(3-(pyrrolidin-3-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 284 
                 N-(3-(2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 285 
                 4-fluoro-7-methyl-N-(3-(pyridin-2-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 286 
                 4-fluoro-N-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 287 
                 N-(3-(4-oxa-7-azaspiro[2.5]octan-7-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 288 
                 4-fluoro-7-methyl-N-(3-(4-(methylamino)-4-oxobutyl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 289 
                 N-(3-(2,5-dimethylmorpholino)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 290 
                 4-fluoro-7-methyl-N-(3-(pyrazolo[1,5-a]pyridin-3-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 291 
                 N-(3-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 292 
                 N-(3-(5-acetyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 293 
                 4-fluoro-7-methyl-N-(3-(3-(methylamino)-3-oxopropyl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 294 
                 4-fluoro-7-methyl-N-(3-(1-methyloctahydro-1H-indol-5-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 295 
                 N-(2-(4-acetylpiperazin-1-yl)pyrimidin-4-yl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 296 
                 N-(3-(1,2,4-oxadiazol-5-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 297 
                 4-fluoro-7-methyl-N-(3-(piperidin-1-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 298 
                 N-(3-((3S,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 299 
                 4-fluoro-N-(3-(imidazo[1,5-a]pyridin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 300 
                 N-(3-(2-amino-2-oxoethyl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 301 
                 N-(3-((3S,4R)-4-(dimethylamino)-3-fluoropiperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 302 
                 N-(3-((1R,3S)-3-(dimethylamino)cyclopentyl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 303 
                 N-(3-((2S,4R)-4-(dimethylamino)-2-methylpiperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 304 
                 N-(3-(4H-1,2,4-triazol-3-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 305 
                 4-fluoro-7-methyl-N-(5-(3-(N-methylacetamido)piperidin-1-yl)tetrahydro-2H- 
               
               
                   
                 pyran-3-yl)-1H-indole-2-carboxamide 
               
               
                 306 
                 N-(3-(3-cyclopropylmorpholino)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 307 
                 4-fluoro-7-methyl-N-(3-(morpholin-3-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 308 
                 N-(3-((2R,4R)-4-(dimethylamino)-2-methylpiperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 309 
                 N-((5-((1H-imidazol-1-yl)methyl)-3-methylpyridin-2-yl)(cyclopropyl)methyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 310 
                 N-(3-(3-aminopiperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 311 
                 N-(3-(difluoromethyl)-5-(4-(dimethylamino)piperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 312 
                 4-fluoro-7-methyl-N-(3-(4-phenylpiperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 313 
                 N-(3-((1r,4r)-4-(dimethylamino)cyclohexyl)-5-fluorophenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 314 
                 4-fluoro-7-methyl-N-(3-(pyrrolidine-2-carboxamido)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 315 
                 ″″″4-fluoro-N-(3-(2-hydroxypropan-2-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 316 
                 4-fluoro-7-methyl-N-(3-(pyrimidin-2-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 317 
                 N-(cyclopropyl(5-((2,4-dimethyl-1H-imidazol-1-yl)methyl)-3-methylpyridin-2- 
               
               
                   
                 yl)methyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 318 
                 N-(3-(2,4-dimethylpiperazin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 319 
                 N-(3-(5-amino-1,3,4-oxadiazol-2-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 320 
                 4-fluoro-7-methyl-N-(2-methyl-3-(4-methylpiperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 321 
                 4-fluoro-7-methyl-N-(3-(2-oxopiperazin-1-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 322 
                 N-(3-(1H-pyrazol-5-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 323 
                 N-(3-(2-(dimethylamino)ethoxy)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 324 
                 N-(3-((1S,3R)-3-(dimethylamino)cyclopentyl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 325 
                 4-fluoro-7-methyl-N-(3-(methyl(piperidin-4-yl)amino)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 326 
                 4-fluoro-7-methyl-N-(3-(6-(methylamino)pyridin-2-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 327 
                 4-fluoro-7-methyl-N-(2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 328 
                 N-(3-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 329 
                 N-(3-(dimethylcarbamoyl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 330 
                 4-fluoro-7-methyl-N-(3-((1-methylpyrrolidin-3-yl)amino)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 331 
                 4-fluoro-N-(3-(3-(2-hydroxyethyl)morpholino)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 332 
                 4-fluoro-7-methyl-N-(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 333 
                 N-(3-chloro-5-(morpholinomethyl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 334 
                 4-fluoro-7-methyl-N-(1-(3-methylpyridin-2-yl)-4-morpholino-4-oxobutyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 335 
                 N-(3-(3-(dimethylamino)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 336 
                 4-fluoro-N-(3-(4-isopropylpiperidin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 337 
                 N-(3-(1H-imidazol-4-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 338 
                 4-fluoro-7-methyl-N-(8-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-6-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 339 
                 N-(3-chloro-5-((1r,4r)-4-(dimethylamino)cyclohexyl)phenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 340 
                 4-fluoro-7-methyl-N-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 341 
                 4-fluoro-N-(3-(2-hydroxyethyl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 342 
                 4-fluoro-7-methyl-N-(3-(methyl(1-methylpyrrolidin-3-yl)amino)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 343 
                 N-(3-((1s,4s)-4-(dimethylamino)cyclohexyl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 344 
                 4-fluoro-7-methyl-N-(6-(4-methylpiperazin-1-yl)pyridin-2-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 345 
                 N-(3-cyano-5-(4-(dimethylamino)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 346 
                 4-fluoro-N-(4′-(hydroxymethyl)-[1,1′-biphenyl]-3-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 347 
                 N-(3-(3-(4-aminopiperidin-1-yl)pyrrolidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 348 
                 4-fluoro-7-methyl-N-(3-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 349 
                 4-fluoro-7-methyl-N-(3-(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 350 
                 4-fluoro-7-methyl-N-(8-(4-methylpiperazin-1-yl)quinolin-6-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 351 
                 4-fluoro-7-methyl-N-(3-(methyl(1-methylpiperidin-4-yl)amino)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 352 
                 4-fluoro-7-methyl-N-(3-((1-methylpiperidin-3-yl)methyl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 353 
                 4-fluoro-N-(3-fluoro-5-((1r,4r)-4-morpholinocyclohexyl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 354 
                 4-fluoro-7-methyl-N-(3-(pyrazolo[1,5-a]pyridin-2-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 355 
                 4-fluoro-7-methyl-N-(5-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-7-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 356 
                 N-(2-(1-(cyclopropylmethyl)-1H-imidazol-4-yl)-1-(3-methylpyridin-2-yl)ethyl)- 
               
               
                   
                 4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 357 
                 N-(3-((1H-imidazol-2-yl)methyl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 358 
                 4-fluoro-7-methyl-N-(1-(3-methylpyridin-2-yl)-2-(4- 
               
               
                   
                 (morpholinomethyl)phenyl)ethyl)-1H-indole-2-carboxamide 
               
               
                 359 
                 N-((1S,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 360 
                 N-(5-(4-acetylpiperazin-1-yl)-1-methylpiperidin-3-yl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 361 
                 4-fluoro-7-methyl-N-(8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepin-9-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 362 
                 N-((1S,3S)-3-(1,4-oxazepan-4-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 363 
                 N-(5-(4-acetylpiperazin-1-yl)tetrahydro-2H-pyran-3-yl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 364 
                 4-fluoro-7-methyl-N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 365 
                 N-(3-(3-acetyl-3,6-diazabicyclo[3.1.1]heptan-6-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 366 
                 N-(1′-acetyl-[1,4′-bipiperidin]-3-yl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 367 
                 4-fluoro-7-methyl-N-(1′-methyl-2′-oxo-[1,4′-bipiperidin]-3-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 368 
                 4-fluoro-7-methyl-N-(5-(pyrimidin-5-yl)tetrahydro-2H-pyran-3-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 369 
                 4-fluoro-7-methyl-N-((1S,3S)-3-(pyrimidin-5-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 370 
                 4-fluoro-7-methyl-N-((1S,3S)-3-(4-methyl-3-oxo-1,4-diazepan-1-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 371 
                 4-fluoro-7-methyl-N-(5-(1-methylpiperidin-4-yl)-1H-imidazol-2-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 372 
                 N-((1R,3R)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 373 
                 N-((1S,3R)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 374 
                 4-fluoro-7-methyl-N-(3-morpholinocyclohexyl)-1H-indole-2-carboxamide 
               
               
                 375 
                 N-(3-(4-(dimethylamino)-4-(trifluoromethyl)piperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 376 
                 N-(3-(4-acetylpiperazin-1-yl)cyclopentyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 377 
                 N-(1-(2-(dimethylamino)-2-oxoethyl)piperidin-3-yl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 378 
                 N-(1-(3-(dimethylamino)-3-oxopropyl)piperidin-3-yl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 379 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(pyrimidin-5-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 380 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(pyrimidin-5-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 381 
                 4-fluoro-7-methyl-N-((1R,3R)-3-morpholinocyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 382 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 383 
                 N-(4-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 384 
                 4-fluoro-7-methyl-N-(1-(2-(methylamino)-2-oxoethyl)piperidin-3-yl)-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 385 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-(N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 386 
                 4-fluoro-7-methyl-N-(1-(3-(methylamino)-3-oxopropyl)piperidin-3-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 387 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-methyl-3-oxo-1,4-diazepan-1-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 388 
                 N-((1R,3R)-3-(1,4-oxazepan-4-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 389 
                 4-fluoro-7-methyl-N-(1-(3-(N-methylacetamido)propyl)piperidin-3-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 390 
                 4-fluoro-7-methyl-N-(3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1- 
               
               
                   
                 yl)-1H-indole-2-carboxamide 
               
               
                 391 
                 4-fluoro-7-methyl-N-(3-(4-methylpiperazin-1-yl)-2H-indazol-7-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 392 
                 4-fluoro-7-methyl-N-((1-(2-(4-methylpiperazin-1-yl)phenyl)cyclopropyl)methyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 393 
                 7-methyl-N-(3-morpholinophenyl)-1H-indole-2-carboxamide 
               
               
                 394 
                 4-fluoro-7-methyl-N-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 395 
                 N-(3-(1-aminocyclopropyl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 396 
                 N-(3-(4-glycylpiperazin-1-yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 397 
                 N-(3-(5-amino-1H-pyrazol-4-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 398 
                 N-(3-(4-(dimethylamino)piperidin-1-yl)-5-ethylphenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 399 
                 4-fluoro-7-methyl-N-(3-(methylsulfonyl)phenyl)-1H-indole-2-carboxamide 
               
               
                 400 
                 N-(cyclopropyl(3-methylimidazo[1,2-a]pyridin-2-yl)methyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 401 
                 4-fluoro-7-methyl-N-(8-(4-methylpiperazin-1-yl)isoquinolin-6-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 402 
                 N-(cyclopropyl(5-methyl-6′-(morpholinomethyl)-[3,3′-bipyridin]-6-yl)methyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 403 
                 4-fluoro-7-methyl-N-(5,6,7,8-tetrahydroisoquinolin-5-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 404 
                 N-(cyclopropyl(3-methyl-5-(pyrimidin-2-yl)pyridin-2-yl)methyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 405 
                 N-(3-(4-((2-(diethylamino)ethyl)sulfonyl)piperazin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 406 
                 N-(cyclopropyl(5-methyl-[3,3′-bipyridin]-6-yl)methyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 407 
                 4-fluoro-7-methyl-N-(2-methyl-5-(4-methylpiperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 408 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)-2-phenylethyl)-1H-indole-2-carboxamide 
               
               
                 409 
                 4-fluoro-7-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)isoquinolin-6-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 410 
                 4-fluoro-7-methyl-N-(5-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 411 
                 4-fluoro-7-methyl-N-(3-(3-methyl-2-oxo-3,8-diazabicyclo[3.2.1]octan-8- 
               
               
                   
                 yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 412 
                 N-(cyclopropyl(3-methyl-5-((1-methylpiperidin-4-yl)carbamoyl)pyridin-2- 
               
               
                   
                 yl)methyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 413 
                 N-(3-(4-((2-aminoethyl)amino)piperidin-1-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 414 
                 4-fluoro-7-methyl-N-(1-(3-methyl-5-(2-(4-methylpiperazin-1-yl)ethyl)pyridin-2- 
               
               
                   
                 yl)-3-phenylpropyl)-1H-indole-2-carboxamide 
               
               
                 415 
                 N-(3-(4-(dimethylamino)piperidin-1-yl)-2H-indazol-7-yl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 416 
                 4-fluoro-7-methyl-N-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 417 
                 4-fluoro-7-methyl-N-(3-(4-(1-phenylethyl)piperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 418 
                 N-(3-(2-aminoethyl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 419 
                 N-((3-chloropyridin-2-yl)(cyclopropyl)methyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 420 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)-4-morpholino-4-oxobutyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 421 
                 4-fluoro-7-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 422 
                 N-(3-(3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 423 
                 N-(cyclopropyl(3-methyl-5-(4-(2-(pyridin-3-yl)acetamido)cyclohexyl)pyridin-2- 
               
               
                   
                 yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 424 
                 N-(cyclopropyl(3-methylpyrazolo[1,5-a]pyridin-2-yl)methyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 425 
                 4-fluoro-7-methyl-N-(3-(pyrrolidin-2-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 426 
                 N-((6′-amino-5-methyl-[3,3′-bipyridin]-6-yl)(cyclopropyl)methyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 427 
                 N-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 428 
                 N-(3-(1H-imidazol-2-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 429 
                 N-(3-(4-((4-aminocyclohexyl)sulfonyl)piperazin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 430 
                 N-(cyclopropyl(5-(2-hydroxy-3-((pyridin-3-ylmethyl)amino)propoxy)-3- 
               
               
                   
                 methylpyridin-2-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 431 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)-4-morpholino-4-oxobutyl)-4-vinyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 432 
                 N-((4-cyano-3-methylpyridin-2-yl)(cyclopropyl)methyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 433 
                 N-(3-(4-(((1H-imidazol-5-yl)methyl)amino)piperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 434 
                 N-(4-(4-hydroxypiperidin-1-yl)-1-(3-methylpyridin-2-yl)-4-oxobutyl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 435 
                 N-(cyclopropyl(3-methyl-5-(2-(4-methylpiperazin-1-yl)ethyl)pyridin-2- 
               
               
                   
                 yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 436 
                 N-(3-(8-(dimethylamino)-3-azabicyclo[3.2.1]octan-3-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 437 
                 N-(isoquinolin-6-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 438 
                 4-fluoro-7-methyl-N-(3-(piperidin-2-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 439 
                 N-(3-(4-(2-aminoacetamido)piperidin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 440 
                 N-(cyclopropyl(3-methyl-5-(4-(3-(pyridin-3-yl)propyl)piperazin-1-yl)pyridin-2- 
               
               
                   
                 yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 441 
                 N-(cyclopropyl(3-methyl-5-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)pyridin-2- 
               
               
                   
                 yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 442 
                 7-methyl-N-(2-methyl-5-(morpholinomethyl)phenyl)-1H-indole-2-carboxamide 
               
               
                 443 
                 N-(6-(4-((2-aminoethyl)sulfonyl)piperazin-1-yl)pyridin-2-yl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 444 
                 N-(3-(5-amino-1H-pyrazol-3-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 445 
                 N-((5-(1H-imidazol-2-yl)-3-methylpyridin-2-yl)(cyclopropyl)methyl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 446 
                 N-(4-(dimethylamino)-1-(3-methylpyridin-2-yl)-4-oxobutyl)-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 447 
                 N-(cyclopropyl(3-methyl-5-(2-(2-(pyridin-3-yl)acetamido)ethyl)pyridin-2- 
               
               
                   
                 yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 448 
                 7-methyl-N-(7-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 449 
                 N-(3-(4-((2-aminoethyl)sulfonyl)piperazin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 450 
                 N-(cyclopropyl(4-methylpyridazin-3-yl)methyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 451 
                 N-((5-(((1S,2R)-2-aminocyclobutyl)carbamoyl)-3-methylpyridin-2- 
               
               
                   
                 yl)(cyclopropyl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 452 
                 N-(3-(4-((2-aminoethyl)amino)piperidin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 453 
                 7-methyl-N-(7-((4-methylpiperazin-1-yl)methyl)naphthalen-2-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 454 
                 4-fluoro-7-methyl-N-(3-sulfamoylphenyl)-1H-indole-2-carboxamide 
               
               
                 455 
                 N-((5-(((1R,2R)-2-aminocyclobutyl)carbamoyl)-3-methylpyridin-2- 
               
               
                   
                 yl)(cyclopropyl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 456 
                 7-methyl-N-(4-methyl-3-(morpholinomethyl)phenyl)-1H-indole-2-carboxamide 
               
               
                 457 
                 7-methyl-N-((1-(2-morpholinophenyl)cyclopropyl)methyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 458 
                 4-fluoro-7-methyl-N-(3-oxo-1,2,3,4-tetrahydroisoquinolin-4-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 459 
                 N-(imidazo[1,2-a]pyridin-6-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 460 
                 N-(4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)-1-(3-methylpyridin-2-yl)-4- 
               
               
                   
                 oxobutyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 461 
                 N-(cyclopropyl(5-(2-hydroxy-3-((3-methoxybenzyl)amino)propoxy)-3- 
               
               
                   
                 methylpyridin-2-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 462 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 463 
                 (R)-N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 464 
                 7-ethyl-N-(1-(3-methylpyridin-2-yl)-4-morpholino-4-oxobutyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 465 
                 7-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)isoquinolin-6-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 466 
                 7-methyl-N-(quinazolin-7-yl)-1H-indole-2-carboxamide 
               
               
                 467 
                 N-(3-(4-(2-aminoethyl)piperazin-1-yl)phenyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 468 
                 N-(3-(3-((dimethylamino)methyl)morpholino)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 469 
                 7-methyl-N-(2-methyl-5-(4-methylpiperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 470 
                 N-(cyclopropyl(3-methyl-5-((1-methylpiperidin-4-yl)carbamoyl)pyridin-2- 
               
               
                   
                 yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 471 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)propyl)-1H-indole-2-carboxamide 
               
               
                 472 
                 N-(cyclopropyl(3-methylquinolin-2-yl)methyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 473 
                 7-methyl-N-(2-(piperidin-4-ylamino)quinazolin-6-yl)-1H-indole-2-carboxamide 
               
               
                 474 
                 7-methyl-N-(2-methyl-1-(3-methylpyridin-2-yl)propyl)-1H-indole-2-carboxamide 
               
               
                 475 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 476 
                 N-(5-(4-((2-aminoethyl)sulfonyl)piperazin-1-yl)-2-methylphenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 477 
                 N-(cyclopropyl(3-methyl-5-((4-methylpiperazin-1-yl)methyl)pyridin-2- 
               
               
                   
                 yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 478 
                 7-methyl-N-(3-(morpholinomethyl)phenyl)-1H-indole-2-carboxamide 
               
               
                 479 
                 7-methyl-N-phenyl-1H-indole-2-carboxamide 
               
               
                 480 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)ethyl)-1H-indole-2-carboxamide 
               
               
                 481 
                 N-(cyclopropyl(7-methylimidazo[1,2-b]pyridazin-6-yl)methyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 482 
                 7-methyl-N-(2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 483 
                 7-methyl-N-(2-(2-morpholinophenyl)propyl)-1H-indole-2-carboxamide 
               
               
                 484 
                 N-(imidazo[1,2-a]pyrimidin-6-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 485 
                 4-ethyl-7-methyl-N-(1-(3-methylpyridin-2-yl)-4-morpholino-4-oxobutyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 486 
                 N-(3-((diethylamino)methyl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 487 
                 7-methyl-N-(7-(morpholinomethyl)naphthalen-2-yl)-1H-indole-2-carboxamide 
               
               
                 488 
                 7-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 489 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)-2-morpholinoethyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 490 
                 7-methyl-N-(2-methyl-5-morpholinophenyl)-1H-indole-2-carboxamide 
               
               
                 491 
                 N-(2-(dimethylamino)-2-oxo-1-(pyridin-2-yl)ethyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 492 
                 N-(cyclopropyl(2-hydroxy-6-methylphenyl)methyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 493 
                 N-(cyclopropyl(5-methylpyrimidin-4-yl)methyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 494 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)-5-morpholino-5-oxopentyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 495 
                 N-(3-((dimethylamino)methyl)-5-methylimidazo[1,2-a]pyridin-6-yl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 496 
                 N-((5-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-3-methylpyridin-2- 
               
               
                   
                 yl)(cyclopropyl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 497 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-5-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 498 
                 4-fluoro-7-methyl-N-(5,6,7,8-tetrahydroquinolin-8-yl)-1H-indole-2-carboxamide 
               
               
                 499 
                 N-(2-(4-acetylpiperazin-1-yl)benzyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 500 
                 N-(2-cyclopropyl-1-(3-methylpyridin-2-yl)ethyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 501 
                 N-(3-(2-amino-1H-imidazol-4-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 502 
                 N-(3-(5-aminoisoxazol-3-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 503 
                 N-(2-amino-2-oxo-1-(pyridin-2-yl)ethyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 504 
                 7-methyl-N-((1r,4r)-4-methylcyclohexyl)-1H-indole-2-carboxamide 
               
               
                 505 
                 7-methyl-N-(tetrahydro-2H-pyran-4-yl)-1H-indole-2-carboxamide 
               
               
                 506 
                 N-(cyclopropyl(3-methyl-6-oxo-1,6-dihydropyridin-2-yl)methyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 507 
                 N-(cyclopropyl(isoquinolin-1-yl)methyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 508 
                 7-methyl-N-((2-morpholinocyclohexyl)methyl)-1H-indole-2-carboxamide 
               
               
                 509 
                 N-(3-(4-acetylpiperazin-1-yl)phenyl)-7-cyclopropyl-1H-indole-2-carboxamide 
               
               
                 510 
                 N-(cyclopropyl(3-methyl-5-(pyrrolidin-3-ylcarbamoyl)pyridin-2-yl)methyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 511 
                 7-methyl-N-(2-morpholinophenethyl)-1H-indole-2-carboxamide 
               
               
                 512 
                 N-((1r,4r)-4-acetamidocyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 513 
                 N-(cyclobutyl(3-methylpyridin-2-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 514 
                 4-methoxy-7-methyl-N-(1-(3-methylpyridin-2-yl)-4-morpholino-4-oxobutyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 515 
                 7-methoxy-N-(1-(3-methylpyridin-2-yl)-4-morpholino-4-oxobutyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 516 
                 N-((5-(((1R,3R)-3-aminocyclopentyl)carbamoyl)-3-methylpyridin-2- 
               
               
                   
                 yl)(cyclopropyl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 517 
                 4-fluoro-7-methyl-N-(2-oxo-2-(phenylamino)-1-(pyridin-2-yl)ethyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 518 
                 N-(cyclopropyl(3-methylpyrazin-2-yl)methyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 519 
                 4-fluoro-7-methyl-N-(5-(1-methylpiperidin-4-yl)-1,3,4-thiadiazol-2-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 520 
                 7-methyl-N-(2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-4-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 521 
                 N-(cyclopropyl(3-ethylpyridin-2-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 522 
                 N-cyclohexyl-7-methyl-1H-indole-2-carboxamide 
               
               
                 523 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)-4-oxo-4-(pyridin-3-ylamino)butyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 524 
                 N-(3-(5-amino-1H-1,2,4-triazol-3-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 525 
                 methyl (R)-3-(4-bromophenyl)-3-(7-methyl-1H-indole-2- 
               
               
                   
                 carboxamido)propanoate 
               
               
                 526 
                 7-methyl-N-(naphthalen-2-yl)-1H-indole-2-carboxamide 
               
               
                 527 
                 methyl (R)-3-(4-cyanophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 528 
                 7-methyl-N-(2-(pyrrolidin-1-yl)benzyl)-1H-indole-2-carboxamide 
               
               
                 529 
                 N-(cyclopropyl(3,6-dimethyl-5-((1-methylpiperidin-4-yl)carbamoyl)pyridin-2- 
               
               
                   
                 yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 530 
                 N-(3-(4-amino-[1,4′-bipiperidin]-1′-yl)phenyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 531 
                 N-(6-(4-((2-aminoethyl)amino)piperidin-1-yl)pyridin-2-yl)-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 532 
                 4-fluoro-7-methyl-N-(3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 533 
                 7-methyl-N-(quinazolin-6-yl)-1H-indole-2-carboxamide 
               
               
                 534 
                 4-fluoro-7-methyl-N-(quinazolin-8-yl)-1H-indole-2-carboxamide 
               
               
                 535 
                 N-((5-(azetidin-3-ylcarbamoyl)-3-methylpyridin-2-yl)(cyclopropyl)methyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 536 
                 N-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 537 
                 N-(6-(diethylamino)-5,6,7,8-tetrahydronaphthalen-2-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 538 
                 7-methyl-N-(4-oxo-3,4-dihydroquinazolin-6-yl)-1H-indole-2-carboxamide 
               
               
                 539 
                 4-fluoro-7-methyl-N-(3-(4-methyl-2-phenylpiperazin-1-yl)phenyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 540 
                 4-fluoro-7-methyl-N-(2-(4-methylpiperazin-1-yl)phenethyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 541 
                 7-methyl-N-(2-(piperazin-1-ylmethyl)quinazolin-6-yl)-1H-indole-2-carboxamide 
               
               
                 542 
                 2-(6-(cyclopropyl(4-fluoro-7-methyl-1H-indole-2-carboxamido)methyl)-5- 
               
               
                   
                 methylpyridin-3-yl)acetic acid 
               
               
                 543 
                 N-((3R,4S)-1-(4-aminobutanoyl)-3-methylpiperidin-4-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 544 
                 6-(cyclopropyl(4-fluoro-7-methyl-1H-indole-2-carboxamido)methyl)-5- 
               
               
                   
                 methylnicotinic acid 
               
               
                 545 
                 4-fluoro-7-methyl-N-(3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 546 
                 N-(2-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 547 
                 N-(3-(2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)phenyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 548 
                 4-fluoro-7-methyl-N-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-3-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 549 
                 N-(2-(4-(2-(dimethylamino)ethyl)piperidin-1-yl)phenethyl)-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 550 
                 N-(2-(benzylamino)-2-oxo-1-(pyridin-2-yl)ethyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 551 
                 N-(3-((dimethylamino)methyl)-7-methylimidazo[1,2-a]pyridin-6-yl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 552 
                 N-((1R,3s,5S)-8-(4-aminobutanoyl)-8-azabicyclo[3.2.1]octan-3-yl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 553 
                 N-((1r,4r)-4-(3-aminopropanamido)cyclohexyl)-7-bromo-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 554 
                 7-methyl-N-(2-(4-methylpiperazin-1-yl)benzyl)-1H-indole-2-carboxamide 
               
               
                 555 
                 N-(3-(4-cyclopropyl-3,4-dihydroquinoxalin-1(2H)-yl)phenyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 556 
                 methyl 3-(2-fluorophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 557 
                 4-fluoro-7-methyl-N-(5-(1-methylpiperidin-4-yl)-1,3,4-oxadiazol-2-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 558 
                 4-fluoro-7-methyl-N-(5-(1-methylpiperidin-4-yl)-1H-pyrazol-3-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 559 
                 4-fluoro-7-methyl-N-(5-(1-methylpiperidin-4-yl)-4H-1,2,4-triazol-3-yl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 560 
                 4-fluoro-7-methyl-N-(2-morpholino-2-oxo-1-(pyridin-2-yl)ethyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 561 
                 4-fluoro-7-methyl-N-(1-(1-methylpiperidin-4-yl)-1H-imidazol-4-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 562 
                 4-fluoro-7-methyl-N-(2-(1-methylpiperidin-4-yl)-1H-imidazol-5-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 563 
                 N-(cyclopentyl(3-methylpyridin-2-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 564 
                 N-(cyclopropyl(2-oxoindolin-7-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 565 
                 N-(1-(4-(dimethylamino)cyclohexyl)-1H-pyrazol-4-yl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 566 
                 N-(2-(2-((dimethylamino)methyl)morpholino)phenethyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 567 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)-4-(piperazin-1-yl)butyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 568 
                 N-(2,2-dimethyl-1-(3-methylpyridin-2-yl)propyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 569 
                 4-fluoro-7-methyl-N-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 570 
                 7-methyl-N-(pyrazolo[1,5-a]pyridin-7-ylmethyl)-1H-indole-2-carboxamide 
               
               
                 571 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)-4-oxo-4-((tetrahydrofuran-3- 
               
               
                   
                 yl)amino)butyl)-1H-indole-2-carboxamide 
               
               
                 572 
                 7-methyl-N-(1-(3-methylpyridin-2-yl)-4-oxo-4-(piperazin-1-yl)butyl)-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 573 
                 N-((5-(((1S,2S)-2-aminocyclobutyl)carbamoyl)-3-methylpyridin-2- 
               
               
                   
                 yl)(cyclopropyl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 574 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-(hydroxymethyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 575 
                 7-methyl-N-(2-morpholinobenzyl)-1H-indole-2-carboxamide 
               
               
                 576 
                 2-(cyclopropyl(7-methyl-1H-indole-2-carboxamido)methyl)-3-methylpyridine 1- 
               
               
                   
                 oxide 
               
               
                 577 
                 N-(cyclopropyl(2-methyl-4-(piperazine-1-carbonyl)phenyl)methyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 578 
                 N-(imidazo[1,2-a]pyridin-7-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 579 
                 N-(4-((4-aminocyclohexyl)amino)-1-(3-methylpyridin-2-yl)-4-oxobutyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 580 
                 N-(2-(1H-imidazol-1-yl)phenethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 581 
                 N-((1r,4r)-4-((3-aminopropyl)sulfonamido)cyclohexyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 582 
                 N-(4-(diethylamino)-1-(3-methylpyridin-2-yl)butyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 583 
                 N-(cyclopropyl(2-methyl-5-(piperazine-1-carbonyl)phenyl)methyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 584 
                 N-((5-(((1R,2S)-2-aminocyclobutyl)carbamoyl)-3-methylpyridin-2- 
               
               
                   
                 yl)(cyclopropyl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 585 
                 4-fluoro-7-methyl-N-(2-(methylamino)-2-oxo-1-(pyridin-2-yl)ethyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 586 
                 ethyl 3-(7-methyl-1H-indole-2-carboxamido)-3-phenylpropanoate 
               
               
                 587 
                 7-methyl-N-((1r,4r)-4-(3-(piperidin-1-yl)propanamido)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 588 
                 N-((3S,4R)-1-(4-aminobutanoyl)-3-methylpiperidin-4-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 589 
                 N-((1r,4r)-4-(3-(diethylamino)propanamido)cyclohexyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 590 
                 N-((3R,4R)-1-(4-aminobutanoyl)-3-methylpiperidin-4-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 591 
                 7-methyl-N-(3-(3-methylpyridin-2-yl)azetidin-3-yl)-1H-indole-2-carboxamide 
               
               
                 592 
                 N-((1s,4s)-4-(3-aminopropanamido)cyclohexyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 593 
                 N-(1-(4-aminobutanoyl)pyrrolidin-3-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 594 
                 N-(1-(4-aminobutanoyl)azetidin-3-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 595 
                 7-methyl-N-(2-(3-methylpyridin-2-yl)propan-2-yl)-1H-indole-2-carboxamide 
               
               
                 596 
                 N-((1s,3s)-3-(3-aminopropanamido)cyclobutyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 597 
                 N-((1r,3r)-3-(3-aminopropanamido)cyclobutyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 598 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-methyl-1H-pyrrolo[2,3- 
               
               
                   
                 c]pyridine-2-carboxamide 
               
               
                 599 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-methyl-1H-pyrrolo[3,2- 
               
               
                   
                 b]pyridine-2-carboxamide 
               
               
                 600 
                 N-(3-(3-aminopropanamido)cyclopentyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 601 
                 N,7-dimethyl-N-(1-(3-methylpyridin-2-yl)-2-morpholinoethyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 602 
                 N-((5-(aminomethyl)-3-methylisoxazol-4-yl)(cyclopropyl)methyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 603 
                 N-(2-(dimethylamino)-1-(pyridin-3-yl)ethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 604 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)pyrazolo[1,5-a]pyrimidine-2- 
               
               
                   
                 carboxamide 
               
               
                 605 
                 7-methyl-N-((1r,4r)-4-(2-(pyridin-3-yl)acetamido)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 606 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-4-(hydroxymethyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 607 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-methylindoline-2-carboxamide 
               
               
                 608 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-methyl-1H-pyrrolo[3,2- 
               
               
                   
                 c]pyridine-2-carboxamide 
               
               
                 609 
                 4-fluoro-7-methyl-N-(quinolin-8-yl)-1H-indole-2-carboxamide 
               
               
                 612 
                 4-fluoro-7-methyl-N-(4-(4-methylpiperazin-1-yl)pyridin-2-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 613 
                 (S)-N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 614 
                 N-((3S,4S)-1-(4-aminobutanoyl)-3-methylpiperidin-4-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 615 
                 N-(cyclopropyl(6-((dimethylamino)methyl)pyridin-2-yl)methyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 616 
                 (R)-N-(2-hydroxy-1-phenylethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 617 
                 7-methyl-N-(2-oxo-6-phenylazepan-4-yl)-1H-indole-2-carboxamide 
               
               
                 618 
                 7-((1H-pyrazol-5-yl)methyl)-N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 619 
                 (2,3-dihydrospiro[indene-1,2′-pyrrolidin]-1′-yl)(7-methyl-1H-indol-2- 
               
               
                   
                 yl)methanone 
               
               
                 620 
                 7-methyl-N-(1-oxo-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 622 
                 N-(5-chloro-2-morpholinophenethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 623 
                 N-(imidazo[1,2-a]pyrazin-6-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 624 
                 7-methyl-N-(2-methyl-3-(morpholinomethyl)phenyl)-1H-indole-2-carboxamide 
               
               
                 625 
                 N-((1S,4S,5S)-2-(4-aminobutanoyl)-2-azabicyclo[2.2.2]octan-5-yl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 626 
                 7-methyl-N-(1-(pyrimidin-2-yl)piperidin-3-yl)-1H-indole-2-carboxamide 
               
               
                 627 
                 N-(2-(dimethylamino)-1-(3-methylpyridin-2-yl)ethyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 628 
                 ethyl 4-(7-methyl-1H-indole-2-carboxamido)piperidine-1-carboxylate 
               
               
                 629 
                 N-((1r,4r)-4-(3-aminopropanamido)-4-methylcyclohexyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 630 
                 ethyl 3-cyclobutyl-2-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 631 
                 N-((1R,4R,5S)-2-(3-aminopropanoyl)-2-azabicyclo[2.2.2]octan-5-yl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 632 
                 7-methyl-N-(pyridin-4-yl)-1H-indole-2-carboxamide 
               
               
                 633 
                 7-methyl-N-(6-(morpholinomethyl)pyridin-2-yl)-1H-indole-2-carboxamide 
               
               
                 634 
                 methyl (R)-3-(3-chlorophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 635 
                 N-(2-(2′-(aminomethyl)-[1,1′-biphenyl]-2-yl)ethyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 636 
                 7-methyl-N-(2-(piperazin-1-yl)benzyl)-1H-indole-2-carboxamide 
               
               
                 637 
                 N-(di(pyridin-2-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 638 
                 N-(2-(dimethylamino)benzyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 639 
                 N-(1-(4-aminobutanoyl)piperidin-4-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 640 
                 N-(8-(3-aminopropanamido)bicyclo[3.2.1]octan-3-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 641 
                 N-((1s,4s)-4-(3-aminopropanamido)-4-methylcyclohexyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 642 
                 7-methyl-N-(2,2,2-trifluoro-1-(3-fluorophenyl)ethyl)-1H-indole-2-carboxamide 
               
               
                 643 
                 7-methyl-N-(1-(pyridin-3-yl)cyclopropyl)-1H-indole-2-carboxamide 
               
               
                 644 
                 N-((1r,4r)-4-(3-aminopropanamido)cyclohexyl)-4,7-dimethyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 645 
                 N-((1r,4r)-4-(3-aminopropanamido)cyclohexyl)-N,7-dimethyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 646 
                 N-(1-((3-aminopropyl)sulfonyl)piperidin-3-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 648 
                 methyl 3-(furan-2-yl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 649 
                 methyl 3-(7-methyl-1H-indole-2-carboxamido)-3-(thiophen-3-yl)propanoate 
               
               
                 650 
                 methyl 3-(7-methyl-1H-indole-2-carboxamido)-3-(thiophen-2-yl)propanoate 
               
               
                 652 
                 N-(1-(4-(1H-pyrazol-1-yl)phenyl)ethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 653 
                 N-(4-chloro-2-morpholinophenethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 654 
                 N-((1S,4R)-bicyclo[2.2.1]heptan-2-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 655 
                 N-((1r,4r)-4-(3-aminopropanamido)cyclohexyl)-3,7-dimethyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 656 
                 N-((1R,3r,5S)-8-(4-aminobutanoyl)-8-azabicyclo[3.2.1]octan-3-yl)-7-methyl- 
               
               
                   
                 3a,7a-dihydro-1H-indole-2-carboxamide 
               
               
                 657 
                 N-((1S,4S,5R)-2-(4-aminobutanoyl)-2-azabicyclo[2.2.2]octan-5-yl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 658 
                 methyl (R)-3-(7-methyl-1H-indole-2-carboxamido)-3-(pyridin-3-yl)propanoate 
               
               
                 659 
                 methyl 3-(3-methoxyphenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 660 
                 N-(cyclopropyl(pyridin-2-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 661 
                 N-((1r,4r)-4-((2-aminoethyl)sulfonamido)cyclohexyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 662 
                 N-((1s,4s)-4-(hydroxymethyl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 663 
                 N-(1-((3-aminopropyl)sulfonyl)piperidin-4-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 664 
                 N-(1-(4-aminobutanoyl)piperidin-3-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 665 
                 7-methyl-N-(pyrimidin-5-yl)-1H-indole-2-carboxamide 
               
               
                 666 
                 methyl (R)-3-(7-methyl-1H-indole-2-carboxamido)-3-phenylpropanoate 
               
               
                 667 
                 N-((6-(2-amino-2-oxoethyl)pyridin-2-yl)(cyclopropyl)methyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 668 
                 7-methyl-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl)-1H-indole-2-carboxamide 
               
               
                 669 
                 methyl 3-(3-bromophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 670 
                 N-(1-acetylpiperidin-4-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 671 
                 methyl 3-(7-methyl-1H-indole-2-carboxamido)-3-(pyridin-3-yl)propanoate 
               
               
                 672 
                 N-((1R,4R,5R)-2-(3-aminopropanoyl)-2-azabicyclo[2.2.2]octan-5-yl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 673 
                 7-methyl-N-(pyridin-2-yl)-1H-indole-2-carboxamide 
               
               
                 674 
                 7-methyl-N-(3-(pyrrolidin-1-ylmethyl)benzyl)-1H-indole-2-carboxamide 
               
               
                 675 
                 ethyl 3,3,3-trifluoro-2-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 676 
                 methyl (S)-3-(7-methyl-1H-indole-2-carboxamido)-3-(pyridin-3-yl)propanoate 
               
               
                 677 
                 methyl (S)-3-(7-methyl-1H-indole-2-carboxamido)-3-(o-tolyl)propanoate 
               
               
                 678 
                 7-methyl-N-(3,3,3-trifluoro-2-hydroxypropyl)-1H-indole-2-carboxamide 
               
               
                 679 
                 7-methyl-N-(2-(5-oxopyrrolidin-2-yl)phenyl)-1H-indole-2-carboxamide 
               
               
                 680 
                 N-(cyclopropyl(pyrimidin-2-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 681 
                 N-(2-(3,5-dimethoxyphenyl)-2-hydroxyethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 682 
                 7-methyl-N-(3-(methylamino)-1-(3-methylpyridin-2-yl)-3-oxopropyl)-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 683 
                 methyl (S)-3-(4-chlorophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 684 
                 (3,4-dihydroisoquinolin-2(1H)-yl)(7-methyl-1H-indol-2-yl)methanone 
               
               
                 685 
                 N-(3-(3-aminopropanamido)bicyclo[3.2.1]octan-8-yl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 686 
                 N-(2-hydroxy-2-(o-tolyl)ethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 687 
                 (S)-7-methyl-N-(2,2,2-trifluoro-1-phenylethyl)-1H-indole-2-carboxamide 
               
               
                 688 
                 7-methyl-N-(1-(4-methylthiazol-2-yl)ethyl)-1H-indole-2-carboxamide 
               
               
                 689 
                 N-(cyclopropyl(pyridin-3-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 690 
                 methyl (S)-3-(7-methyl-1H-indole-2-carboxamido)-3-phenylpropanoate 
               
               
                 691 
                 7-methyl-N-(4-(morpholinomethyl)phenyl)-1H-indole-2-carboxamide 
               
               
                 692 
                 (R)-N-(1-hydroxy-3-phenylpropan-2-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 693 
                 7-methyl-N-((1-methyl-1H-pyrazol-5-yl)methyl)-1H-indole-2-carboxamide 
               
               
                 694 
                 dimethyl (7-methyl-1H-indole-2-carbonyl)-D-aspartate 
               
               
                 695 
                 N-(2-hydroxy-2-(3-methoxyphenyl)ethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 697 
                 N-((1r,4r)-4-(3-aminopropanamido)cyclohexyl)-7-chloro-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 698 
                 N-((1r,4r)-4-acetamidocyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 699 
                 7-methyl-N-(2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide 
               
               
                 700 
                 ethyl 3-(7-methyl-1H-indole-2-carboxamido)-3-(pyridin-4-yl)propanoate 
               
               
                 701 
                 methyl 2-(7-methyl-1H-indole-2-carboxamido)-2-phenylacetate 
               
               
                 702 
                 7-methyl-N-((5-methylisoxazol-4-yl)methyl)-1H-indole-2-carboxamide 
               
               
                 703 
                 (S)-N-(2-hydroxy-1-phenylethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 704 
                 7-methyl-N-(2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 705 
                 N-(2-hydroxy-1-phenylethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 706 
                 N-((1r,4r)-4-aminocyclohexyl)-7-bromo-1H-indole-2-carboxamide 
               
               
                 707 
                 methyl 3-(3-fluorophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 708 
                 dimethyl (7-methyl-1H-indole-2-carbonyl)-L-aspartate 
               
               
                 709 
                 7-methyl-N-(3-(morpholinomethyl)benzyl)-1H-indole-2-carboxamide 
               
               
                 710 
                 N-(imidazo[1,2-alpyrazin-6-ylmethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 711 
                 N-((1r,4r)-4-(3-aminopropanamido)cyclohexyl)-3-ethyl-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 712 
                 7-methyl-N-(1-(1-methyl-1H-pyrazol-3-yl)ethyl)-1H-indole-2-carboxamide 
               
               
                 713 
                 (R)-7-methyl-N-(1-(m-tolyl)ethyl)-1H-indole-2-carboxamide 
               
               
                 714 
                 7-methyl-N-(1-(naphthalen-1-yl)ethyl)-1H-indole-2-carboxamide 
               
               
                 715 
                 7-methyl-N-(piperidin-4-yl)-1H-indole-2-carboxamide 
               
               
                 716 
                 7-methyl-N-(2-(piperidin-1-yl)benzyl)-1H-indole-2-carboxamide 
               
               
                 717 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-(trifluoromethyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 718 
                 (7-methyl-1H-indol-2-yl)(1,3,4,5-tetrahydro-2H-benzo[c]azepin-2-yl)methanone 
               
               
                 719 
                 7-methyl-N-((5-methylisoxazol-3-yl)methyl)-1H-indole-2-carboxamide 
               
               
                 720 
                 N-(2-(2,6-difluorophenyl)-2-hydroxyethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 721 
                 N-((2,5-dimethyloxazol-4-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 722 
                 7-methyl-N-((3-methylpyridin-2-yl)(pyrrolidin-3-yl)methyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 723 
                 7-methyl-N-((5-methylpyrazin-2-yl)methyl)-1H-indole-2-carboxamide 
               
               
                 724 
                 7-methyl-N-(4-(morpholinomethyl)pyridin-2-yl)-1H-indole-2-carboxamide 
               
               
                 725 
                 N-(3-(dimethylamino)-1-(pyridin-3-yl)propyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 726 
                 (R)-7-methyl-N-(2,2,2-trifluoro-1-phenylethyl)-1H-indole-2-carboxamide 
               
               
                 727 
                 N-(cyclopropyl(5-((dimethylamino)methyl)pyridin-3-yl)methyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 728 
                 N-(3-(dimethylamino)-1-(3-methylpyridin-2-yl)propyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 729 
                 N-((1H-imidazol-5-yl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 730 
                 N-((1r,4r)-4-aminocyclohexyl)-4,7-dimethyl-1H-indole-2-carboxamide 
               
               
                 731 
                 N-(2-cyclopropyl-2-hydroxyethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 732 
                 7-methyl-N-((4-methyl-1,2,5-oxadiazol-3-yl)methyl)-1H-indole-2-carboxamide 
               
               
                 733 
                 7-methyl-N-(oxazol-4-ylmethyl)-1H-indole-2-carboxamide 
               
               
                 735 
                 7-methyl-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)-1H-indole-2-carboxamide 
               
               
                 736 
                 N-((1r,4r)-4-aminocyclohexyl)-3,7-dimethyl-1H-indole-2-carboxamide 
               
               
                 738 
                 N-((1r,4r)-4-(3-aminopropanamido)cyclohexyl)-5,7-dimethyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 746 
                 7-methyl-N-(2-morpholinoethyl)-1H-indole-2-carboxamide 
               
               
                 747 
                 7-methyl-N-((tetrahydrofuran-2-yl)methyl)-1H-indole-2-carboxamide 
               
               
                 748 
                 N-(2,3-dihydro-1H-inden-1-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 749 
                 7-methyl-N-(1-phenylethyl)-1H-indole-2-carboxamide 
               
               
                 750 
                 7-methyl-N-(3-(piperidin-1-yl)benzyl)-1H-indole-2-carboxamide 
               
               
                 751 
                 7-methyl-N-(3-(piperidin-1-ylsulfonyl)benzyl)-1H-indole-2-carboxamide 
               
               
                 752 
                 N-(1-benzylpiperidin-4-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 753 
                 7-methyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1H-indole-2-carboxamide 
               
               
                 754 
                 N-(2-hydroxy-2-(4-methoxyphenyl)ethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 755 
                 7-methyl-N-(4-(morpholinomethyl)benzyl)-1H-indole-2-carboxamide 
               
               
                 756 
                 N-((1r,4r)-4-aminocyclohexyl)-5,7-dimethyl-1H-indole-2-carboxamide 
               
               
                 757 
                 2-(4-(7-methyl-1H-indole-2-carbonyl)piperazin-1-yl)nicotinamide 
               
               
                 758 
                 7-methyl-N-(4-(piperidin-1-ylsulfonyl)benzyl)-1H-indole-2-carboxamide 
               
               
                 759 
                 N-((1s,3s)-3-(hydroxymethyl)cyclobutyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 761 
                 N-((1r,4r)-4-aminocyclohexyl)-N,7-dimethyl-1H-indole-2-carboxamide 
               
               
                 763 
                 (S)-N-(1-hydroxy-3-methylbutan-2-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 764 
                 methyl 3-(4-chlorophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 765 
                 (S)-N-(1-hydroxy-3-phenylpropan-2-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 766 
                 tert-butyl (2-(7-methyl-1H-indole-2-carboxamido)propyl)carbamate 
               
               
                 767 
                 N-(2-(cyclopropylmethoxy)benzyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 768 
                 7-methyl-N-((1-methyl-1H-1,2,4-triazol-5-yl)methyl)-1H-indole-2-carboxamide 
               
               
                 769 
                 N-(1-cyclopropyl-2,2,2-trifluoroethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 771 
                 1-(7-methyl-1H-indole-2-carbonyl)piperidine-4-carboxamide 
               
               
                 773 
                 methyl 3-(4-isopropylphenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 774 
                 methyl 3-(2-bromophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 775 
                 methyl 3-(7-methyl-1H-indole-2-carboxamido)-3-phenylpropanoate 
               
               
                 776 
                 methyl 3-(4-fluorophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 777 
                 methyl 3-(4-methoxyphenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 778 
                 methyl 3-(4-bromophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 779 
                 N-(benzo[d]oxazol-2-ylmethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 780 
                 7-methyl-N-((1r,4r)-4-(trifluoromethyl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 781 
                 2-(4-(7-methyl-1H-indole-2-carbonyl)piperazin-1-yl)acetamide 
               
               
                 782 
                 7-methyl-N-(2-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)-1H-indole-2-carboxamide 
               
               
                 783 
                 methyl 3-(7-methyl-1H-indole-2-carboxamido)-3-(p-tolyl)propanoate 
               
               
                 784 
                 N-(3,3-difluoro-2-hydroxypropyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 785 
                 7-methyl-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)-1H-indole-2-carboxamide 
               
               
                 786 
                 1-(7-methyl-1H-indole-2-carbonyl)pyrrolidine-2-carboxamide 
               
               
                 787 
                 4-(7-methyl-1H-indole-2-carbonyl)piperazine-1-carboxamide 
               
               
                 788 
                 7-methyl-N-(1-(2-(trifluoromethyl)phenyl)ethyl)-1H-indole-2-carboxamide 
               
               
                 790 
                 7-methyl-N-(1-(3-(trifluoromethyl)phenyl)ethyl)-1H-indole-2-carboxamide 
               
               
                 791 
                 7-methyl-N-((1r,4r)-4-(2,2,2-trifluoroacetamido)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 793 
                 7-methyl-N-(2-morpholinophenyl)-1H-indole-2-carboxamide 
               
               
                 794 
                 (3-aminopiperidin-1-yl)(7-methyl-1H-indol-2-yl)methanone 
               
               
                 795 
                 7-methyl-N-(pyridin-3-yl)-1H-indole-2-carboxamide 
               
               
                 796 
                 N-(imidazo[1,2-a]pyridin-2-yl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 797 
                 ethyl (1R,2R)-2-(7-methyl-1H-indole-2-carboxamido)cyclohexane-1-carboxylate 
               
               
                 798 
                 3-amino-N-(1-(7-methyl-1H-indole-2-carbonyl)piperidin-3-yl)propanamide 
               
               
                 799 
                 (3-(dimethylamino)piperidin-1-yl)(7-methyl-1H-indol-2-yl)methanone 
               
               
                 800 
                 (7-methyl-1H-indol-2-yl)(3-(methylamino)piperidin-1-yl)methanone 
               
               
                 801 
                 N-(cyclopropyl(o-tolyl)methyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 802 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-isopropyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 803 
                 N-(cyclopropyl(pyridin-2-yl)methyl)-7-ethyl-1H-indole-2-carboxamide 
               
               
                 804 
                 7-methyl-N-(quinazolin-2-yl)-1H-indole-2-carboxamide 
               
               
                 805 
                 7-cyclopropyl-N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 808 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-6-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 809 
                 7-methyl-N-(3-(methylamino)-3-oxo-1-(pyridin-3-yl)propyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 810 
                 (5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)(7-methyl-1H-indol-2-yl)methanone 
               
               
                 811 
                 (5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(7-methyl-1H-indol-2- 
               
               
                   
                 yl)methanone 
               
               
                 812 
                 (5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)(7-methyl-1H-indol-2- 
               
               
                   
                 yl)methanone 
               
               
                 814 
                 2-(7-methyl-1H-indole-2-carbonyl)-1,2,3,4-tetrahydro-5H-benzo[c]azepin-5-one 
               
               
                 815 
                 N-(3-(dimethylamino)-2-phenylpropyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 816 
                 7-methyl-N-(2-oxo-7-phenylazepan-4-yl)-1H-indole-2-carboxamide 
               
               
                 817 
                 N-((3-benzylpyridin-2-yl)(cyclopropyl)methyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 818 
                 N-(2-([1,1′-biphenyl]-2-yl)ethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 819 
                 N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-7-propyl-1H-indole-2-carboxamide 
               
               
                 820 
                 (2,3-dihydrospiro[indene-1,3′-pyrrolidin]-1′-yl)(7-methyl-1H-indol-2- 
               
               
                   
                 yl)methanone 
               
               
                 821 
                 7-(cyclobutylmethyl)-N-(cyclopropyl(3-methylpyridin-2-yl)methyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 822 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-oxo-1,4-diazepan-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 823 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxo-1,4-diazepan-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 824 
                 ethyl 4-((1S,3R)-3-(4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamido)cyclohexyl)piperazine-1-carboxylate 
               
               
                 825 
                 ethyl 4-((1R,3R)-3-(4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamido)cyclohexyl)piperazine-1-carboxylate 
               
               
                 826 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-(2,2,2-trifluoroethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 827 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-(2,2,2-trifluoroethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 828 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-(morpholine-4-carbonyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 829 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-(morpholine-4-carbonyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 830 
                 N-((1R,3S)-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 831 
                 N-((1R,3R)-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 832 
                 4-fluoro-7-methyl-N-((1R)-3-(4-methyl-5-oxo-1,4-diazepan-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 833 
                 N-((1R,3S)-3-(3-acetamidopyrrolidin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 834 
                 N-((1R,3R)-3-(3-acetamidopyrrolidin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 835 
                 N-((1R,3S)-3-(4-ethyl-3-oxopiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 836 
                 N-((1R,3R)-3-(4-ethyl-3-oxopiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 837 
                 4-fluoro-N-((1R,3S)-3-(4-isobutyrylpiperazin-1-yl)cyclohexyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 838 
                 4-fluoro-N-((1R,3R)-3-(4-isobutyrylpiperazin-1-yl)cyclohexyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 839 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-propionylpiperazin-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 840 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-propionylpiperazin-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 841 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-3-(N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 842 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-3-(N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 843 
                 4-fluoro-N-((1R,3S)-3-(3-(N-(2-methoxyethyl)acetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 844 
                 4-fluoro-N-((1R,3R)-3-(3-(N-(2-methoxyethyl)acetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 845 
                 4-fluoro-N-((1R,3R)-3-(3-(N-(2-methoxyethyl)acetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 846 
                 4-fluoro-N-((1R,3S)-3-(4-(2-methoxyacetyl)piperazin-1-yl)cyclohexyl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 847 
                 4-fluoro-N-((1R,3R)-3-(4-(2-methoxyacetyl)piperazin-1-yl)cyclohexyl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 848 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((R)-3-(N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 849 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((R)-3-(N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 850 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-(methylsulfonyl)piperazin-1-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 851 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-(methylsulfonyl)piperazin-1-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 852 
                 N-((1R,3S)-3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 853 
                 N-((1R,3R)-3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 854 
                 N-((1R,3S)-3-(4-(dimethylglycyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 855 
                 N-((1R,3R)-3-(4-(dimethylglycyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 856 
                 N-((1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 857 
                 N-((1R,3R)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 858 
                 4-fluoro-7-methyl-N-((1R)-3-(4-(2-(methylamino)-2-oxoethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 859 
                 N-((1R)-3-(4-(2-(dimethylamino)-2-oxoethyl)piperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 860 
                 N-((1R,3S)-3-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 861 
                 N-((1R,3R)-3-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 862 
                 4-fluoro-N-((1R)-3-(3-(N-isopropylacetamido)pyrrolidin-1-yl)cyclohexyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 863 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 864 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 865 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazin- 
               
               
                   
                 7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 866 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazin- 
               
               
                   
                 7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 867 
                 N-(1-(1-acetylpiperidin-4-yl)azepan-3-yl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 868 
                 N-((1R,3S)-3-(5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 869 
                 N-((1R,3R)-3-(5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 870 
                 4-fluoro-N-((1R,3S)-3-(4-(2-hydroxyacetyl)piperazin-1-yl)cyclohexyl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 871 
                 4-fluoro-N-((1R,3R)-3-(4-(2-hydroxyacetyl)piperazin-1-yl)cyclohexyl)-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 872 
                 4-fluoro-N-((1R,3S)-3-(3-(N-(2-hydroxyethyl)acetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 873 
                 4-fluoro-N-((1R,3R)-3-(3-(N-(2-hydroxyethyl)acetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 874 
                 4-fluoro-7-methyl-N-((1R)-3-(1-oxo-2,8-diazaspiro[4.5]decan-8-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 875 
                 ethyl (R)-3-(4-fluoro-7-methyl-1H-indole-2-carboxamido)-[1,4′-bipiperidine]-1′- 
               
               
                   
                 carboxylate 
               
               
                 876 
                 ethyl (S)-3-(4-fluoro-7-methyl-1H-indole-2-carboxamido)-[1,4′-bipiperidine]-1′- 
               
               
                   
                 carboxylate 
               
               
                 877 
                 1-(4-((1-(4-fluoro-7-methyl-1H-indole-2-carbonyl)piperidin-3- 
               
               
                   
                 yl)methyl)piperazin-1-yl)ethan-1-one 
               
               
                 878 
                 N-((1R,3S)-3-(4-(2,2-difluoroacetyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 879 
                 N-((1R,3R)-3-(4-(2,2-difluoroacetyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 880 
                 4-fluoro-N-((1R,3S)-3-(3-(2-methoxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 881 
                 4-fluoro-N-((1R,3R)-3-(3-(2-methoxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 882 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(1-oxo-2,7-diazaspiro[4.5]decan-7- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 883 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(1-oxo-2,7-diazaspiro[4.5]decan-7- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 884 
                 N-((1R,3S)-3-(2,4-dimethyl-3-oxopiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 885 
                 N-((1R,3R)-3-(2,4-dimethyl-3-oxopiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 886 
                 1-(4-(1-(4-fluoro-7-methyl-1H-indole-2-carbonyl)piperidine-3- 
               
               
                   
                 carbonyl)piperazin-1-yl)ethan-1-one 
               
               
                 887 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-methyl-3-oxo-1,4-diazepan-1-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 888 
                 N-((1R,3S)-3-(6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 889 
                 N-((1R,3R)-3-(6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 890 
                 4-fluoro-7-methyl-N-((1R)-3-(2-oxo-1,3,8-triazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 891 
                 (R)-N-(1′-(dimethylglycyl)-[1,4′-bipiperidin]-3-yl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 892 
                 (S)-N-(1′-(dimethylglycyl)-[1,4′-bipiperidin]-3-yl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 893 
                 4-fluoro-7-methyl-N-((1R)-3-(5-oxo-1,4-diazepan-1-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 894 
                 4-fluoro-7-methyl-N-((1R)-3-(2-oxo-1,8-diazaspiro[4.5]decan-8-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 895 
                 4-fluoro-7-methyl-N-(3-(2-oxo-3-oxa-1,8-diazaspiro[4.5]decan-8-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 896 
                 4-fluoro-7-methyl-N-((1R)-3-(3-oxo-2,8-diazaspiro[4.5]decan-8-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 897 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(7-oxo-2,6-diazaspiro[3.4]octan-2- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 898 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(7-oxo-2,6-diazaspiro[3.4]octan-2- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 899 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(N-methylmethylsulfonamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 900 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((R)-3-(N-methylmethylsulfonamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 901 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-3-(N-methylmethylsulfonamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 902 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(pyridin-3-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 903 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(pyridin-3-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 904 
                 4-fluoro-7-methyl-N-((1S,3S)-3-(pyridin-3-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 905 
                 4-fluoro-7-methyl-N-((1S,3R)-3-(pyridin-3-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 906 
                 N-((1R,3S)-3-(4-acetyl-3-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 907 
                 N-((1R,3R)-3-(4-acetyl-3-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 908 
                 N-((1R,3S)-3-(3-(2-(dimethylamino)-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 909 
                 N-((1R,3R)-3-(3-(2-(dimethylamino)-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 910 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-oxo-[1,3′-bipyrrolidin]-1′-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 911 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(2-oxo-[1,3′-bipyrrolidin]-1′-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 912 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(pyridin-4-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 913 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(pyridin-4-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 914 
                 4-fluoro-7-methyl-N-((1S,3R)-3-(pyridin-4-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 915 
                 4-fluoro-7-methyl-N-((1S,3S)-3-(pyridin-4-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 916 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-methyl-2-oxopiperazin-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 917 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-methyl-2-oxopiperazin-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 918 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-(oxetane-3-carbonyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 919 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-(oxetane-3-carbonyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 920 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((R)-6-oxohexahydropyrrolo[1,2-a]pyrazin- 
               
               
                   
                 2(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 921 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((R)-6-oxohexahydropyrrolo[1,2-a]pyrazin- 
               
               
                   
                 2(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 922 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-6-oxohexahydropyrrolo[1,2-a]pyrazin- 
               
               
                   
                 2(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 923 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-6-oxohexahydropyrrolo[1,2-a]pyrazin- 
               
               
                   
                 2(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 924 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-(tetrahydrofuran-3-yl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 925 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-(tetrahydrofuran-3-yl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 926 
                 N-((1R,3S)-3-(8-acetyl-3,8-diazabicyclo[3.2.1]octan-3-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 927 
                 N-((1R,3R)-3-(8-acetyl-3,8-diazabicyclo[3.2.1]octan-3-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 928 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxo-2,8-diazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 929 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-oxo-2,8-diazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 930 
                 N-((1R,3S)-3-((R)-4-acetyl-3-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 931 
                 N-((1R,3R)-3-((R)-4-acetyl-3-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 932 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(5-oxo-1,4-diazepan-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 933 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(5-oxo-1,4-diazepan-1-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 934 
                 4-fluoro-N-((1R,3S)-3-(3-(2-hydroxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 935 
                 4-fluoro-N-((1R,3R)-3-(3-(2-hydroxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 936 
                 N-((1R,3S)-3-(5-acetyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 937 
                 N-((1R,3R)-3-(5-acetyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 938 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-oxo-1,8-diazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 939 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(2-oxo-1,8-diazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 940 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-oxo-1,3,8-triazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 941 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(2-oxo-1,3,8-triazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 942 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-3-(N-methylmethylsulfonamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 943 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((R)-3-(N-methylmethylsulfonamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 944 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-methyl-5-oxo-1,4-diazepan-1-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 945 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-methyl-5-oxo-1,4-diazepan-1-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 946 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(N-methyloxetane-3-carboxamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 947 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-(N-methyloxetane-3-carboxamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 948 
                 N-((1R,3S)-3-(4-(ethylcarbamoyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 949 
                 N-((1R,3R)-3-(4-(ethylcarbamoyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 950 
                 N-((1R,3S)-3-(1-acetyl-1,6-diazaspiro[3.3]heptan-6-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 951 
                 N-((1R,3R)-3-(1-acetyl-1,6-diazaspiro[3.3]heptan-6-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 952 
                 N-((1R,3S)-3-(3-acetyl-3,8-diazabicyclo[3.2.1]octan-8-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 953 
                 N-((1R,3R)-3-(3-acetyl-3,8-diazabicyclo[3.2.1]octan-8-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 954 
                 N-((1R,3S)-3-(5-((dimethylamino)methyl)-1,3,4-oxadiazol-2-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 955 
                 N-((1S,3R)-3-(5-((dimethylamino)methyl)-1,3,4-oxadiazol-2-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 956 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(piperazin-1-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 957 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(piperazin-1-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 958 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(2-oxooxazolidin-3-yl)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 959 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-(2-oxooxazolidin-3-yl)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 960 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(N-methylacetamido)azetidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 961 
                 N-((1R,3S)-3-(5-acetyl-2,5-diazabicyclo[2.2.2]octan-2-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 962 
                 N-((1R,3R)-3-(5-acetyl-2,5-diazabicyclo[2.2.2]octan-2-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 963 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-oxo-3-oxa-1,8-diazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 964 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(2-oxo-3-oxa-1,8-diazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 965 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-oxo-1-(2,2,2-trifluoroethyl)-1,8- 
               
               
                   
                 diazaspiro[4.5]decan-8-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 966 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(2-oxo-1-(2,2,2-trifluoroethyl)-1,8- 
               
               
                   
                 diazaspiro[4.5]decan-8-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 967 
                 N-((1R,3S)-3-((S)-4-acetyl-3-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 968 
                 N-((1R,3R)-3-((S)-4-acetyl-3-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 969 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(N-methylisobutyramido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 970 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-(N-methylisobutyramido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 971 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(N- 
               
               
                   
                 methylcyclopropanecarboxamido)pyrrolidin-1-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 972 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-(N- 
               
               
                   
                 methylcyclopropanecarboxamido)pyrrolidin-1-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 973 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxo-4-(tetrahydrofuran-3-yl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 974 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-oxo-4-(tetrahydrofuran-3-yl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 975 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(5-methyl-1,3,4-oxadiazol-2-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 976 
                 4-fluoro-7-methyl-N-((1S,3R)-3-(5-methyl-1,3,4-oxadiazol-2-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 977 
                 N-((1R,3S)-3-(4-cyclopropyl-3-oxopiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 978 
                 N-((1R,3R)-3-(4-cyclopropyl-3-oxopiperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 979 
                 N-((1R,3S)-3-(4-acetyl-1,4-diazepan-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 980 
                 N-((1R,3R)-3-(4-acetyl-1,4-diazepan-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 981 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-(methylsulfonyl)-1,4-diazepan-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 982 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-(methylsulfonyl)-1,4-diazepan-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 983 
                 4-fluoro-N-((1R,3S)-3-((R)-3-(2-hydroxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 984 
                 4-fluoro-N-((1R,3R)-3-((R)-3-(2-hydroxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 985 
                 N-((3S,5S)-5-(4-acetylpiperazin-1-yl)tetrahydro-2H-pyran-3-yl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 986 
                 N-((3S,5R)-5-(4-acetylpiperazin-1-yl)tetrahydro-2H-pyran-3-yl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 987 
                 N-((3R,5R)-5-(4-acetylpiperazin-1-yl)tetrahydro-2H-pyran-3-yl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 988 
                 N-((3R,5S)-5-(4-acetylpiperazin-1-yl)tetrahydro-2H-pyran-3-yl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 989 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(trifluoromethyl)-5,6-dihydro- 
               
               
                   
                 [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 990 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-(trifluoromethyl)-5,6-dihydro- 
               
               
                   
                 [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 991 
                 N-((1R,3S)-3-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 992 
                 N-((1R,3R)-3-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 993 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(trifluoromethyl)-5,6-dihydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(8H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 994 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-(trifluoromethyl)-5,6-dihydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(8H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 995 
                 4-fluoro-N-((1R,3S)-3-((S)-3-(2-hydroxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 996 
                 4-fluoro-N-((1R,3R)-3-((S)-3-(2-hydroxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 997 
                 isopropyl 4-((1S,3R)-3-(4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamido)cyclohexyl)piperazine-1-carboxylate 
               
               
                 998 
                 isopropyl 4-((1R,3R)-3-(4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamido)cyclohexyl)piperazine-1-carboxylate 
               
               
                 999 
                 tetrahydro-2H-pyran-4-yl 4-((1S,3R)-3-(4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamido)cyclohexyl)piperazine-1-carboxylate 
               
               
                 1000 
                 tetrahydro-2H-pyran-4-yl 4-((1R,3R)-3-(4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamido)cyclohexyl)piperazine-1-carboxylate 
               
               
                 1001 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(trifluoromethyl)-5,6-dihydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(8H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1002 
                 N-((1R,3S)-3-(3-(dimethylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1003 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(pyrimidin-4-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1004 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-oxo-4-(tetrahydrofuran-3-yl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1005 
                 N-((1R,3S)-3-(4-ethyl-2-oxopiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1006 
                 N-((3S,5R)-5-(4-acetylpiperazin-1-yl)-1-methylpiperidin-3-yl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1007 
                 N-((1R,3S)-3-(1-acetylpiperidin-4-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1008 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxo-2-oxa-4,9-diazaspiro[5.5]undecan-9- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1009 
                 N-((1R,3S)-3-(2,2-dioxido-2-thia-1,3,8-triazaspiro[4.5]decan-8-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1010 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-oxo-4-oxa-1,9-diazaspiro[5.5]undecan-9- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1011 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(5-methyl-1,2,4-oxadiazol-3-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1012 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(6-oxo-1,6-dihydro-1,2,4-triazin-3- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1013 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(6-oxo-1,6-dihydropyrimidin-2-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1014 
                 N-((1R,3S)-3-(5-((dimethylamino)methyl)-1,2,4-oxadiazol-3-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1015 
                 N-((1R,3R)-3-(4-acetylpiperazin-1-yl)-4-fluorocyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1016 
                 N-((1R,3R)-3-(4-acetylpiperazin-1-yl)-4-(trifluoromethyl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1017 
                 N-((1R,3S)-3-(4-acetyl-2-(trifluoromethyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1018 
                 N-((1R,3S)-3-(4-acetyl-3-(trifluoromethyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1019 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxo-2,8-diazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1020 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(7-oxo-5-oxa-2,8-diazaspiro[3.5]nonan-2- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1021 
                 N-((1R,3S)-3-(4-acetyl-2-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1022 
                 N-((1R,3S)-3-(4-acetyl-3-(hydroxymethyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1023 
                 N-((1R,3S)-3-(4-acetyl-2-(hydroxymethyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1024 
                 N-((1R,3S)-3-(7-acetyl-4,7-diazaspiro[2.5]octan-4-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1025 
                 N-((1R,3S)-3-(4-acetyl-4,7-diazaspiro[2.5]octan-7-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1026 
                 N-((1R,3S)-3-(3,4-dimethyl-2-oxopiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1027 
                 4-fluoro-7-methyl-N-(1-(pyridin-4-yl)piperidin-3-yl)-1H-indole-2-carboxamide 
               
               
                 1028 
                 4-fluoro-7-methyl-N-(1′-methyl-2′-oxo-[1,4′-bipiperidin]-3-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1029 
                 isopropyl 4-((1S,3R)-3-(4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamido)cyclohexyl)piperazine-1-carboxylate 
               
               
                 1030 
                 tetrahydro-2H-pyran-4-yl 4-((1S,3R)-3-(4-fluoro-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamido)cyclohexyl)piperazine-1-carboxylate 
               
               
                 1031 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-(trifluoromethyl)-5,6-dihydro- 
               
               
                   
                 [1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1032 
                 N-((1R,3S)-3-((4-acetylpiperazin-1-yl)methyl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1033 
                 N-((1R,3S)-3-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 1034 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(trifluoromethyl)-5,6-dihydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(8H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1035 
                 4-fluoro-N-((1R,3R,4R)-4-fluoro-3-(2-oxo-1,8-diazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1036 
                 4-fluoro-N-((1R,3R,4R)-4-fluoro-3-((S)-3-(N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1037 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-((tetrahydro-2H-pyran-4- 
               
               
                   
                 yl)carbamoyl)piperazin-1-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1038 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((3aS,6aS)-1-methyl-2- 
               
               
                   
                 oxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1039 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((3aR,6aR)-1-methyl-2- 
               
               
                   
                 oxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1040 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-methyl-5-oxohexahydropyrrolo[3,2-b]pyrrol- 
               
               
                   
                 1(2H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1041 
                 4-fluoro-N-((1R,3S)-3-((S)-3-(2-hydroxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1042 
                 4-fluoro-N-((1R,3S)-3-((R)-3-(2-methoxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1043 
                 4-fluoro-N-((1R,3S)-3-((S)-3-(2-methoxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1044 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(6-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1045 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-oxohexahydropyrazino[2,1-c][1,4]oxazin- 
               
               
                   
                 8(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1046 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(8-methyl-6,9-dioxooctahydro-2H-pyrazino[1,2- 
               
               
                   
                 a]pyrazin-2-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1047 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(6-oxooctahydro-2H-pyrazino[1,2-c]pyrimidin- 
               
               
                   
                 2-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1048 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(6-oxo-1,3,4,6-tetrahydro-2H-pyrido[1,2- 
               
               
                   
                 a]pyrazin-2-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1049 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[1,2- 
               
               
                   
                 a]pyrimidin-8-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1050 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1051 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-methyl-3-oxohexahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1052 
                 4-fluoro-N-((1R,3S)-3-(3-(2-hydroxy-N,2-dimethylpropanamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1053 
                 N-((1R,3S)-3-(3-(N-ethyl-2-hydroxyacetamido)pyrrolidin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1054 
                 N-((1R,3S)-3-(3-(N-ethylmethylsulfonamido)pyrrolidin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1055 
                 N-((1R,3S)-3-(4-acetyl-3-ethylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1056 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-methyl-3-oxo-2,5,6,8-tetrahydro- 
               
               
                   
                 [1,2,4]triazolo[4,3-a]pyrazin-7(3H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1057 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(2-methyl-3-oxo-2,5,6,8-tetrahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(3H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1058 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxo-2,5,6,8-tetrahydro-[1,2,4]triazolo[4,3- 
               
               
                   
                 a]pyrazin-7(3H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1059 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxo-2,5,6,8-tetrahydroimidazo[1,5-a]pyrazin- 
               
               
                   
                 7(3H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1060 
                 4-fluoro-N-((1R,3S)-3-((S)-3-((1-hydroxy-N- 
               
               
                   
                 methylmethyl)sulfonamido)pyrrolidin-1-yl)cyclohexyl)-7-methyl-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1061 
                 4-fluoro-N-((1R,3S)-3-((S)-3-(N-(2-hydroxyethyl)methylsulfonamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1062 
                 N-((1R,3S)-3-((3R,5R)-4-acetyl-3,5-dimethylpiperazin-1-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 1063 
                 4-fluoro-N-((1R,3R)-3-((S)-3-(2-methoxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1064 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(pyrimidin-4-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1065 
                 4-fluoro-7-methyl-N-((1S,3R)-3-(5-methyl-1,2,4-oxadiazol-3-yl)cyclohexyl)-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1066 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(2-(trifluoromethyl)-5,6-dihydro- 
               
               
                   
                 [1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1067 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-oxohexahydropyrazino[2,1-c][1,4]oxazin- 
               
               
                   
                 8(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1068 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(6-oxo-1,6-dihydropyrimidin-4-yl)cyclohexyl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1069 
                 N-((1R,3S)-3-((R)-4-acetyl-3-(trifluoromethyl)piperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1070 
                 N-((1R,3S)-3-((S)-4-acetyl-3-(trifluoromethyl)piperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1071 
                 N-((1R,3R)-3-((R)-4-acetyl-3-(trifluoromethyl)piperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1072 
                 N-((1R,3R)-3-((S)-4-acetyl-3-(trifluoromethyl)piperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1073 
                 N-((1R,3S)-3-((S)-4-acetyl-2-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1074 
                 N-((1R,3R)-3-((S)-4-acetyl-2-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1075 
                 N-((1R,3R)-3-((R)-4-acetyl-3-(hydroxymethyl)piperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1076 
                 N-((1R,3R)-3-((S)-4-acetyl-3-(hydroxymethyl)piperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1077 
                 N-((1S,3R)-3-((4-acetylpiperazin-1-yl)methyl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1078 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-6-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1079 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((R)-6-oxooctahydro-2H-pyrido[1,2-a]pyrazin- 
               
               
                   
                 2-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1080 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-6-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1081 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((R)-3-oxohexahydroimidazo[1,5-a]pyrazin- 
               
               
                   
                 7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1082 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-3-oxohexahydroimidazo[1,5-a]pyrazin- 
               
               
                   
                 7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1083 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((R)-3-oxohexahydroimidazo[1,5-a]pyrazin- 
               
               
                   
                 7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1084 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-3-oxohexahydroimidazo[1,5-a]pyrazin- 
               
               
                   
                 7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1085 
                 N-((1R,3S)-3-((S)-4-acetyl-3-ethylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1086 
                 N-((1R,3R)-3-((S)-4-acetyl-3-ethylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1087 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1088 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1089 
                 N-((1R,3S)-3-((R)-3-(dimethylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 1090 
                 N-((1R,3S)-3-((S)-3-(dimethylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 1091 
                 N-((1R,3R)-3-((R)-4-acetyl-2-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1092 
                 N-((1R,3S)-3-((R)-4-acetyl-2-methylpiperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1-indole-2-carboxamide 
               
               
                 1093 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((R)-6-oxooctahydro-2H-pyrido[1,2-a]pyrazin-2- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1094 
                 N-((1R,3S)-3-((R)-4-acetyl-3-ethylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1095 
                 N-((1R,3R)-3-((R)-4-acetyl-3-ethylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1096 
                 N-((1R,3R)-3-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 1097 
                 N-((1R,3S)-3-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 1098 
                 N-((1R,3S)-3-((S)-4-acetyl-3-(hydroxymethyl)piperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1099 
                 N-((1R,3S)-3-((R)-4-acetyl-3-(hydroxymethyl)piperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1100 
                 N-((1R,3R)-3-(4-acetyl-4,7-diazaspiro[2.5]octan-7-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1101 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-8-methyl-6,9-dioxooctahydro-2H- 
               
               
                   
                 pyrazino[1,2-a]pyrazin-2-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1102 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((R)-8-methyl-6,9-dioxooctahydro-2H- 
               
               
                   
                 pyrazino[1,2-a]pyrazin-2-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1103 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-8-methyl-6,9-dioxooctahydro-2H- 
               
               
                   
                 pyrazino[1,2-a]pyrazin-2-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1104 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((R)-8-methyl-6,9-dioxooctahydro-2H- 
               
               
                   
                 pyrazino[1,2-a]pyrazin-2-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1105 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxo-2,5,6,8-tetrahydro-[1,2,4]triazolo[4,3- 
               
               
                   
                 a]pyrazin-7(3H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1106 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-oxo-2,5,6,8-tetrahydro-[1,2,4]triazolo[4,3- 
               
               
                   
                 a]pyrazin-7(3H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1107 
                 N-((3S,5S)-5-(4-acetylpiperazin-1-yl)-1-methylpiperidin-3-yl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1108 
                 N-((3R,5R)-5-(4-acetylpiperazin-1-yl)-1-methylpiperidin-3-yl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1109 
                 N-((3R,5S)-5-(4-acetylpiperazin-1-yl)-1-methylpiperidin-3-yl)-4-fluoro-7-methyl- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1110 
                 N-((1S,3R)-3-(5-((dimethylamino)methyl)-1,2,4-oxadiazol-3-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1111 
                 4-fluoro-7-methyl-N-(3-(3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazin-7(1H)- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1112 
                 4-fluoro-N-((1R,3S)-3-(4-isobutyryl-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1113 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-propionyl-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1114 
                 N-((1R,3S)-3-(4-((E)-N′-cyano-N-methylcarbamimidoyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1115 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(4-((E)-1-(methylamino)-2-nitrovinyl)piperazin- 
               
               
                   
                 1-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1116 
                 N-((1R,3S)-3-(4-((E)-1-(cyanoimino)ethyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1117 
                 4-fluoro-N-((1R,3S)-3-(4-(2-hydroxyacetyl)-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1118 
                 N-((1R,3S)-3-(1-(4-acetylpiperazin-1-yl)ethyl)cyclohexyl)-4-fluoro-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1119 
                 N-((1R,3S)-3-((R)-3-(N-ethyl-2-hydroxyacetamido)pyrrolidin-1-yl)cyclohexyl)- 
               
               
                   
                 4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1120 
                 N-((1R,3R)-3-((R)-3-(N-ethyl-2-hydroxyacetamido)pyrrolidin-1-yl)cyclohexyl)- 
               
               
                   
                 4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1121 
                 N-((1R,3S)-3-((R)-3-(N-ethylmethylsulfonamido)pyrrolidin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1122 
                 N-((1R,3R)-3-((R)-3-(N-ethylmethylsulfonamido)pyrrolidin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1123 
                 N-((1R,3R)-3-((3R,5R)-4-acetyl-3,5-dimethylpiperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1124 
                 N-((1R,3R)-3-(1-acetylpiperidin-4-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole- 
               
               
                   
                 2-carboxamide 
               
               
                 1125 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-2-methyl-3-oxohexahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1126 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((R)-2-methyl-3-oxohexahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1127 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-2-methyl-3-oxohexahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1128 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((R)-2-methyl-3-oxohexahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1129 
                 N-((1R,3S)-3-((S)-3-(N-ethyl-2-hydroxyacetamido)pyrrolidin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1130 
                 N-((1R,3R)-3-((S)-3-(N-ethyl-2-hydroxyacetamido)pyrrolidin-1-yl)cyclohexyl)- 
               
               
                   
                 4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1131 
                 N-((1R,3S)-3-((S)-3-(N-ethylmethylsulfonamido)pyrrolidin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1132 
                 N-((1R,3R)-3-((S)-3-(N-ethylmethylsulfonamido)pyrrolidin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1133 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((R)-3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazin- 
               
               
                   
                 7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1134 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((R)-3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazin- 
               
               
                   
                 7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1135 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazin- 
               
               
                   
                 7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1136 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazin- 
               
               
                   
                 7(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1137 
                 N-((1R,3R)-3-(7-acetyl-4,7-diazaspiro[2.5]octan-4-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1138 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-4-oxohexahydropyrazino[2,1-c][1,4]oxazin- 
               
               
                   
                 8(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1139 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-4-oxohexahydropyrazino[2,1-c][1,4]oxazin- 
               
               
                   
                 8(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1140 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((R)-4-oxohexahydropyrazino[2,1-c][1,4]oxazin- 
               
               
                   
                 8(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1141 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((R)-4-oxohexahydropyrazino[2,1- 
               
               
                   
                 c][1,4]oxazin-8(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1142 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(2-methyl-3-oxo-2,5,6,8-tetrahydro- 
               
               
                   
                 [1,2,4]triazolo[4,3-a]pyrazin-7(3H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1143 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(6-oxo-1,3,4,6-tetrahydro-2H-pyrido[1,2- 
               
               
                   
                 a]pyrazin-2-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1144 
                 4-fluoro-N-((1R,3S)-3-((S)-3-(2-hydroxy-N,2-dimethylpropanamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1145 
                 4-fluoro-N-((1R,3R)-3-((S)-3-(2-hydroxy-N,2-dimethylpropanamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1146 
                 4-fluoro-N-((1R,3S)-3-((R)-3-(2-hydroxy-N,2-dimethylpropanamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1147 
                 4-fluoro-N-((1R,3R)-3-((R)-3-(2-hydroxy-N,2-dimethylpropanamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1148 
                 N-((1R,3R)-3-(4-((E)-1-(cyanoimino)ethyl)piperazin-1-yl)cyclohexyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1149 
                 4-fluoro-N-((1R,3S)-3-((R)-3-(N-(2-hydroxyethyl)methylsulfonamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1150 
                 4-fluoro-N-((1R,3R)-3-((R)-3-(N-(2-hydroxyethyl)methylsulfonamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1151 
                 4-fluoro-N-((1R,3R)-3-((S)-3-(N-(2-hydroxyethyl)methylsulfonamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1152 
                 N-((1R,3R)-3-(4-((E)-N′-cyano-N-methylcarbamimidoyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1153 
                 N-(2-chlorobenzyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1154 
                 (S)-N-(1-(2-chlorophenyl)ethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1155 
                 N-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1156 
                 N-(1-(2-chlorophenyl)ethyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1157 
                 methyl 3-(2-chlorophenyl)-3-(7-methyl-1H-indole-2-carboxamido)propanoate 
               
               
                 1158 
                 N-(3-chloro-5-(4-(3-(pyrrolidin-1-yl)propyl)piperidin-1-yl)phenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1159 
                 4-fluoro-7-methyl-N-(1-methyl-5-(1-methylpiperidin-4-yl)-1H-imidazol-2-yl)- 
               
               
                   
                 1H-indole-2-carboxamide 
               
               
                 1160 
                 4-fluoro-N-((1R,3R)-3-((R)-3-(2-methoxy-N-methylacetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1161 
                 4-fluoro-N-((1R,3S)-3-((R)-3-(N-(2-hydroxyethyl)methylsulfonamido)pyrrolidin- 
               
               
                   
                 1-yl)cyclohexyl)-7-methyl-1H-indene-2-carboxamide 
               
               
                 1162 
                 N-((1R,3S)-3-((3S,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 1163 
                 N-((1R,3R)-3-((3S,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 1164 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((R)-4-propionyl-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1165 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[1,2- 
               
               
                   
                 a]pyrimidin-8-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1166 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(3-oxo-2,5,6,8-tetrahydroimidazo[1,5-a]pyrazin- 
               
               
                   
                 7(3H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1167 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((S)-4-propionyl-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1168 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((S)-4-propionyl-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1169 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-((E)-1-(methylamino)-2-nitrovinyl)piperazin- 
               
               
                   
                 1-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1170 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(4-((tetrahydro-2H-pyran-4- 
               
               
                   
                 yl)carbamoyl)piperazin-1-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1171 
                 4-fluoro-N-((1R,3S)-3-((S)-4-isobutyryl-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1172 
                 4-fluoro-N-((1R,3R)-3-((S)-4-isobutyryl-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1173 
                 4-fluoro-N-((1R,3S)-3-((S)-4-(2-hydroxyacetyl)-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1174 
                 4-fluoro-N-((1R,3R)-3-((S)-4-(2-hydroxyacetyl)-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1175 
                 4-fluoro-N-((1R,3R)-3-((R)-4-isobutyryl-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1176 
                 4-fluoro-N-((1R,3R)-3-((R)-4-(2-hydroxyacetyl)-3-(trifluoromethyl)piperazin-1- 
               
               
                   
                 yl)cyclohexyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1177 
                 N-((1R,3S)-3-((3aR,6aS)-5-acetylhexahydropyrrolo[3,4-c]pyrrol-2(1H)- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1178 
                 N-((1R,3R)-3-((3aR,6aS)-5-acetylhexahydropyrrolo[3,4-c]pyrrol-2(1H)- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1179 
                 4-fluoro-7-methyl-N-((1R,3R)-3-(2-methyl-3-oxo-2,5,6,8-tetrahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(3H)-yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1180 
                 N-((1R,3S)-3-((3aS,6aS)-1-acetylhexahydropyrrolo[3,4-b]pyrrol-5(1H)- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1181 
                 N-((1R,3R)-3-((3aS,6aS)-1-acetylhexahydropyrrolo[3,4-b]pyrrol-5(1H)- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1182 
                 N-((1R,3S)-3-((3aR,6aR)-1-acetylhexahydropyrrolo[3,4-b]pyrrol-5(1H)- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1183 
                 N-((1R,3R)-3-((3aR,6aR)-1-acetylhexahydropyrrolo[3,4-b]pyrrol-5(1H)- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1184 
                 N-((1R,3S)-3-((3aS,6aS)-4-acetylhexahydropyrrolo[3,2-b]pyrrol-1(2H)- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1185 
                 N-((1R,3S)-3-((3aR,6aR)-4-acetylhexahydropyrrolo[3,2-b]pyrrol-1(2H)- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1186 
                 N-((1R,3R)-3-((3aS,6aS)-4-acetylhexahydropyrrolo[3,2-b]pyrrol-1(2H)- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1187 
                 N-((1R,3R)-3-((3aR,6aR)-4-acetylhexahydropyrrolo[3,2-b]pyrrol-1(2H)- 
               
               
                   
                 yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1188 
                 4-fluoro-7-methyl-N-((1S,3R)-3-(6-oxo-1,4,5,6-tetrahydro-1,2,4-triazin-3- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1189 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-(N-(oxetan-3-yl)acetamido)pyrrolidin-1- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1190 
                 4-fluoro-7-methyl-N-((1R,3S)-3-(3-oxo-2,8-diazaspiro[4.5]decan-8- 
               
               
                   
                 yl)cyclohexyl)-1H-indole-2-carboxamide 
               
               
                 1191 
                 4-fluoro-7-methyl-N-(1′-methyl-2′-oxo-[1,4′-bipiperidin]-3-yl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1192 
                 N-((1R,3S)-3-((3R,5R)-4-acetyl-3,5-dimethylpiperazin-1-yl)cyclohexyl)-4-fluoro- 
               
               
                   
                 7-methyl-1H-indole-2-carboxamide 
               
               
                 1193 
                 N-((1R,3R)-3-((3R,5R)-4-acetyl-3,5-dimethylpiperazin-1-yl)cyclohexyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1194 
                 (R)-4-fluoro-N-(3-fluoro-5-(3-(N-methylacetamido)pyrrolidin-1-yl)phenyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1195 
                 (S)-4-fluoro-N-(3-fluoro-5-(3-(N-methylacetamido)pyrrolidin-1-yl)phenyl)-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1196 
                 4-fluoro-N-(3-fluoro-5-((S)-3-((R)-2-methyl-3-oxohexahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(1H)-yl)pyrrolidin-1-yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1197 
                 4-fluoro-N-(3-fluoro-5-((S)-3-((S)-2-methyl-3-oxohexahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(1H)-yl)pyrrolidin-1-yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1198 
                 4-fluoro-N-(3-fluoro-5-((R)-3-((S)-2-methyl-3-oxohexahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(1H)-yl)pyrrolidin-1-yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1199 
                 4-fluoro-N-(3-fluoro-5-((R)-3-((R)-2-methyl-3-oxohexahydroimidazo[1,5- 
               
               
                   
                 a]pyrazin-7(1H)-yl)pyrrolidin-1-yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1200 
                 (R)-N-(3-(3-(dimethylamino)-2-oxopyrrolidin-1-yl)-5-fluorophenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1201 
                 (S)-N-(3-(3-(dimethylamino)-2-oxopyrrolidin-1-yl)-5-fluorophenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1202 
                 (R)-N-(3-(3-(4-(2-(dimethylamino)-2-oxoethyl)piperazin-1-yl)pyrrolidin-1-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1203 
                 (R)-N-(3-(3-(4-(2-(dimethylamino)-2-oxoethyl)piperazin-1-yl)pyrrolidin-1-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1204 
                 (S)-N-(3-(3-(4-(2-amino-2-oxoethyl)piperazin-1-yl)pyrrolidin-1-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1205 
                 (R)-N-(3-(3-(4-(2-amino-2-oxoethyl)piperazin-1-yl)pyrrolidin-1-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1206 
                 (S)-N-(3-(3-(1,1-dioxidothiomorpholino)pyrrolidin-1-yl)-5-fluorophenyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1207 
                 (R)-N-(3-(3-(1,1-dioxidothiomorpholino)pyrrolidin-1-yl)-5-fluorophenyl)-4- 
               
               
                   
                 fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1208 
                 (R)-N-(3-(3-(4-acetylpiperazin-1-yl)pyrrolidin-1-yl)-5-fluorophenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1209 
                 (S)-N-(3-(3-(4-acetylpiperazin-1-yl)pyrrolidin-1-yl)-5-fluorophenyl)-4-fluoro-7- 
               
               
                   
                 methyl-1H-indole-2-carboxamide 
               
               
                 1210 
                 (S)-4-fluoro-N-(3-fluoro-5-(3-morpholinopyrrolidin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1211 
                 (R)-4-fluoro-N-(3-fluoro-5-(3-morpholinopyrrolidin-1-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1212 
                 N-(3-((3aR,6aR)-4-acetylhexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1213 
                 N-(3-((3aR,6aS)-4-acetylhexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1214 
                 N-(3-((3aS,6aS)-4-acetylhexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1215 
                 N-(3-((3aS,6aR)-4-acetylhexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1216 
                 N-(3-((3aR,6aR)-1-acetylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1217 
                 N-(3-((3aS,6aR)-1-acetylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1218 
                 N-(3-((3aS,6aS)-1-acetylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1219 
                 N-(3-((3aR,6aS)-1-acetylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-5- 
               
               
                   
                 fluorophenyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide 
               
               
                 1220 
                 4-fluoro-N-(3-fluoro-5-((S)-3-((S)-2-(hydroxymethyl)morpholino)pyrrolidin-1- 
               
               
                   
                 yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1221 
                 4-fluoro-N-(3-fluoro-5-((S)-3-((R)-2-(hydroxymethyl)morpholino)pyrrolidin-1- 
               
               
                   
                 yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1222 
                 4-fluoro-N-(3-fluoro-5-((R)-3-((R)-2-(hydroxymethyl)morpholino)pyrrolidin-1- 
               
               
                   
                 yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1223 
                 4-fluoro-N-(3-fluoro-5-((R)-3-((S)-2-(hydroxymethyl)morpholino)pyrrolidin-1- 
               
               
                   
                 yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1224 
                 (R)-4-fluoro-N-(3-fluoro-5-(3-(4-methyl-3-oxopiperazin-1-yl)pyrrolidin-1- 
               
               
                   
                 yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1225 
                 (S)-4-fluoro-N-(3-fluoro-5-(3-(4-methyl-3-oxopiperazin-1-yl)pyrrolidin-1- 
               
               
                   
                 yl)phenyl)-7-methyl-1H-indole-2-carboxamide 
               
               
                 1226 
                 (S)-4-fluoro-N-(3-fluoro-5-(2-oxo-[1,3′-bipyrrolidin]-1′-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1227 
                 (R)-4-fluoro-N-(3-fluoro-5-(2-oxo-[1,3′-bipyrrolidin]-1′-yl)phenyl)-7-methyl-1H- 
               
               
                   
                 indole-2-carboxamide 
               
               
                 1228 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((3aS,6aS)-1-methyl-2- 
               
               
                   
                 oxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1229 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((3aS,6aS)-1-methyl-2- 
               
               
                   
                 oxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1230 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((3aR,6aR)-1-methyl-2- 
               
               
                   
                 oxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1231 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((3aR,6aR)-1-methyl-2- 
               
               
                   
                 oxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1232 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((3aS,6aS)-4-methyl-5- 
               
               
                   
                 oxohexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1233 
                 4-fluoro-7-methyl-N-((1R,3S)-3-((3aR,6aR)-4-methyl-5- 
               
               
                   
                 oxohexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1234 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((3aS,6aS)-4-methyl-5- 
               
               
                   
                 oxohexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                 1235 
                 4-fluoro-7-methyl-N-((1R,3R)-3-((3aR,6aR)-4-methyl-5- 
               
               
                   
                 oxohexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)cyclohexyl)-1H-indole-2- 
               
               
                   
                 carboxamide 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
             
               
                 TABLE 1B 
               
               
                   
               
               
                   
                   
                 SETD2 
                 SETD2 
               
               
                 Cpd. No. 
                 STRUCTURE 
                 (1434-1711) 
                 A549 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                  15 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 0.02 
                 0.05 
               
               
                   
               
               
                 1228 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 0.04 
                 0.09 
               
               
                   
               
               
                 1229 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 8.8 
                 2 
               
               
                   
               
               
                 1230 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 0.04 
                 0.09 
               
               
                   
               
               
                 1231 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 9.8 
                 2 
               
               
                   
               
               
                 1232 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 0.008 
                 0.01 
               
               
                   
               
               
                 1233 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 0.04 
                 0.04 
               
               
                   
               
               
                 1234 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 4.2 
                 2 
               
               
                   
               
               
                 1235 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 10 
                 2 
               
               
                   
               
            
           
         
       
     
     The present disclosure encompasses the preparation and use of salts of the Compounds of the Disclosure, including non-toxic pharmaceutically acceptable salts. Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts and basic salts. The pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulphate and the like; organic acid salts such as citrate, lactate, tartrate, maleate, fumarate, mandelate, acetate, dichloroacetate, trifluoroacetate, oxalate, formate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate and the like; and amino acid salts such as arginate, asparginate, glutamate and the like. The term “pharmaceutically acceptable salt” as used herein, refers to any salt, e.g., obtained by reaction with an acid or a base, of a Compound of the Disclosure that is physiologically tolerated in the target subject (e.g., a mammal, e.g., a human). 
     Acid addition salts can be formed by mixing a solution of the particular Compound of the Disclosure with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, dichloroacetic acid, or the like. Basic salts can be formed by mixing a solution of the compound of the present disclosure with a solution of a pharmaceutically acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate and the like. 
     The present disclosure encompasses the preparation and use of solvates of Compounds of the Disclosure. Solvates typically do not significantly alter the physiological activity or toxicity of the compounds, and as such may function as pharmacological equivalents. The term “solvate” as used herein is a combination, physical association and/or solvation of a compound of the present disclosure with a solvent molecule such as, e.g. a disolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to compound of the present disclosure is about 2:1, about 1:1 or about 1:2, respectively. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. Thus, “solvate” encompasses both solution-phase and isolatable solvates. Compounds of the Disclosure can be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, ethanol, and the like, and it is intended that the disclosure includes both solvated and unsolvated forms of Compounds of the Disclosure. One type of solvate is a hydrate. A “hydrate” relates to a particular subgroup of solvates where the solvent molecule is water. Solvates typically can function as pharmacological equivalents. Preparation of solvates is known in the art. See, for example, M. Caira et al,  J. Pharmaceut. Sci.,  93(3):601-611 (2004), which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by E. C. van Tonder et al.,  AAPS Pharm. Sci. Tech.,  5(1):Article 12 (2004), and A. L. Bingham et al.,  Chem. Commun.  603-604 (2001). A typical, non-limiting, process of preparing a solvate would involve dissolving a Compound of the Disclosure in a desired solvent (organic, water, or a mixture thereof) at temperatures above 20° C. to about 25° C., then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration. Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate. 
     II. Second Therapeutic Agents 
     In some embodiments, the therapeutic methods of the present disclosure comprise administering a therapeutically effective amount of a Compound of the Disclosure in combination with a therapeutically effective amount of a Second Therapeutic Agent. 
     The term “Second Therapeutic Agent” as used herein comprises one or more glucocorticoid receptor agonists, one or more immunomodulatory drugs, one or more proteasome inhibitors, one or more Bcl-2 inhibitors, one or more pleiotropic pathway modulators, one or more XPO1 inhibitors, one or more histone deacetylase inhibitors, or one or more EZH2 inhibitors, or a combination thereof. In one embodiment, the Second Therapeutic Agent comprises one compound from one drug class, i.e., one glucocorticoid receptor agonist, one immunomodulatory drug, one proteasome inhibitor, one Bcl-2 inhibitor, one pleiotropic pathway modulator, one XPO1 inhibitor, one histone deacetylase inhibitor, or one EZH2 inhibitor. In another embodiment, the Second Therapeutic Agent comprises two different compounds from one drug class, e.g., two different glucocorticoid receptor agonists, e.g., dexamethasone and prednisone, two different immunomodulatory drugs, two different proteasome inhibitors, two different Bcl-2 inhibitors, two different pleiotropic pathway modulators, two different XPO1 inhibitors, two different histone deacetylase inhibitors, or two different EZH2 inhibitors. In another embodiment, the Second Therapeutic Agent comprises three different compounds from one drug class, e.g., three different glucocorticoid receptor agonists, e.g., dexamethasone, prednisone, and methylprednisolone, three different immunomodulatory drugs, three different proteasome inhibitors, three different Bcl-2 inhibitors, three different pleiotropic pathway modulators, three different XPO1 inhibitors, three different histone deacetylase inhibitors, or three different EZH2 inhibitors. In another embodiment, the Second Therapeutic Agent comprises three different compounds from two drug classes, e.g., two different glucocorticoid receptor agonists, e.g., dexamethasone and prednisone, and one immunomodulatory drug; two different glucocorticoid receptor agonists and one proteasome inhibitor; and so on. 
     In another embodiment, the Second Therapeutic Agent comprises compounds from different drug classes, for example, a first compound from a first drug class and second compound from a second drug class, wherein the first drug class and the second drug class are different. As a specific non-limiting example, the Second Therapeutic agent comprises an EZH2 inhibitor, e.g., tazemetostat, and an immunomodulatory drug, e.g., lenoliminide. Non-limiting examples of combinations of drug classes are provide in the following table: 
     
       
         
           
               
               
               
             
               
                   
               
               
                 No. 
                 Drug Class # 1 
                 Drug Class # 2 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 1 
                 GR agonist 
                 IMiD 
               
               
                 2 
                 GR agonist 
                 Proteasome inhibitor 
               
               
                 3 
                 GR agonist 
                 Bcl-2 inhibitor 
               
               
                 4 
                 GR agonist 
                 Pleiotropic pathway modulator 
               
               
                 5 
                 GR agonist 
                 XPO1 inhibitor 
               
               
                 6 
                 GR agonist 
                 HD inhibitor 
               
               
                 7 
                 GR agonist 
                 EZH2 inhibitor 
               
               
                 8 
                 IMiD 
                 Proteasome inhibitor 
               
               
                 9 
                 IMiD 
                 Bcl-2 inhibitor 
               
               
                 10 
                 IMiD 
                 Pleiotropic pathway modulator 
               
               
                 11 
                 IMiD 
                 XPO1 inhibitor 
               
               
                 12 
                 IMiD 
                 HD inhibitor 
               
               
                 13 
                 IMiD 
                 EZH2 inhibitor 
               
               
                 14 
                 Proteasome inhibitor 
                 Bcl-2 inhibitor 
               
               
                 15 
                 Proteasome inhibitor 
                 Pleiotropic pathway modulator 
               
               
                 16 
                 Proteasome inhibitor 
                 XPO1 inhibitor 
               
               
                 17 
                 Proteasome inhibitor 
                 HD inhibitor 
               
               
                 18 
                 Proteasome inhibitor 
                 EZH2 inhibitor 
               
               
                 19 
                 Bcl-2 inhibitor 
                 Pleiotropic pathway modulator 
               
               
                 20 
                 Bcl-2 inhibitor 
                 XPO1 inhibitor 
               
               
                 21 
                 Bcl-2 inhibitor 
                 HD inhibitor 
               
               
                 22 
                 Bcl-2 inhibitor 
                 EZH2 inhibitor 
               
               
                 23 
                 Pleiotropic pathway modulator 
                 XPO1 inhibitor 
               
               
                 24 
                 Pleiotropic pathway modulator 
                 HD inhibitor 
               
               
                 25 
                 Pleiotropic pathway modulator 
                 EZH2 inhibitor 
               
               
                 26 
                 XPO1 inhibitor 
                 HD inhibitor 
               
               
                 27 
                 XPO1 inhibitor 
                 EZH2 inhibitor 
               
               
                 28 
                 HD inhibitor 
                 EZH2 inhibitor 
               
               
                   
               
            
           
         
       
     
     In another embodiment, the Second Therapeutic Agent comprises three compounds from three different drug classes. For example, in one embodiment, the Second Therapeutic Agent comprises a first compound from a first drug class, and a second compound from a second drug class, and a third compound from a third drug class, wherein the first drug class, the second drug class, and the third drug class are different. Non-limiting examples of combinations of drug classes are provide in the following table: 
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 No. 
                 Drug Class # 1 
                 Drug Class # 2 
                 Drug Class # 3 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 1 
                 GR agonist 
                 IMiD 
                 Proteasome inhibitor 
               
               
                 2 
                 GR agonist 
                 IMiD 
                 Bcl-2 inhibitor 
               
               
                 3 
                 GR agonist 
                 IMiD 
                 Pleiotropic pathway 
               
               
                   
                   
                   
                 modulator 
               
               
                 4 
                 GR agonist 
                 IMiD 
                 XPO1 inhibitor 
               
               
                 5 
                 GR agonist 
                 IMiD 
                 HD inhibitor 
               
               
                 6 
                 GR agonist 
                 IMiD 
                 EZH2 inhibitor 
               
               
                 7 
                 GR agonist 
                 Proteasome inhibitor 
                 Bcl-2 inhibitor 
               
               
                 8 
                 GR agonist 
                 Proteasome inhibitor 
                 Pleiotropic pathway 
               
               
                   
                   
                   
                 modulator 
               
               
                 9 
                 GR agonist 
                 Proteasome inhibitor 
                 XPO1 inhibitor 
               
               
                 10 
                 GR agonist 
                 Proteasome inhibitor 
                 HD inhibitor 
               
               
                 11 
                 GR agonist 
                 Proteasome inhibitor 
                 EZH2 inhibitor 
               
               
                 12 
                 GR agonist 
                 Bcl-2 inhibitor 
                 Pleiotropic pathway 
               
               
                   
                   
                   
                 modulator 
               
               
                 13 
                 GR agonist 
                 Bcl-2 inhibitor 
                 XPO1 inhibitor 
               
               
                 14 
                 GR agonist 
                 Bcl-2 inhibitor 
                 HD inhibitor 
               
               
                 15 
                 GR agonist 
                 Bcl-2 inhibitor 
                 EZH2 inhibitor 
               
               
                 16 
                 GR agonist 
                 Pleiotropic pathway 
                 XPO1 inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 17 
                 GR agonist 
                 Pleiotropic pathway 
                 HD inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 18 
                 GR agonist 
                 Pleiotropic pathway 
                 EZH2 inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 19 
                 GR agonist 
                 XPO1 inhibitor 
                 HD inhibitor 
               
               
                 20 
                 GR agonist 
                 XPO1 inhibitor 
                 EZH2 inhibitor 
               
               
                 21 
                 GR agonist 
                 HD inhibitor 
                 EZH2 inhibitor 
               
               
                 22 
                 IMiD 
                 Proteasome inhibitor 
                 Bcl-2 inhibitor 
               
               
                 23 
                 IMiD 
                 Proteasome inhibitor 
                 Pleiotropic pathway 
               
               
                   
                   
                   
                 modulator 
               
               
                 24 
                 IMiD 
                 Proteasome inhibitor 
                 XPO1 inhibitor 
               
               
                 25 
                 IMiD 
                 Proteasome inhibitor 
                 HD inhibitor 
               
               
                 26 
                 IMiD 
                 Proteasome inhibitor 
                 EZH2 inhibitor 
               
               
                 27 
                 IMiD 
                 Bcl-2 inhibitor 
                 Pleiotropic pathway 
               
               
                   
                   
                   
                 modulator 
               
               
                 28 
                 IMiD 
                 Bcl-2 inhibitor 
                 XPO1 inhibitor 
               
               
                 29 
                 IMiD 
                 Bcl-2 inhibitor 
                 HD inhibitor 
               
               
                 30 
                 IMiD 
                 Bcl-2 inhibitor 
                 EZH2 inhibitor 
               
               
                 31 
                 IMiD 
                 Pleiotropic pathway 
                 XPO1 inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 32 
                 IMiD 
                 Pleiotropic pathway 
                 HD inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 33 
                 IMiD 
                 Pleiotropic pathway 
                 EZH2 inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 34 
                 IMiD 
                 XPO1 inhibitor 
                 HD inhibitor 
               
               
                 35 
                 IMiD 
                 XPO1 inhibitor 
                 EZH2 inhibitor 
               
               
                 36 
                 IMiD 
                 HD inhibitor 
                 EZH2 inhibitor 
               
               
                 37 
                 Proteasome inhibitor 
                 Bcl-2 inhibitor 
                 Pleiotropic pathway 
               
               
                   
                   
                   
                 modulator 
               
               
                 38 
                 Proteasome inhibitor 
                 Bcl-2 inhibitor 
                 XPO1 inhibitor 
               
               
                 39 
                 Proteasome inhibitor 
                 Bcl-2 inhibitor 
                 HD inhibitor 
               
               
                 40 
                 Proteasome inhibitor 
                 Bcl-2 inhibitor 
                 EZH2 inhibitor 
               
               
                 41 
                 Proteasome inhibitor 
                 Pleiotropic pathway 
                 XPO1 inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 42 
                 Proteasome inhibitor 
                 Pleiotropic pathway 
                 HD inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 43 
                 Proteasome inhibitor 
                 Pleiotropic pathway 
                 EZH2 inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 44 
                 Proteasome inhibitor 
                 XPO1 inhibitor 
                 HD inhibitor 
               
               
                 45 
                 Proteasome inhibitor 
                 XPO1 inhibitor 
                 EZH2 inhibitor 
               
               
                 46 
                 Proteasome inhibitor 
                 HD inhibitor 
                 EZH2 inhibitor 
               
               
                 47 
                 Bcl-2 inhibitor 
                 Pleiotropic pathway 
                 XPO1 inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 48 
                 Bcl-2 inhibitor 
                 Pleiotropic pathway 
                 HD inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 49 
                 Bcl-2 inhibitor 
                 Pleiotropic pathway 
                 EZH2 inhibitor 
               
               
                   
                   
                 modulator 
               
               
                 50 
                 Bcl-2 inhibitor 
                 XPO1 inhibitor 
                 HD inhibitor 
               
               
                 51 
                 Bcl-2 inhibitor 
                 XPO1 inhibitor 
                 EZH2 inhibitor 
               
               
                 52 
                 Bcl-2 inhibitor 
                 HD inhibitor 
                 EZH2 inhibitor 
               
               
                 53 
                 Pleiotropic pathway 
                 XPO1 inhibitor 
                 HD inhibitor 
               
               
                   
                 modulator 
               
               
                 54 
                 Pleiotropic pathway 
                 XPO1 inhibitor 
                 EZH2 inhibitor 
               
               
                   
                 modulator 
               
               
                 55 
                 Pleiotropic pathway 
                 HD inhibitor 
                 EZH2 inhibitor 
               
               
                   
                 modulator 
               
               
                 56 
                 XPO1 inhibitor 
                 HD inhibitor 
                 EZH2 inhibitor 
               
               
                   
               
            
           
         
       
     
     The term “glucocorticoid receptor agonist” or “GR agonist” as used herein refers to a compound that activates the glucocorticoid receptor. Glucocorticoid receptor agonists and methods of administering glucocorticoid receptor agonists to a subject are known in the art. See, e.g., Pufall, M. A.,  Adv Exp Med Biol.  872:315-333 (2015). Exemplary glucocorticoid receptor agonists include, but are not limited to, dexamethasone, hydrocortisone, corticosterone, prednisolone, methylprednisolone, prednisone, triamcinolone, mapracorat, ciclesonide, and (20S)-protopanaxatriol. In one embodiment, the glucocorticoid receptor agonist is prednisone. In another embodiment, the glucocorticoid receptor agonist is dexamethasone. 
     The term “immunomodulatory drug” or “IMiD” as used herein refers to a compound that inhibits the production of tumour necrosis factor, interleukin 6, immunoglobulin G, and/or VEGF, andand/or co-stimulates T cells and NK cells, and/or increases interferon gamma and interleukin 2 production. Immunomodulatory drugs and methods of administering immunomodulatory drugs to a subject are known in the art. Exemplary immunomodulatory drugs include, but art not limited to, thalidomide, lenalidomide, and pomalidomide. In one embodiment, the immunomodulatory drug is pomalidomide. 
     The term “proteasome inhibitor” as used herein refers to a compound that blocks the action of proteasomes and thus prevents the degredation of pro-apoptotic factors such as p53 protein. Proteasome inhibitors and methods of administering proteasome inhibitors to a subject are known in the art. Exemplary proteasome inhibitors include, but art not limited to, bortezomib, carfilzomib, and ixazomib. In one embodiment, the proteasome inhibitor inhibitor is bortezomib. 
     The term “Bcl-2 inhibitor” as used herein refers to a compound that inhibits the anti-apoptotic Bcl-2 protein. Bcl-2 inhibitors and methods of administering Bcl-2 inhibitors to a subject are known in the art. Examplary Bcl-2 inhibitors include but are not limited to, navitoclax (ABT-263), ABT-737, Sabutoclax, AT-1019 (Gossypol), TW-37, venetoclax (ABT-199), obatoclax, HA14-1, A-1155463, A-1331852, and WEHI-539. In one embodiment, the Bcl-2 inhibitor is venetoclax. 
     The term “pleiotropic pathway modulator” as used herein refers to compound that binds to cereblon to promote protein degredation. Pleiotropic pathway modulators and methods of administering pleiotropic pathway modulators to a subject are known in the art are known in the art. See, e.g., Hagner et al.,  Blood  126:779-789 (2017). A non-limiting exemplary pleiotropic pathway modulator is CC-122. 
     The term “XPO1 inhibitor” as used herein refers to an inhibitor of exportin-1 (also known as chromosome region maintenance 1 protein homolog; CRM1). XPO1 inhibitors and methods of administering XPO1 inhibitors to a subject are known in the art. See, e.g., Wang and Liu,  Stem Cell Invest  6:6 (2019). A non-limiting exemplary XPO1 inhibitor is selinexor. 
     The term “histone deacetylase inhibitor” or “HD inhibitor” as used herein refers to a compound that inhibit histone deactylase enzymes. Histone deacetylase inhibitors and methods of administering histone deacetylase inhibitors to a subject are known in the art. See, e.g., Eckschlager et al.,  Int. J. Mol. Sci.  18:1414 (2017) doi: 10.3390/ijms18071414. Exemplary histone deacetylase inhibitors include, but are not limited to, romidepsin, belinostat, panobinostat, and vorinostate. In one embodiment, the histone deacetylase inhibitor is panobinostat. 
     The term “EZH2 inhibitor” as used herein refers to a compound that inhibits the enhancer of zeste homolog 2 enzyme. EZH2 inhibitors and methods of administering EZH2 inhibitors to a subject are known in the art. See, e.g., Lue and Amengual,  Curr Hematol Malig Rep  13:369-382 (2018). Exemplary EZH2 inhibitors include, but are not limited to, tazemetostat, EPZ011989, EPZ005687, GSK126, PF-06821497, and valemetostat. In one embodiment, the EZH2 inhibitor is tazemetostat. 
     The disclosure provides the following particular embodiments relating to combination therapy (CT): 
     CT Embodiment I. A method of treating a subject in need thereof, the method comprising administering to the subject: (a) a therapeutically effective amount of a Compound of the Disclosure; and (b) a therapeutically effective amount of a Second Therapeutic Agent, wherein the Second Therapeutic Agent comprises a glucocorticoid receptor agonist, an immunomodulatory drug, a proteasome inhibitor, a Bcl-2 inhibitor, a pleiotropic pathway modulator, a XPO1 inhibitor, a histone deacetylase inhibitor, or an EZH2 inhibitor, or a combination thereof; and the subject has cancer. 
     CT Embodiment II. The method of CT Embodiment I, wherein the Second Therapeutic Agent comprises a glucocorticoid receptor agonist. 
     CT Embodiment III. The method of CT Embodiment II, wherein the glucocorticoid receptor agonist is dexamethasone. 
     CT Embodiment IV. The method of any one of CT Embodiments I-III, wherein the Second Therapeutic Agent comprises an immunomodulatory drug. 
     CT Embodiment V. The method of CT Embodiment IV, wherein the immunomodulatory drug is pomalidomide or lenalidomide. 
     CT Embodiment VI. The method of any one of CT Embodiments I-V, wherein the Second Therapeutic Agent comprises a proteasome inhibitor. 
     CT Embodiment VII. The method of CT Embodiment VI, wherein the proteasome inhibitor is bortezomib. 
     CT Embodiment VIII. The method of any one of CT Embodiment I-VII, wherein the Second Therapeutic Agent comprises a Bcl-2 inhibitor. 
     CT Embodiment IX. The method of CT Embodiment VIII, wherein the Bcl-2 inhibitor is venetoclax. 
     CT Embodiment X. The method of any one of CT Embodiments I-IX, wherein the Second Therapeutic Agent comprises a pleiotropic pathway modulator. 
     CT Embodiment XI. The method of CT Embodiment X, wherein the pleiotropic pathway modulator is CC-122. 
     CT Embodiment XII. The method of any one of CT Embodiments I-XI, wherein the Second Therapeutic Agent comprises a XPO1 inhibitor. 
     CT Embodiment XIII. The method of CT Embodiment XII, wherein the XPO1 inhibitor is selinexor 
     CT Embodiment XIV.The method of any one of CT Embodiments I-XIII, wherein the Second Therapeutic Agent comprises a histone deacetylase inhibitor. 
     CT Embodiment XV. The method of CT Embodiment XIV, wherein the histone deacetylase inhibitor is panobinostat. 
     CT Embodiment XVI. The method of any one of CT Embodiments I-XV, wherein the Second Therapeutic Agent is an EZH2 inhibitor. 
     CT Embodiment XVII. The method of CT Embodiment XVI, wherein the EZH2 inhibitor is tazemetostat. 
     III. Therapeutic Methods 
     The present disclosure is directed generally to a method for treating a disease, condition, or disorder in a subject suffering from, or at risk of suffering from, the disease, condition, or disorder, the method comprising administering to the subject an effective amount of a Compound of the Disclosure and, optionally, a Second Therapeutic Agent. In one embodiment, the disease, condition, or disorder is responsive to or mediated by the inhibition of SETD2 protein by a Compound of the Disclosure. 
     In the therapeutic methods provided herein, a Compound of the Disclosure can be administered to a subject having cancer as a single agent. A Compound of the Disclosure can also be administered to a subject having cancer in combination with a Second Therapeutic Agent. A Compound of the Disclosure and the Second Therapeutic Agent can be administered in combination under one or more of the following conditions: as separate pharmaceutical compositions, at different periodicities, e.g., simultaneously or sequentially, at different durations, at different concentrations, by different administration routes, etc. Additional optional therapeutic, e.g., anticancer, agents may also be administered to the cancer patient. 
     The present disclosure is also directed to a method of inhibiting SETD2 protein in subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a Compound of the Disclosure. 
     In one aspect, the present disclosure provides a method of treating a disease, disorder, or condition in a subject comprising administering a therapeutically effective amount of a Compound of the Disclosure. 
     In another aspect, the present disclosure provides a method of treating a disease, disorder, or condition in a subject comprising administering a therapeutically effective amount of a Compound of the Disclosure in combination with a Second Therapeutic Agent. 
     In another aspect, the present disclosure provides a method of treating cancer in a subject comprising administering a therapeutically effective amount of a Compound of the Disclosure. In another aspect, the present disclosure provides a method of treating cancer in a subject comprising administering a therapeutically effective amount of a Compound of the Disclosure in combination with a Second Therapeutic Agent. While not being limited to a specific mechanism, in some embodiments, Compounds of the Disclosure treat cancer by inhibiting SETD2 protein. Examples of treatable cancers include, but are not limited to, the cancers listed in Table 2. 
     
       
         
           
               
               
             
               
                 TABLE 2 
               
               
                   
               
             
            
               
                 adrenal cancer 
                 lymphoepithelioma 
               
               
                 acinic cell carcinoma 
                 lymphoma 
               
               
                 acoustic neuroma 
                 acute lymphocytic leukemia 
               
               
                 acral lentigious melanoma 
                 acute myelogeous leukemia 
               
               
                 acrospiroma 
                 chronic lymphocytic leukemia 
               
               
                 acute eosinophilic leukemia 
                 liver cancer 
               
               
                 acute erythroid leukemia 
                 small cell lung cancer 
               
               
                 acute lymphoblastic leukemia 
                 non-small cell lung cancer 
               
               
                 acute megakaryoblastic leukemia 
                 MALT lymphoma 
               
               
                 acute monocytic leukemia 
                 malignant fibrous histiocytoma 
               
               
                 acute promyelocytic leukemia 
                 malignant peripheral nerve sheath 
               
               
                   
                 tumor 
               
               
                 adenocarcinoma 
                 malignant triton tumor 
               
               
                 adenoid cystic carcinoma 
                 mantle cell lymphoma 
               
               
                 adenoma 
                 marginal zone B-cell lymphoma 
               
               
                 adenomatoid odontogenic tumor 
                 mast cell leukemia 
               
               
                 adenosquamous carcinoma 
                 mediastinal germ cell tumor 
               
               
                 adipose tissue neoplasm 
                 medullary carcinoma of the breast 
               
               
                 adrenocortical carcinoma 
                 medullary thyroid cancer 
               
               
                 adult T-cell leukemia/lymphoma 
                 medulloblastoma 
               
               
                 aggressive NK-cell leukemia 
                 melanoma 
               
               
                 AIDS-related lymphoma 
                 meningioma 
               
               
                 alveolar rhabdomyosarcoma 
                 merkel cell cancer 
               
               
                 alveolar soft part sarcoma 
                 mesothelioma 
               
               
                 ameloblastic fibroma 
                 metastatic urothelial carcinoma 
               
               
                 anaplastic large cell lymphoma 
                 mixed Mullerian tumor 
               
               
                 anaplastic thyroid cancer 
                 mucinous tumor 
               
               
                 angioimmunoblastic T-cell 
                 multiple myeloma 
               
               
                 lymphoma 
               
               
                 angiomyolipoma 
                 muscle tissue neoplasm 
               
               
                 angiosarcoma 
                 mycosis fungoides 
               
               
                 astrocytoma 
                 myxoid liposarcoma 
               
               
                 atypical teratoid rhabdoid tumor 
                 myxoma 
               
               
                 B-cell chronic lymphocytic 
                 myxosarcoma 
               
               
                 leukemia 
               
               
                 B-cell prolymphocytic leukemia 
                 nasopharyngeal carcinoma 
               
               
                 B-cell lymphoma 
                 neurinoma 
               
               
                 basal cell carcinoma 
                 neuroblastoma 
               
               
                 biliary tract cancer 
                 neurofibroma 
               
               
                 bladder cancer 
                 neuroma 
               
               
                 blastoma 
                 nodular melanoma 
               
               
                 bone cancer 
                 ocular cancer 
               
               
                 Brenner tumor 
                 oligoastrocytoma 
               
               
                 Brown tumor 
                 oligodendroglioma 
               
               
                 Burkitt&#39;s lymphoma 
                 oncocytoma 
               
               
                 breast cancer 
                 optic nerve sheath meningioma 
               
               
                 brain cancer 
                 optic nerve tumor 
               
               
                 carcinoma 
                 oral cancer 
               
               
                 carcinoma in situ 
                 osteosarcoma 
               
               
                 carcinosarcoma 
                 ovarian cancer 
               
               
                 cartilage tumor 
                 Pancoast tumor 
               
               
                 cementoma 
                 papillary thyroid cancer 
               
               
                 myeloid sarcoma 
                 paraganglioma 
               
               
                 chondroma 
                 pinealoblastoma 
               
               
                 chordoma 
                 pineocytoma 
               
               
                 choriocarcinoma 
                 pituicytoma 
               
               
                 choroid plexus papilloma 
                 pituitary adenoma 
               
               
                 clear-cell sarcoma of the kidney 
                 pituitary tumor 
               
               
                 craniopharyngioma 
                 plasmacytoma 
               
               
                 cutaneous T-cell lymphoma 
                 polyembryoma 
               
               
                 cervical cancer 
                 precursor T-lymphoblastic lymphoma 
               
               
                 colorectal cancer 
                 primary central nervous system 
               
               
                   
                 lymphoma 
               
               
                 Degos disease 
                 primary effusion lymphoma 
               
               
                 desmoplastic small round cell 
                 preimary peritoneal cancer 
               
               
                 tumor 
               
               
                 diffuse large B-cell lymphoma 
                 prostate cancer 
               
               
                 dysembryoplastic neuroepithelial 
                 pancreatic cancer 
               
               
                 tumor 
               
               
                 dysgerminoma 
                 pharyngeal cancer 
               
               
                 embryonal carcinoma 
                 pseudomyxoma periotonei 
               
               
                 endocrine gland neoplasm 
                 renal cell carcinoma 
               
               
                 endodermal sinus tumor 
                 renal medullary carcinoma 
               
               
                 enteropathy-associated T-cell 
                 retinoblastoma 
               
               
                 lymphoma 
               
               
                 esophageal cancer 
                 rhabdomyoma 
               
               
                 fetus in fetu 
                 rhabdomyosarcoma 
               
               
                 fibroma 
                 Richter&#39;s transformation 
               
               
                 fibrosarcoma 
                 rectal cancer 
               
               
                 follicular lymphoma 
                 sarcoma 
               
               
                 follicular thyroid cancer 
                 Schwannomatosis 
               
               
                 ganglioneuroma 
                 seminoma 
               
               
                 gastrointestinal cancer 
                 Sertoli cell tumor 
               
               
                 germ cell tumor 
                 sex cord-gonadal stromal tumor 
               
               
                 gestational choriocarcinoma 
                 signet ring cell carcinoma 
               
               
                 giant cell fibroblastoma 
                 skin cancer 
               
               
                 giant cell tumor of the bone 
                 small blue round cell tumors 
               
               
                 glial tumor 
                 small cell carcinoma 
               
               
                 glioblastoma multiforme 
                 soft tissue sarcoma 
               
               
                 glioma 
                 somatostatinoma 
               
               
                 gliomatosis cerebri 
                 soot wart 
               
               
                 glucagonoma 
                 spinal tumor 
               
               
                 gonadoblastoma 
                 splenic marginal zone lymphoma 
               
               
                 granulosa cell tumor 
                 squamous cell carcinoma 
               
               
                 gynandroblastoma 
                 synovial sarcoma 
               
               
                 gallbladder cancer 
                 Sezary&#39;s disease 
               
               
                 gastric cancer 
                 small intestine cancer 
               
               
                 hairy cell leukemia 
                 squamous carcinoma 
               
               
                 hemangioblastoma 
                 stomach cancer 
               
               
                 head and neck cancer 
                 T-cell lymphoma 
               
               
                 hemangiopericytoma 
                 testicular cancer 
               
               
                 hematological malignancy 
                 thecoma 
               
               
                 hepatoblastoma 
                 thyroid cancer 
               
               
                 hepatosplenic T-cell lymphoma 
                 transitional cell carcinoma 
               
               
                 Hodgkin&#39;s lymphoma 
                 throat cancer 
               
               
                 non-Hodgkin&#39;s lymphoma 
                 urachal cancer 
               
               
                 invasive lobular carcinoma 
                 urogenital cancer 
               
               
                 intestinal cancer 
                 urothelial carcinoma 
               
               
                 kidney cancer 
                 uveal melanoma 
               
               
                 laryngeal cancer 
                 uterine cancer 
               
               
                 lentigo maligna 
                 verrucous carcinoma 
               
               
                 lethal midline carcinoma 
                 visual pathway glioma 
               
               
                 leukemia 
                 vulvar cancer 
               
               
                 leydig cell tumor 
                 vaginal cancer 
               
               
                 liposarcoma 
                 Waldenstrom&#39;s macroglobulinemia 
               
               
                 lung cancer 
                 Warthin&#39;s tumor 
               
               
                 lymphangioma 
                 Wilms&#39; tumor. 
               
               
                 lymphangiosarcoma 
               
               
                   
               
            
           
         
       
     
     In another embodiment, the cancer is pancreatic cancer or esophageal cancer. 
     In another embodiment, the cancer is selected from the group consisting of esophageal cancer, kidney cancer, stomach cancer, hepatocellular carcinoma, glioblastoma, central nervous system (CNS) cancer, soft tissue cancer, lung cancer, breast cancer, bladder/urinary tract cancer, head and neck cancer, prostate cancer, hematological cancer, pancreatic cancer, skin cancer, endometrial cancer, ovarian cancer, and colorectal cancer. 
     In another embodiment, the cancer or cancer cell is a hematological cancer. Exemplary hematological cancers include, but are not limited to, the cancers listed in Table 3. 
     
       
         
           
               
               
             
               
                 TABLE 3 
               
               
                   
               
             
            
               
                 acute lymphocytic leukemia (ALL) 
                 acute eosinophilic leukemia 
               
               
                 acute myeloid leukemia (AML) 
                 acute erythroid leukemia 
               
               
                 chronic lymphocytic leukemia (CLL) 
                 acute lymphoblastic leukemia 
               
               
                 small lymphocytic lymphoma (SLL) 
                 acute megakaryoblastic leukemia 
               
               
                 multiple myeloma (MM) 
                 acute monocytic leukemia 
               
               
                 Hodgkins lymphoma (HL) 
                 acute promyelocytic leukemia 
               
               
                 non-Hodgkin&#39;s lymphoma (NHL) 
                 acute myelogeous leukemia 
               
               
                 mantle cell lymphoma (MCL) 
                 B-cell prolymphocytic leukemia 
               
               
                 marginal zone B-cell lymphoma 
                 B-cell lymphoma 
               
               
                 splenic marginal zone lymphoma 
                 MALT lymphoma 
               
               
                 follicular lymphoma (FL) 
                 precursor T-lymphoblastic 
               
               
                   
                 lymphoma 
               
               
                 Waldenstrom&#39;s macroglobulinemia 
                 T-cell lymphoma 
               
               
                 (WM) 
               
               
                 diffuse large B-cell lymphoma 
                 mast cell leukemia 
               
               
                 (DLBCL) 
               
               
                 marginal zone lymphoma (MZL) 
                 adult T cell leukemia/lymphoma 
               
               
                 hairy cell leukemia (HCL) 
                 aggressive NK-cell leukemia 
               
               
                 Burkitt&#39;s lymphoma (BL) 
                 angioimmunoblastic T-cell 
               
               
                   
                 lymphoma 
               
               
                 Richter&#39;s transformation 
               
               
                   
               
            
           
         
       
     
     In another embodiment, the cancer is multiple myeloma. 
     In another embodiment, the multiple myeloma is characterized as having chromosomal translocations involving the immunoglobulin heavy chain locus at 14q32. In another embodiment, the chromosomal translocation is a t(4;14) translocation, i.e., the multiple myeloma is t(4;14) multiple myeloma. 
     In another embodiment, the cancer is mantle cell lymphoma. 
     In another embodiment, the cancer is diffuse large B-cell lymphoma. 
     In another embodiment, the present disclosure provides a therapeutic method of modulating protein methylation, gene expression, cell proliferation, cell differentiation and/or apoptosis in vivo in the cancers mentioned above by administering a therapeutically effective amount of a Compound of the Disclosure to a subject in need of such therapy and, optionally, a Second Therapeutic Agent. 
     The present disclosure provides the following particular embodiments relating to Compounds of the Disclosure, methods of treating cancer with a Compound of the Disclosure, and methods of treating cancer with a Compound of the Disclosure in combination with a Second Therapeutic Agent. 
     Embodiment I. A method of treating a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a Compound of the Disclosure and, optionally, a Second Therapeutic Agent, wherein the subject has cancer, and the Second Therapeutic Agent is selected from the group consisting of a glucocorticoid receptor agonist, an immunomodulatory drug, a proteasome inhibitor, a Bcl-2 inhibitor, a pleiotropic pathway modulator, a XPO1 inhibitor, a histone deacetylase inhibitor, and an EZH2 inhibitor, or a combination thereof. 
     Embodiment II. The method of Embodiment I, wherein the cancer is any one or more of the cancers of Table 2. 
     Embodiment III. The method of Embodiment I, wherein the cancer is a hematological cancer. 
     Embodiment IV. The method of Embodiment III, wherein the hematological cancer is any one or more of the cancers of Table 3, e.g., multiple myeloma. 
     Embodiment V. The method of Embodiment IV, wherein the hematological cancer is t(4;14) multiple myeloma. 
     Embodiment VI. The method of any one of Embodiments I-V further comprising administering a therapeutically effective amount of a Second Therapeutic Agent. 
     Embodiment VII. A pharmaceutical composition comprising a Compound of the Disclosure and a pharmaceutically acceptable carrier for use in treating cancer, wherein the pharmaceutical composition comprising a Compound of the Disclosure is, optionally, to be administered in combination with a Second Therapeutic Agent, wherein the Second Therapeutic Agent is selected from the group consisting of a glucocorticoid receptor agonist, an immunomodulatory drug, a proteasome inhibitor, a Bcl-2 inhibitor, a pleiotropic pathway modulator, a XPO1 inhibitor, a histone deacetylase inhibitor, and an EZH2 inhibitor, or a combination thereof. 
     Embodiment VIII. The pharmaceutical composition of Embodiment VII, wherein the cancer is any one or more of the cancers of Table 2. 
     Embodiment IX. The pharmaceutical composition of Embodiment VII, wherein the cancer is a hematological cancer. 
     Embodiment X. The pharmaceutical composition of Embodiment IX, wherein the hematological cancer is any one or more of the cancers of Table 3, e.g., multiple myeloma. 
     Embodiment XI. The pharmaceutical composition of Embodiment X, wherein the hematological cancer is t(4;14) multiple myeloma. 
     Embodiment XII. A Compound of the Disclosure for use in treatment of cancer, wherein the Compound of the Disclosure is, optionally, to be administered in combination with a Second Therapeutic Agent, wherein the Second Therapeutic Agent is selected from the group consisting of a glucocorticoid receptor agonist, an immunomodulatory drug, a proteasome inhibitor, a Bcl-2 inhibitor, a pleiotropic pathway modulator, a XPO1 inhibitor, a histone deacetylase inhibitor, and an EZH2 inhibitor, or a combination thereof. 
     Embodiment XIII. The compound for use of Embodiment XII, wherein the cancer is any one or more of the cancers of Table 2. 
     Embodiment XIV. The compound for use of Embodiment XII, wherein the cancer is a hematological cancer. 
     Embodiment XV. The compound for use of Embodiment XIV, wherein the hematological cancer is any one or more of the cancers of Table 3, e.g., multiple myeloma. 
     Embodiment XVI. The compound for use of Embodiment XV, wherein the hematological cancer is t(4;14) multiple myeloma. 
     Embodiment XVII. Use of a Compound of the Disclosure for the manufacture of a medicament for treatment of cancer, wherein the medicament is, optionally, to be administered in combination with a Second Therapeutic Agent, wherein the Second Therapeutic Agent is selected from the group consisting of a glucocorticoid receptor agonist, an immunomodulatory drug, a proteasome inhibitor, a Bcl-2 inhibitor, a pleiotropic pathway modulator, a XPO1 inhibitor, a histone deacetylase inhibitor, and an EZH2 inhibitor, or a combination thereof. 
     Embodiment XVIII. The use of Embodiment XVII, wherein the cancer is any one or more of the cancers of Table 2. 
     Embodiment XVIII. The use of Embodiment XVII, wherein the cancer is a hematological cancer. 
     Embodiment XIX. The use of Embodiment XVII, wherein the hematological cancer is any one or more of the cancers of Table 3, e.g., multiple myeloma. 
     Embodiment XX. The use of Embodiment XIX, wherein the hematological cancer is t(4;14) multiple myeloma. 
     Embodiment XXI The use of any one of Embodiments XVII-XX for comprising a Secondary Therapeutic Agent. 
     Embodiment XXII. A kit comprising a Compound of the Disclosure and, optionally, a Second Therapeutic Agent, and instructions for administering the Compound of the Disclosure to a subject having cancer. 
     Embodiment XXIII. The kit of Embodiment XXII, wherein the cancer is any one or more of the cancers of Table 2. 
     Embodiment XXIV. The kit of Embodiment XXII, wherein the cancer is a hematological cancer. 
     Embodiment XXV. The kit of Embodiment XXIV, wherein the hematological cancer is any one or more of the cancers of Table 3, e.g., multiple myeloma. 
     Embodiment XXVI. The kit of Embodiment XXV, wherein the hematological cancer is t(4;14) multiple myeloma. 
     Embodiment XXVII. The kit of any one of Embodiments XXII-XXVI further comprising a Secondary Therapeutic Agent. 
     Embodiment XXVIII. The method of Embodiment VI, wherein the Compound of the Disclosure and the Second Therapeutic agent are administered simultaneously. 
     Embodiment XXIX. The method of Embodiment VI, wherein the Compound of the Disclosure and the Second Therapeutic agent are administered sequentially. 
     Embodiment XXX. The pharmaceutical composition of any one of Embodiments VII-XI, wherein the pharmaceutical composition is formulated for simultaneous administration of the Compound of the Disclosure and the Second Therapeutic Agent. 
     Embodiment XXXI. The pharmaceutical composition of any one of Embodiments VII-XI, wherein the pharmaceutical composition is formulated for sequential administration of the Compound of the Disclosure and the Second Therapeutic Agent. 
     Embodiment XXXII. The compound for use of any one of Embodiments XII-XVI, wherein the combination of the Compound of the Disclosure and the Second Therapeutic Agent is administered simultaneously. 
     Embodiment XXXIII. The compound for use of any one of Embodiments XII-XVI, wherein the combination of the Compound of the Disclosure and the Second Therapeutic Agent are administered sequentially. 
     Embodiment XXXIV. The use of any one of Embodiments XVII-XX, wherein the combination of the Compound of the Disclosure and the Second Therapeutic Agent is administered simultaneously. 
     Embodiment XXXV. The use of any one of Embodiments XVII-XX, wherein the combination of the Compound of the Disclosure and the Second Therapeutic Agent is administered sequentially. 
     The present disclosure also provides the following particular embodiments. 
     Embodiment 1. A method of treating a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of: 
     (a) compound of Formula I: 
     
       
         
         
             
             
         
       
     
     wherein: 
     R 1a  is selected from the group consisting of halogen, alkyl, alkoxy, cycloalkyl, (hydroxy)alkyl, and (cycloalkyl)alkyl; 
     Q 1  is selected from the group consisting of —C(R 1b )═ and —N═; 
     Q 2  is selected from the group consisting of —C(R 1c )═ and —N═; 
     Q 3  is selected from the group consisting of —C(R 1d )═ and —N═; 
     provided that at least one of Q 1 , Q 2 , or Q 3  is —C(R 1b )═, —C(R 1c )═, or —C(R 1d )═, respectively; 
     R 1b , R 1c , and R 1d  are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, (hydroxy)alkyl, and alkoxy; 
     R 1e  is selected from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, (hydroxy)alkyl, and (cycloalkyl)alkyl; 
        is a single or double bond; 
     G 1  is selected from the group consisting of: optionally substituted aryl; 
     optionally substituted heteroaryl; optionally substituted heterocyclo; optionally substituted cycloalkyl; (aryl)alkyl; (heteroaryl)alkyl; (heterocyclo)alkyl; (amino)(aryl)alkyl; (heteroaryl)(aryl)alkyl; (heteroaryl)(heterocyclo)alkyl; (heteroaryl)(carboxamido)alkyl; (heteroaryl)(cycloalkyl)alkyl; (aryl)(alkoxycarbonyl)alkyl; (cycloalkyl)alkyl; (heteroaryl)(amino)alkyl; (cycloalkyl)(alkoxycarbonyl)alkyl; (heteroaryl)(alkoxycarbonyl)alkyl; (heterocyclo)(cycloalkyl)alkyl; (aryl)(cycloalkyl)alkyl; (aryl)(hydroxy)alkyl; (cycloalkyl)(hydroxy)alkyl; (hydroxy)alkyl; optionally substituted alkyl; (aryl)(haloalkyl)alkyl; (cycloalkyl)(haloalkyl)alkyl; (hydroxy)(haloalkyl)alkyl; and (alkoxycarbonyl)(haloalkyl)alkyl; and 
     G 2  is selected from the group consisting of hydrogen and alkyl; or 
     G 1  and G 2  taken together with the nitrogen atom to which they are attached form an optionally substituted heterocyclo, 
     provided that the compound of Formula I is not N-(1-(1-(L-alanyl)piperidin-4-yl)ethyl)-7-methyl-1H-indole-2-carboxamide; N-((1r,4r)-4-(3-aminopropanamido) cyclohexyl)-7-methyl-1H-indole-2-carboxamide; or N-((1r,4r)-4-aminocyclohexyl)-7-methyl-1H-indole-2-carboxamide, 
     or a pharmaceutically acceptable salt or solvate thereof; and 
     (b) a Second Therapeutic Agent, 
     wherein: 
     the Second Therapeutic Agent comprises one or more glucocorticoid receptor agonists, one or more immunomodulatory drugs, one or more proteasome inhibitors, one or more Bcl-2 inhibitors, one or more pleiotropic pathway modulators, one or more XPO1 inhibitors, one or morehistone deacetylase inhibitors, or one or more EZH2 inhibitors, or a combination thereof. 
     Embodiment 2. The method of Embodiment 1, wherein the compound is a compound of Formula II: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 3. The method of Embodiments 1 or 2, wherein G 1  is selected from the group consisting of: optionally substituted C 6 -C 10  aryl; optionally substituted 5- to 9-membered heteroaryl; optionally substituted 3- to 10-membered heterocyclo; optionally substituted C 6 -C 8  cycloalkyl; (5- to 9-membered heteroaryl) C 1 -C 6  alkyl; (5- to 9-membered heteroaryl)(C 6-10  aryl)C 1 -C 4  alkyl; (5- to 9-membered heteroaryl heteroaryl)(C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl; and (C 3 -C 6  cycloalkyl)C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 4. The method of Embodiment 3, wherein the compound is a compound of of Formula IV: 
     
       
         
         
             
             
         
       
     
     wherein: 
     Z 4  is selected from the group consisting of —O—, —C(R 28a )(R 28b )—, and —N(R 23 )—; or Z 4  is absent; 
     Z 5  is selected from the group consisting of —CH 2 — and —CH 2 CH 2 —; 
     R 11a  is selected from the group consisting of optionally substituted alkyl, optionally substituted heterocyclo, optionally substituted heteroaryl, and —N(R 12b )C(═O)R 13c ; 
     R 12b  is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and heterocyclo, (C 1 -C 4  alkoxy)C 1 -C 4  alkyl, and (hydroxy)C 1 -C 4  alkyl; and 
     R 13c  is selected from the group consisting of alkyl, haloalkyl, alkoxy, (alkoxy)alkyl, (hydroxy)alkyl, (cyano)alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycle, amino, (amino)alkyl, (C 3 -C 6  cycloalkyl)oxy, and (4- to 8-membered heterocyclo)oxy; 
     R 23  is selected from the group consisting of hydrogen and C 1 -C 4  alkyl; and 
     R 28a  and R 28b  are independently selected from the group consisting of hydrogen, alkyl, and halo; 
     or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 5. The method of Embodiment 4, wherein the compound is a compound of Formula IV-A: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 6. The method of Embodiment 4, wherein the compound is a compound of Formula IV-B: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 7. The method of Embodiment 4, wherein the compound is a compound of Formula IV-C: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 8. The method of Embodiment 4, wherein the compound is a compound of Formula IV-D: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 9. The method of any one of Embodiments 4-8, wherein: 
     R 11a  is selected from the group consisting of: 
     (A) unsubstituted 4- to 14-membered heterocyclo; 
     (B) substituted 4- to 14-membered heterocyclo having one, two or three substituents independently selected from the group consisting of: 
     —N(R 12a )C(═O)R 13a ; (ii) —C(═O)R 13b ; (iv) C 1 -C 4  alkyl; (iv) (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (v) (hydroxy)C 1 -C 4  alkyl; (vi) C 1 -C 4  haloalkyl; (vii) amino; (vii) hydroxy; (viii) —N(R 12a )S(═O) 2 R 24 ; (ix) —S(═O) 2 R 24 ; (x) unsubstituted C 3 -C 6  cycloalkyl; (xi) substituted C 3 -C 6  cycloalkyl having one or two substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; (xii) unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (xiii)—C(═N—R 60 )R 61 ; and(xiv) —C(═C—NO 2 )R 64 ; 
     (C) unsubstituted 5- to 10-membered heteroaryl; 
     (D) substituted 5- or 6-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo and C 1 -C 4  alkyl; 
     (E) C 1 -C 6  alkyl; and 
     (F) —N(R 12b )C(═O)R 13c ; 
     R 12a  and R 12b  are each independently selected from the group consisting of hydrogen, C 1 -C 4  alkyl, (C 1 -C 4  alkoxy)C 1 -C 4  alkyl, and (hydroxy)C 1 -C 4  alkyl; 
     R 13a , R 13b , and R 13c  are each independently selected from the group consisting of (A) C 1 -C 6  alkyl; (B) C 1 -C 6  haloalkyl; (C) unsubstituted C 3 -C 6  cycloalkyl; (D) C 1 -C 6  alkoxy; (E) (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (F) (hydroxy)C 1 -C 4  alkyl; (G) (cyano)alkyl; (H) unsubstituted C 6 -C 10  aryl; (I) substituted C 6 -C 10  aryl, having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (J) unsubstituted 5- or 6-membered heteroaryl; (K) substituted 5- or 6-membered heteroaryl having one, two, three, or four substituents independently selected from the group consisting of halo, amino, hydroxy, and C 1 -C 4  alkyl; (L) unsubstituted 4- to 14-membered heterocyclo; (M) substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (N) amino; (O) (amino)alkyl; (P) (C 3 -C 6  cycloalkyl)oxy; and (Q) (4- to 8-membered heterocyclo)oxy; and 
     R 24  is selected from the group consisting of C 1 -C 4  alkyl and (hydroxy)C 1 -C 4  alkyl; 
     R 60  is selected from the group consisting of cyano, nitro, hydroxy, C 1 -C 6  alkoxy, —C(═O)R 62 , and —S(═O) 2 R 62 ; 
     R 61  is selected from the group consisting of C 1 -C 6  alkyl, C 3 -C 6  cycloalkyl, and —NR 63a R 63b ; 
     R 62  is selected from the group consisting of C 1 -C 6  alkyl, C 3 -C 6  cycloalkyl, and —NR 63a R 63b ; 
     R 63a  is selected from the group consisting of hydrogen, C 1 -C 6  alkyl, and C 3 -C 6  cycloalkyl; 
     R 63b  is selected from the group consisting of hydrogen, C 1 -C 6  alkyl, and C 3 -C 6  cycloalkyl; or 
     R 63a  and R 63b  taken together with the nitrogen atom to which they are attached form a 4- to 6-membered optionally substituted heterocyclo; 
     R 64  is selected from the group consisting of C 1 -C 6  alkyl, C 3 -C 6  cycloalkyl, and —NR 63c R 63d ; 
     R 63c  is selected from the group consisting of hydrogen, C 1 -C 6  alkyl, and C 3 -C 6  cycloalkyl; 
     R 63d  is selected from the group consisting of hydrogen, C 1 -C 6  alkyl, and C 3 -C 6  cycloalkyl; or 
     R 63c  and R 63d  taken together with the nitrogen atom to which they are attached form a 4- to 6-membered optionally substituted heterocyclo, or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 10. The method of Embodiment 9, wherein R 11a  is a substituted 4- to 14-membered heterocyclo selected from the group consisting of: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     R 12a  is selected from the group consisting of hydrogen, C 1 -C 3  alkyl, (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; and (hydroxy)C 1 -C 4  alkyl; 
     R 13a  is selected from the group consisting of C 1 -C 4  alkyl; amino; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (hydroxy)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; 
     R 13b  is selected from the group consisting of C 1 -C 4  alkyl; amino; C 1 -C 4  haloalkyl; C 1 -C 4  alkoxy; (hydroxy)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (amino)alkyl; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (C 3 -C 6  cycloalkyl)oxy; and (4- to 8-membered heterocyclo)oxy; 
     R 21  is selected from the group consisting of hydrogen, —C(═O)R 13b , C 1 -C 4  alkyl, C 1 -C 4  haloalkyl, unsubstituted 4- to 14-membered heterocyclo, and —S(═O) 2 R 24 ; 
     R 22  is C 1 -C 4  alkyl; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two sub stituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; 
     R 24  is selected from the group consisting of C 1 -C 4  alkyl and (hydroxy)C 1 -C 4  alkyl; 
     R 25  is selected from the group consisting of hydrogen, C 1 -C 4  alkyl, and C 1 -C 4  haloalkyl; 
     R 25b  and R 25c  are independently selected from the group consisting of C 1 -C 4  alkyl and C 1 -C 4  haloalkyl; 
     R 26  is selected from the group consisting of unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; and 
     R 21a  and R 25a  taken together with the atoms to which they are attached form an optionally substituted 4- to 8-membered heterocyclo, or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 11. The method of Embodiment 9, wherein R 11a  is a substituted 4- to 14-membered heterocyclo selected from the group consisting of: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     R 27a  and R 27b  are each independently selected from the group consisting of hydrogen, C 1 -C 4  alkyl, C 1 -C 4  haloalkyl, (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; and (hydroxy)C 1 -C 4  alkyl; 
     R 27c  is selected from the group consisting of hydrogen; —C(═O)R 13b ; C 1 -C 4  alkyl; C 1 -C 4  haloalkyl; unsubstituted 4- to 14-membered heterocyclo; and substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; and —S(═O) 2 R 24 ; 
     R 27d  is selected from the group consisting of hydrogen; C 1 -C 4  alkyl; and C 1 -C 4  haloalkyl; 
     R 13b  is selected from the group consisting of C 1 -C 4  alkyl; aminoC 1 -C 4  haloalkyl; C 1 -C 4  alkoxy; (hydroxy)C 1 -C 4  alkyl; (C 1 -C 4  alkoxy)C 1 -C 4  alkyl; (amino)alkyl; unsubstituted C 3 -C 6  cycloalkyl; substituted C 3 -C 6  cycloalkyl having one or two substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 4  alkyl, amino, and (amino)C 1 -C 4  alkyl; unsubstituted 4- to 14-membered heterocyclo; substituted 4- to 14-membered heterocyclo having one or two substituents independently selected from the group consisting of amino, hydroxy, and C 1 -C 4  alkyl; (C 3 -C 6  cycloalkyl)oxy; and (4- to 8-membered heterocyclo)oxy; and 
     R 24  is selected from the group consisting of C 1 -C 4  alkyl and (hydroxy)C 1 -C 4  alkyl, or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 12. The method of Embodiment 11, wherein R 11a  is a substituted 4- to 14-membered heterocyclo selected from the group consisting of: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 13. The method of Embodiment 9, wherein R 11a  is a substituted 4- to 14-membered heterocyclo selected from the group consisting of: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 14. The method of any one of Embodiments 4-13, wherein Z 4  is —CH 2 —, or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 15. The method of any one of Embodiments 1-14, wherein R 1d  is fluoro, or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 16. The method of Embodiment 1, wherein the compound is a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 17. The method of Embodiment 1, wherein the compound is a compound of Table 1B, or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 18. The method of any one of Embodiments 1-17, wherein the second therapeutic agent comprises a glucocorticoid receptor agonist. 
     Embodiment 19. The method of Embodiment 18, wherein the glucocorticoid receptor agonist is dexamethasone. 
     Embodiment 20. The method of any one of Embodiments 1-19, wherein the second therapeutic agent comprises an immunomodulatory drug. 
     Embodiment 21. The method of Embodiment 20, wherein the immunomodulatory drug is pomalidomide or lenalidomide. 
     Embodiment 22. The method of any one of Embodiments 1-21, wherein the second therapeutic agent comprises a proteasome inhibitor. 
     Embodiment 23. The method of Embodiment 22, wherein the proteasome inhibitor is bortezomib. 
     Embodiment 24. The method of any one of Embodiments 1-23, wherein the second therapeutic agent comprises a Bcl-2 inhibitor. 
     Embodiment 25. The method of Embodiment 24, wherein the Bcl-2 inhibitor is venetoclax. 
     Embodiment 26. The method of any one of Embodiments 1-25, wherein the second therapeutic agent comprises a pleiotropic pathway modulator. 
     Embodiment 27. The method of Embodiment 26, wherein the pleiotropic pathway modulator is CC-122. 
     Embodiment 28. The method of any one of Embodiments 1-27, wherein the second therapeutic agent comprises a XPO1 inhibitor. 
     Embodiment 29. The method of Embodiment 28, wherein the XPO1 inhibitor is selinexor. 
     Embodiment 30. The method of any one of Embodiments 1-29, wherein the second therapeutic agent comprises a histone deacetylase inhibitor. 
     Embodiment 31. The method of Embodiment 30, wherein the histone deacetylase inhibitor is panobinostat. 
     Embodiment 32. The method of any one of Embodiments 1-31, wherein the second therapeutic agent is an EZH2 inhibitor. 
     Embodiment 33. The method of Embodiment 32, wherein the EZH2 inhibitor is tazemetostat. 
     Embodiment 34. The method of any one of Embodiments 1-33, wherein the compound of Formula I and the Second Therapeutic Agent are administered to the subject separately. 
     Embodiment 35. The method of any one of Embodiments 1-34, wherein the subject in need thereof has cancer. 
     Embodiment 36. The method of Embodiment 35, wherein the cancer is any one or more of the cancers of Table 2. 
     Embodiment 37. The method of Embodiment 38, wherein the cancer is a hematological cancer. 
     Embodiment 38. The method of Embodiment 37, wherein the hematological cancer is any one or more of the cancers of Table 3. 
     Embodiment 39. A kit comprising: 
     (a) compound of Formula I: 
     
       
         
         
             
             
         
       
     
     wherein: 
     R 1a  is selected from the group consisting of halogen, alkyl, alkoxy, cycloalkyl, (hydroxy)alkyl, and (cycloalkyl)alkyl; 
     Q 1  is selected from the group consisting of —C(R 1b )═ and —N═; 
     Q 2  is selected from the group consisting of —C(R 1c )═ and —N═; 
     Q 3  is selected from the group consisting of —C(R 1d )═ and —N═; 
     provided that at least one of Q 1 , Q 2 , or Q 3  is —C(R 1b )═, —C(R 1c )═, or —C(R 1d )═, respectively; 
     R 1b , R 1c , and R 1d  are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, (hydroxy)alkyl, and alkoxy; 
     R 1e  is selected from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, (hydroxy)alkyl, and (cycloalkyl)alkyl; 
        is a single or double bond; 
     G 1  is selected from the group consisting of: optionally substituted aryl; 
     optionally substituted heteroaryl; optionally substituted heterocyclo; optionally substituted cycloalkyl; (aryl)alkyl; (heteroaryl)alkyl; (heterocyclo)alkyl; (amino)(aryl)alkyl; (heteroaryl)(aryl)alkyl; (heteroaryl)(heterocyclo)alkyl; (heteroaryl)(carboxamido)alkyl; (heteroaryl)(cycloalkyl)alkyl; (aryl)(alkoxycarbonyl)alkyl; (cycloalkyl)alkyl; (heteroaryl)(amino)alkyl; (cycloalkyl)(alkoxycarbonyl)alkyl; (heteroaryl)(alkoxycarbonyl)alkyl; (heterocyclo)(cycloalkyl)alkyl; (aryl)(cycloalkyl)alkyl; (aryl)(hydroxy)alkyl; (cycloalkyl)(hydroxy)alkyl; (hydroxy)alkyl; optionally substituted alkyl; (aryl)(haloalkyl)alkyl; (cycloalkyl)(haloalkyl)alkyl; (hydroxy)(haloalkyl)alkyl; and (alkoxycarbonyl)(haloalkyl)alkyl; and 
     G 2  is selected from the group consisting of hydrogen and alkyl; or 
     G 1  and G 2  taken together with the nitrogen atom to which they are attached form an optionally substituted heterocyclo, 
     provided that the compound of Formula I is not N-(1-(1-(L-alanyl)piperidin-4-yl)ethyl)-7-methyl-1H-indole-2-carboxamide; N-((1r,4r)-4-(3-aminopropanamido) cyclohexyl)-7-methyl-1H-indole-2-carboxamide; or N-((1r,4r)-4-aminocyclohexyl)-7-methyl-1H-indole-2-carboxamide, 
     or a pharmaceutically acceptable salt or solvate thereof; and 
     (b) a Second Therapeutic Agent, 
     wherein: 
     the Second Therapeutic Agent comprises one or more glucocorticoid receptor agonists, one or more immunomodulatory drugs, one or more proteasome inhibitors, one or more Bcl-2 inhibitors, one or more pleiotropic pathway modulators, one or more XPO1 inhibitor, one or more histone deacetylase inhibitors, or one or more EZH2 inhibitors, or a combination thereof. 
     Embodiment 40. The kit of Embodiment 39 further comprising instructions for administering the compound of Formula I and the Second Therapeutic Agent to a subject having cancer. 
     Embodiment 41. A compound selected from the group consisting of: 
     4-fluoro-7-methyl-N-((1R,3S)-3-((3aS,6aS)-1-methyl-2-oxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide; 
     4-fluoro-7-methyl-N-((1R,3R)-3-((3aS,6aS)-1-methyl-2-oxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide; 
     4-fluoro-7-methyl-N-((1R,3S)-3-((3aR,6aR)-1-methyl-2-oxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide; 
     4-fluoro-7-methyl-N-((1R,3R)-3-((3aR,6aR)-1-methyl-2-oxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)cyclohexyl)-1H-indole-2-carboxamide; 
     4-fluoro-7-methyl-N-((1R,3S)-3-((3aS,6aS)-4-methyl-5-oxohexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)cyclohexyl)-1H-indole-2-carboxamide; 
     4-fluoro-7-methyl-N-((1R,3S)-3-((3aR,6aR)-4-methyl-5-oxohexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)cyclohexyl)-1H-indole-2-carboxamide; 
     4-fluoro-7-methyl-N-((1R,3R)-3-((3aS,6aS)-4-methyl-5-oxohexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)cyclohexyl)-1H-indole-2-carboxamide; and 
     4-fluoro-7-methyl-N-((1R,3R)-3-((3aR,6aR)-4-methyl-5-oxohexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl)cyclohexyl)-1H-indole-2-carboxamide, 
     or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 42. A pharmaceutical composition comprising the compound of Embodiment 41, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier. 
     Embodiment 43. A method of treating a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of Embodiment 41, or a pharmaceutically acceptable salt or solvate thereof. 
     Embodiment 44. The method of Embodiment 43, wherein the subject in need thereof has cancer. 
     Embodiment 45. The method of Embodiment 44, wherein the cancer is any one or more of the cancers of Table 2. 
     Embodiment 46. The method of Embodiment 44, wherein the cancer is a hematological cancer. 
     Embodiment 47. The method of Embodiment 46, wherein the hematological cancer is any one or more of the cancers of Table 3. 
     Embodiment 48. The pharmaceutical composition of Embodiment 43 for use in treating a subject. 
     Embodiment 49. The pharmaceutical composition of Embodiment 48, wherein the subject has cancer. 
     Embodiment 50. The pharmaceutical composition of Embodiment 49, wherein the cancer is any one or more of the cancers of Table 2. 
     Embodiment 51. The pharmaceutical composition of Embodiment 49, wherein the cancer is a hematological cancer. 
     Embodiment 52. The method of Embodiment 51, wherein the hematological cancer is any one or more of the cancers of Table 3. 
     Embodiment 53. The compound of Embodiment 41 for use in treating a subject. 
     Embodiment 54. The compound for use of Embodiment 53, wherein the subject has cancer. 
     Embodiment 55. The compound for use of Embodiment 54, wherein the cancer is any one or more of the cancers of Table 2. 
     Embodiment 56. The compound for use of Embodiment 54, wherein the cancer is a hematological cancer. 
     Embodiment 57. The method of Embodiment 56, wherein the hematological cancer is any one or more of the cancers of Table 3. 
     Embodiment 58. Use of a compound of Embodiment 21 in the manufacture of a medicament for treating a subject. 
     Embodiment 59. The use of Embodiment 58, wherein the subject has cancer. 
     Embodiment 60. The use of Embodiment 59, wherein the cancer is any one or more of the cancers of Table 2. 
     Embodiment 61. The use of Embodiment 59, wherein the cancer is a hematological cancer. 
     Embodiment 62. The use of Embodiment 61, wherein the hematological cancer is any one or more of the cancers of Table 3. 
     Embodiment 63. A kit comprising the compound of Embodiment 41 and instructions for administering the compound to a subject. 
     Embodiment 64. The kit of Embodiment 63, wherein the subject cancer. 
     Compounds of the Disclosure can be administered to a subject in the form of a raw chemical without any other components present. Compounds of the Disclosure can also be administered to a subject as part of a pharmaceutical composition containing the compound combined with a suitable pharmaceutically acceptable carrier. Such a carrier can be selected from pharmaceutically acceptable excipients and auxiliaries. The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable vehicle” encompasses any of the standard pharmaceutical carriers, solvents, surfactants, or vehicles. Suitable pharmaceutically acceptable vehicles include aqueous vehicles and nonaqueous vehicles. Standard pharmaceutical carriers and their formulations are described in Remington&#39;s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 19th ed. 1995. 
     Pharmaceutical compositions within the scope of the present disclosure include all compositions where a Compound of the Disclosure is combined with one or more pharmaceutically acceptable carriers. In one embodiment, the Compound of the Disclosure is present in the composition in an amount that is effective to achieve its intended therapeutic purpose. While individual needs may vary, a determination of optimal ranges of effective amounts of each compound is within the skill of the art. Typically, a Compound of the Disclosure can be administered to a mammal, e.g., a human, orally at a dose of from about 0.0025 to about 1500 mg per kg body weight of the mammal, or an equivalent amount of a pharmaceutically acceptable salt or solvate thereof, per day to treat the particular disorder. A useful oral dose of a Compound of the Disclosure administered to a mammal is from about 0.0025 to about 50 mg per kg body weight of the mammal, or an equivalent amount of the pharmaceutically acceptable salt or solvate thereof. For intramuscular injection, the dose is typically about one-half of the oral dose. 
     A unit oral dose may comprise from about 0.01 mg to about 1 g of the Compound of the Disclosure, e.g., about 0.01 mg to about 500 mg, about 0.01 mg to about 250 mg, about 0.01 mg to about 100 mg, 0.01 mg to about 50 mg, e.g., about 0.1 mg to about 10 mg, of the compound. The unit dose can be administered one or more times daily, e.g., as one or more tablets or capsules, each containing from about 0.01 mg to about 1 g of the compound, or an equivalent amount of a pharmaceutically acceptable salt or solvate thereof. 
     A Compound of Disclosure or pharmaceutical composition comprising a Compound of the Disclosure and, optionally a Second Therapeutic Agent can be administered to any subject, e.g., a cancer patient in need thereof, that may experience the beneficial effects of a Compound of the Disclosure. Foremost among such subject are mammals, e.g., humans and companion animals, although the disclosure is not intended to be so limited. In one embodiment, the subject is a human. 
     A pharmaceutical composition of the present disclosure can be administered by any means that achieves its intended purpose. For example, administration can be by the oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, intranasal, transmucosal, rectal, intravaginal or buccal route, or by inhalation. The dosage administered and route of administration will vary, depending upon the circumstances of the particular subject, and taking into account such factors as age, gender, health, and weight of the recipient, condition or disorder to be treated, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. 
     In one embodiment, a pharmaceutical composition of the present disclosure can be administered orally. In another embodiment, a pharmaceutical composition of the present disclosure can be administered orally and is formulated into tablets, dragees, capsules, or an oral liquid preparation. In one embodiment, the oral formulation comprises extruded multiparticulates comprising the Compound of the Disclosure. 
     Alternatively, a pharmaceutical composition of the present disclosure can be administered rectally, and is formulated in suppositories. 
     Alternatively, a pharmaceutical composition of the present disclosure can be administered by injection. 
     Alternatively, a pharmaceutical composition of the present disclosure can be administered transdermally. 
     Alternatively, a pharmaceutical composition of the present disclosure can be administered by inhalation or by intranasal or transmucosal administration. 
     Alternatively, a pharmaceutical composition of the present disclosure can be administered by the intravaginal route. 
     A pharmaceutical composition of the present disclosure can contain from about 0.01 to 99 percent by weight, e.g., from about 0.25 to 75 percent by weight, of a Compound of the Disclosure, e.g., about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, or about 75% by weight of a Compound of the Disclosure. 
     A pharmaceutical composition of the present disclosure is manufactured in a manner which itself will be known in view of the instant disclosure, for example, by means of conventional mixing, granulating, dragee-making, dissolving, extrusion, or lyophilizing processes. Thus, pharmaceutical compositions for oral use can be obtained by combining the active compound with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores. 
     Suitable excipients include fillers such as saccharides (for example, lactose, sucrose, mannitol or sorbitol), cellulose preparations, calcium phosphates (for example, tricalcium phosphate or calcium hydrogen phosphate), as well as binders such as starch paste (using, for example, maize starch, wheat starch, rice starch, or potato starch), gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, one or more disintegrating agents can be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. 
     Auxiliaries are typically flow-regulating agents and lubricants such as, for example, silica, talc, stearic acid or salts thereof (e.g., magnesium stearate or calcium stearate), and polyethylene glycol. Dragee cores are provided with suitable coatings that are resistant to gastric juices. For this purpose, concentrated saccharide solutions can be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate can be used. Dye stuffs or pigments can be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses. 
     Examples of other pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, or soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain a compound in the form of granules, which can be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers, or in the form of extruded multiparticulates. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils or liquid paraffin. In addition, stabilizers can be added. 
     Possible pharmaceutical preparations for rectal administration include, for example, suppositories, which consist of a combination of one or more active compounds with a suppository base. Suitable suppository bases include natural and synthetic triglycerides, and paraffin hydrocarbons, among others. It is also possible to use gelatin rectal capsules consisting of a combination of active compound with a base material such as, for example, a liquid triglyceride, polyethylene glycol, or paraffin hydrocarbon. 
     Suitable formulations for parenteral administration include aqueous solutions of the active compound in a water-soluble form such as, for example, a water-soluble salt, alkaline solution, or acidic solution. Alternatively, a suspension of the active compound can be prepared as an oily suspension. Suitable lipophilic solvents or vehicles for such as suspension may include fatty oils (for example, sesame oil), synthetic fatty acid esters (for example, ethyl oleate), triglycerides, or a polyethylene glycol such as polyethylene glycol-400 (PEG-400). An aqueous suspension may contain one or more substances to increase the viscosity of the suspension, including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. The suspension may optionally contain stabilizers. 
     In some embodiments, the Compound of the Disclosure and the Second Therapeutic Agent are administered in combination to a subject as part of a single pharmaceutical composition. 
     In some embodiments, the Compound of the Disclosure and the Second Therapeutic Agent are administered in combination to a subject separately, e.g., as two or more separate pharmaceutical compositions. For example, the Second Therapeutic Agent may comprise one of a glucocorticoid receptor agonist, an immunomodulatory drug, a proteasome inhibitor, a Bcl-2 inhibitor, a pleiotropic pathway modulator, a XPO1 inhibitor, a histone deacetylase inhibitor, or an EZH2 inhibitor. In this case, two separate pharmaceutical compositions—one comprising the Compound of the Disclosure and one comprising the Second Therapeutic Agent—are administered to a subject. The Second Therapeutic Agent may comprise a combination of two of a glucocorticoid receptor agonist, an immunomodulatory drug, a proteasome inhibitor, a Bcl-2 inhibitor, a pleiotropic pathway modulator, a XPO1 inhibitor, a histone deacetylase inhibitor, or an EZH2 inhibitor. In this case, three separate pharmaceutical compositions—one comprising the Compound of the Disclosure, one comprising the first Second Therapeutic Agent, and one comprising the second Second Therapeutic Agent—are administered to a subject. Likewise, if the Second Therapeutic Agent comprises a combination of three or more of a glucocorticoid receptor agonist, an immunomodulatory drug, a proteasome inhibitor, a Bcl-2 inhibitor, a pleiotropic pathway modulator, a XPO1 inhibitor, a histone deacetylase inhibitor, or an EZH2 inhibitor. The separate pharmaceutical compositions can be administered to the subject, for example, at different periodicities, at different durations, or by different administration routes. 
     In some embodiments, a Compound of the Disclosure is administered to the patient prior to the Second Therapeutic Agent, e.g., 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks prior to the administration of the Second Therapeutic Agent. 
     In some embodiments, a Compound of the Disclosure is administered after the Second Therapeutic Agent, e.g., 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks after the administration of the Second Therapeutic Agent. 
     In some embodiments, a Compound of the Disclosure and the Second Therapeutic Agent are administered concurrently. 
     In some embodiments, a Compound of the Disclosure and the Second Therapeutic Agent are administered concurrently but on different schedules, e.g., a Compound of the Disclosure is administered daily while the Second Therapeutic Agent is administered once a week, once every two weeks, once every three weeks, or once every four weeks. 
     In practice, a physician determines the actual dosing regimen that is most suitable for an individual patient, which can vary with the age, weight, and response of the particular patient. 
     In another embodiment, the present disclosure provides kits which comprise a Compound of the Disclosure (or a composition comprising a Compound of the Disclosure) packaged in a manner that facilitates their use to practice methods of the present disclosure. In one embodiment, the kit includes a Compound of the Disclosure (or a composition comprising a Compound of the Disclosure) packaged in a container, such as a sealed bottle or vessel, with a label affixed to the container or included in the kit that describes use of the compound or composition to practice the method of the disclosure. In one embodiment, the compound or composition is packaged in a unit dosage form. The kit further can include a device suitable for administering the composition according to the intended route of administration. The kit further can include a Second Therapeutic Agent. In some embodiments, the kit comprises a Compound of the Disclosure and a Second Therapeutic Agent as separate pharmaceutical compositions. 
     IV. Biomarkers 
     In another embodiment, present disclosure provides methods of treating a subject having cancer, e.g., multiple myeloma, comprising (a) determining whether a biomarker is present or absent in a biological sample taken from the subject; and (b) administering a therapeutically effective amount of a Compound of the Disclosure and, optionally, a Second Therapeutic Agent to the subject if the biomarker is present in the biological sample. See, e.g., Goossens et al.,  Transl Cancer Res.  4:256-269 (2015); Kamel and Al-Amodi,  Genomics Proteomics Bioinformatics  15:220-235 (2017); and Konikova and Kusenda, Neoplasma 50:31-40 (2003). 
     Biomarkers include, but are not limited to, chromosomal translocations in a cancer, e.g., mulitple myeloma, cell and WHSC1/NSD2/MMSET expression. In one embodiment, the measurable aspect of the biomarker is its expression status. In one embodiment, the measurable aspect of the biomarker is its mutation status. 
     In one embodiment, the biomarker is WHSC1/NSD2/MMSET expression which is differentially present in a subject of one phenotypic status, e.g., a subject having a hematological cancer, as compared with another phenotypic status, e.g., a normal undiseased subject or a patient having cancer without overexpression WHSC1/NSD2/MMSET. In one embodiment, the biomarker is overexpression of WHSC1/NSD2/MMSET. 
     Biomarker standards can be predetermined, determined concurrently, or determined after a biological sample is obtained from the subject. Biomarker standards for use with the methods described herein can, for example, include data from samples from subjects without cancer; data from samples from subjects with cancer, e.g., breast cancer, that is not metastatic; and data from samples from subjects with cancer, e.g., breast cancer, that metastatic. Comparisons can be made to establish predetermined threshold biomarker standards for different classes of subjects, e.g., diseased vs. non-diseased subjects. The standards can be run in the same assay or can be known standards from a previous assay. 
     A biomarker is differentially present between different phenotypic status groups if the mean or median expression or mutation levels of the biomarker is calculated to be different, i.e., higher or lower, between the groups. Thus, biomarkers provide an indication that a subject, e.g., a cancer patient, belongs to one phenotypic status or another. 
     The determination of the expression level or mutation status of a biomarker in a patient can be performed using any of the many methods known in the art. Any method known in the art for quantitating specific proteins and/or detecting WHSC1/NSD2/MMSET expression and/or chromosomal translocations, or the expression or mutation levels of any other biomarker in a patient or a biological sample may be used in the methods of the disclosure. Examples include, but are not limited to, PCR (polymerase chain reaction), or RT-PCR, flow cytometry, Northern blot, Western blot, ELISA (enzyme linked immunosorbent assay), RIA (radioimmunoassay), gene chip analysis of RNA expression, immunohistochemistry or immunofluorescence. See, e.g., Slagle et al. Cancer 83: 1401 (1998); Hudlebusch et al.,  Clin Cancer Res  17: 2919-2933 (2011). Certain embodiments of the disclosure include methods wherein biomarker RNA expression (transcription) is determined. Other embodiments of the disclosure include methods wherein protein expression in the biological sample is determined. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., (1988); Ausubel et al., Current Protocols in Molecular Biology, John Wiley &amp; Sons, New York 3rd Edition, (1995); Kamel and Al-Amodi,  Genomics Proteomics Bioinformatics  15:220-235 (2017). For northern blot or RT-PCR analysis, RNA is isolated from the tumor tissue sample using RNAse free techniques. Such techniques are commonly known in the art. 
     In one embodiment of the disclosure, a biological sample is obtained from the patient and the biological sample is assayed for determination of a biomarker expression or mutation status. 
     In one embodiment, the present disclosure provides a method of treating a subject having cancer, e.g., multiple myeloma, the method comprising: (a) determining whether a chromosomal translocation is present or absent in a biological sample taken from the subject; and (b) administering a therapeutically effective amount of a Compound of the Disclosure and, optionally, a Second Theraputic Agent to the subject if a chromosomal translocation is present in the biological sample. 
     In another embodiment, the present disclosure provides a method of treating a subject having cancer, e.g., multiple myeloma, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure and, optionally, a Second Therapetuic Agent to the subject having a chromosomal translocation. 
     In another embodiment, the present disclosure provides a method, comprising administering a therapeutically effective amount of a Compound of the Disclosure and, optionally, a Second Therapeutic Agent, to a subject in need thereof, wherein: (a) the subject has multiple myeloma; and (b) the multiple myeloma is characterized as having a chromosomal translocation. 
     In any of the above embodiments, the chromosomal translocation is a t(4;14) translocation. 
     In one embodiment, the present disclosure provides a method of treating a subject having multiple myeloma, the method comprising: (a) determining whether an overexpression of WHSC1/NSD2/MMSET is present or absent in a biological sample taken from the subject; and (b) administering a therapeutically effective amount of a Compound of the Disclosure and, optionally, a Second Therapeutic Agent, to the subject if an overexpression of WHSC1/NSD2/MMSET is present in the biological sample. 
     In one embodiment, the present disclosure provides a method of treating a subject having multiple myeloma, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure and, optionally, a Second Therapeutic Agent, to the subject if an overexpression of WHSC1/NSD2/MMSET is present in subject. 
     In another embodiment, the present disclosure provides a method, comprising administering a therapeutically effective amount of a Compound of the Disclosure and, optionally, a Second Therapeutic Agent, to a subject in need thereof, wherein: (a) the subject has multiple myeloma; and (b) the multiple myeloma is characterized as having an overexpression of WHSC1/NSD2/MMSET. 
     V. Definitions 
     The term “halo” as used herein by itself or as part of another group refers to —Cl, —F, —Br, or —I. 
     The term “nitro” as used herein by itself or as part of another group refers to —NO 2 . 
     The term “cyano” as used herein by itself or as part of another group refers to —CN. 
     The term “hydroxy” as herein used by itself or as part of another group refers to —OH. 
     The term “alkyl” as used herein by itself or as part of another group refers to a straight- or branched-chain aliphatic hydrocarbon containing one to twelve carbon atoms, i.e., a C 1 -C 12  alkyl, or the number of carbon atoms designated, e.g., a C 1  alkyl such as methyl, a C 2  alkyl such as ethyl, etc. In one embodiment, the alkyl is a C 1 -C 10  alkyl. In another embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1 -C 3  alkyl, i.e., methyl, ethyl, propyl, or isopropyl. Non-limiting exemplary C 1 -C 12  alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tent-butyl, iso-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, and decyl. 
     The term “optionally substituted alkyl” as used herein by itself or as part of another group refers to an alkyl group that is either unsubstituted or substituted with one, two, or three substituents, wherein each substituent is independently nitro, haloalkoxy, aryloxy, aralkyloxy, alkylthio, sulfonamido, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carbamate, carboxy, alkoxycarbonyl, carboxyalkyl, —N(R 56a )C(═O)R 56b , —N(R 56c )S(═O) 2 R 56d , —C(═O)R 57 , —S(═O)R 56e , —S(═O) 2 R 58 , —N(R 56a )C(═N—R 60 )R 61 , —N(R 56a )C(═C—NO 2 )R 64 , —C(—N—R 60 )R 61 , or —C(═C—NO 2 )R 64 ; wherein: 
     R 56a  is hydrogen or alkyl; 
     R 56b  is alkyl, haloalkyl, optionally substituted cycloalkyl, alkoxy, (alkoxy)alkyl, (aryl)alkyl, (heteroaryl)alkyl, (amino)alkyl, (hydroxy)alkyl, (cyano)alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted C 6 -C 10  aryl, or optionally substituted heteroaryl; 
     R 56c  is hydrogen or alkyl; 
     R 56d  is alkyl, haloalkyl, optionally substituted cycloalkyl, alkoxy, (alkoxy)alkyl, (aryl)alkyl, (heteroaryl)alkyl, (amino)alkyl, (hydroxy)alkyl, (cyano)alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted C 6 -C 10  aryl, or optionally substituted heteroaryl; 
     R 56e  is alkyl, haloalkyl, optionally substituted cycloalkyl, alkoxy, (alkoxy)alkyl, (aryl)alkyl, (heteroaryl)alkyl, (amino)alkyl, (hydroxy)alkyl, (cyano)alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted C 6 -C 10  aryl, or optionally substituted heteroaryl; 
     R 57  is haloalkyl, amino, optionally substituted cycloalkyl, alkoxy, (alkoxy)alkyl, (aryl)alkyl, (heteroaryl)alkyl, (amino)alkyl, (hydroxy)alkyl, (cyano)alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, (C 3 -C 6  cycloalkyl)oxy, or (4- to 8-membered heterocyclo)oxy; 
     R 58  is haloalkyl, optionally substituted cycloalkyl, alkoxy, (alkoxy)alkyl, (aryl)alkyl, (heteroaryl)alkyl, (amino)alkyl, (hydroxy)alkyl, (cyano)alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycle, or optionally substituted heteroaryl; 
     R 6 ° is selected from the group consisting of cyano, nitro, hydroxy, C 1 -C 6  alkoxy, —C(═O)R 62 , and —S(═O) 2 R 62 ; 
     R 61  is selected from the group consisting of C 1 -C 6  alkyl, C 3 -C 6  cycloalkyl, and —NR 63a R 63b ; 
     R 62  is selected from the group consisting of C 1 -C 6  alkyl, C 3 -C 6  cycloalkyl, and —NR 63a R 63b ; 
     R 63a  is selected from the group consisting of hydrogen, C 1 -C 6  alkyl, and C 3 -C 6  cycloalkyl; 
     R 63b  is selected from the group consisting of hydrogen, C 1 -C 6  alkyl, and C 3 -C 6  cycloalkyl; or 
     R 63a  and R 63b  taken together with the nitrogen atom to which they are attached form a 4- to 6-membered optionally substituted heterocyclo; 
     R 64  is selected from the group consisting of C 1 -C 6  alkyl, C 3 -C 6  cycloalkyl, and —NR 63c R 63d ; and 
     R 63c  is selected from the group consisting of hydrogen, C 1 -C 6  alkyl, and C 3 -C 6  cycloalkyl; 
     R 63d  is selected from the group consisting of hydrogen, C 1 -C 6  alkyl, and C 3 -C 6  cycloalkyl; or 
     R 63c  and R 63d  taken together with the nitrogen atom to which they are attached form a 4- to 6-membered optionally substituted heterocyclo. 
     In one embodiment, the optionally substituted alkyl is either unsubstituted or substituted with one, two, or three substituents, wherein each substituent is independently nitro, haloalkoxy, aryloxy, aralkyloxy, alkylthio, sulfonamido, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carbamate, carboxy, alkoxycarbonyl, carboxyalkyl, —N(R 56a )C(═O)R 56b , —N(R 56c )S(═O) 2 R 56d , —C(═O)R 57 , —S(═O)R 56e , or —S(═O) 2 R 58 . 
     In another embodiment, the optionally substituted alkyl is substituted with two substituents. In another embodiment, the optionally substituted alkyl is substituted with one substituent. In another embodiment, the optionally substituted alkyl is an optionally substituted C 1 -C 6  alkyl. In another embodiment, the optionally substituted alkyl is an optionally substituted C 1 -C 4  alkyl. In one embodiment, the optionally substituted alkyl is an optionally substituted is a C 1  or C 2  alkyl. Non-limiting exemplary optionally substituted alkyl groups include —CH(CO 2 Me)CH 2 CO 2 Me and —CH(CH 3 )CH 2 N(H)C(═O)O(CH 3 ) 3 . 
     The term “alkenyl” as used herein by itself or as part of another group refers to an alkyl group containing one, two, or three carbon-to-carbon double bonds. In one embodiment, the alkenyl group is a C 2 -C 6  alkenyl group. In another embodiment, the alkenyl group is a C 2 -C 4  alkenyl group. In another embodiment, the alkenyl group has one carbon-to-carbon double bond. Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl. 
     The term “optionally substituted alkenyl” as used herein by itself or as part of another refers to an alkenyl group that is either unsubstituted or substituted with one, two or three substituents, wherein each substituent is independently halo, nitro, cyano, hydroxy, amino (e.g., alkylamino, dialkylamino), haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carboxy, carboxyalkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclo. Non-limiting exemplary optionally substituted alkenyl groups include —CH═CHPh. 
     The term “alkynyl” as used herein by itself or as part of another group refers to an alkyl group containing one, two, or three carbon-to-carbon triple bonds. In one embodiment, the alkynyl has one carbon-to-carbon triple bond. In another embodiment, the alkynyl is a C 1 -C 6  alkynyl. In another embodiment, the alkynyl is a C 2 -C 4  alkynyl. In another embodiment, the alkynyl has one carbon-to-carbon triple bond. Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups. 
     The term “optionally substituted alkynyl” as used herein by itself or as part of another group refers to an alkynyl group that is either unsubstituted or substituted with one, two or three substituents, wherein each substituent is independently halo, nitro, cyano, hydroxy, amino (e.g., alkylamino, dialkylamino), haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carboxy, carboxyalkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclo. Non-limiting exemplary optionally substituted alkynyl groups include —CH≡CHPh. 
     The term “haloalkyl” as used herein by itself or as part of another group refers to an alkyl group substituted by one or more fluorine, chlorine, bromine, and/or iodine atoms. In one embodiment, the alkyl is substituted by one, two, or three fluorine and/or chlorine atoms. In another embodiment, the alkyl is substituted by one, two, or three fluorine atoms. In another embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl group is a C 1  or C 2  alkyl. Non-limiting exemplary haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and trichloromethyl groups. 
     The terms “hydroxyalkyl” or “(hydroxy)alkyl” as used herein by themselves or as part of another group refer to an alkyl group substituted with one, two, or three hydroxy groups. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. In another embodiment, the hydroxyalkyl is a monohydroxyalkyl group, i.e., substituted with one hydroxy group. In another embodiment, the hydroxyalkyl group is a dihydroxyalkyl group, i.e., substituted with two hydroxy groups. Non-limiting exemplary (hydroxyl)alkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups, such as 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-1-methylpropyl, and 1,3-dihydroxyprop-2-yl. 
     The term “alkoxy” as used herein by itself or as part of another group refers to an alkyl group attached to a terminal oxygen atom. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl group. Non-limiting exemplary alkoxy groups include methoxy, ethoxy, and tert-butoxy. 
     The term “haloalkoxy” as used herein by itself or as part of another group refers to a haloalkyl group attached to a terminal oxygen atom. In one embodiment, the haloalkyl is a C 1 -C 6  alkyl. In another embodiment, the haloalkyl group is a C 1 -C 4  haloalkyl group. Non-limiting exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy. 
     The term “alkylthio” as used herein by itself or as part of another group refers to an alkyl group attached to a terminal sulfur atom. In one embodiment, the alkyl group is a C 1 -C 4  alkyl group. Non-limiting exemplary alkylthio groups include —SCH 3 , and —SCH 2 CH 3 . 
     The terms “alkoxyalkyl” or “(alkoxy)alkyl” as used herein by themselves or as part of another group refers to an alkyl group substituted with one alkoxy group. In one embodiment, the alkoxy is a C 1 -C 6  alkoxy. In another embodiment, the alkoxy is a C 1 -C 4  alkoxy. In another embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. Non-limiting exemplary alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, iso-propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sec-butoxymethyl, and pentyloxymethyl. 
     The term “heteroalkyl” as used herein by itself or part of another group refers to a stable straight or branched chain hydrocarbon radical containing 1 to 10 carbon atoms and at least two heteroatoms, which can be the same or different, selected from O, N, or S, wherein the sulfur atom(s) can optionally be oxidized. The heteroatoms can be placed at any interior position of the heteroalkyl group or at a position at which the heteroalkyl group is attached to the remainder of the molecule. In one embodiment, the heteroalkyl contains two oxygen atoms. In another embodiment, the heteroalkyl contains one oxygen and one nitrogen atom. In another embodiment, the heteroalkyl contains two nitrogen atoms. Non-limiting exemplary heteroalkyl groups include —OCH 2 CH 2 NH 2 , —NHCH 2 CH 2 OCH 3 , and —OCH 2 CH 2 OCH 3 . 
     The term “cycloalkyl” as used herein by itself or as part of another group refers to saturated and partially unsaturated, e.g., containing one or two double bonds, monocyclic, bicyclic, or tricyclic aliphatic hydrocarbons containing three to twelve carbon atoms, i.e., a C 3-12  cycloalkyl, or the number of carbons designated, e.g., a C 3  cycloalkyl such a cyclopropyl, a C 4  cycloalkyl such as cyclobutyl, etc. In one embodiment, the cycloalkyl is bicyclic, i.e., it has two rings. In another embodiment, the cycloalkyl is monocyclic, i.e., it has one ring. In another embodiment, the cycloalkyl is a C 3-8  cycloalkyl. In another embodiment, the cycloalkyl is a C 3-6  cycloalkyl, i.e., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In another embodiment, the cycloalkyl is a C 5  cycloalkyl, i.e., cyclopentyl. In another embodiment, the cycloalkyl is a C 6  cycloalkyl, i.e., cyclohexyl. Non-limiting exemplary C 3-12  cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, and spiro[3.3]heptane. 
     The term “optionally substituted cycloalkyl” as used herein by itself or as part of another group refers to a cycloalkyl group is either unsubstituted or substituted with one, two, or three substituents, wherein each substituent is independently halo, nitro, cyano, hydroxy, amino (e.g., —NH 2 , alkylamino, dialkylamino, aralkylamino, hydroxyalkylamino, or (heterocyclo)alkylamino), heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, —N(R 56a )C(═O)R 56b , —N(R 56c )S(═O) 2 R 56d , —C(═O)R 57 , —S(═O)R 56e , —S(═O) 2 R 58 , —OR 59 , —N(R 56a )C(═N—R 60 )R 61 , —N(R 56a )C(═C—NO 2 )R 64 , —C(═N—R 60 )R 61 , or —C(═C—NO 2 )R 64 ; wherein R 56a , R 56b , R 56c , R 56d , R 56e , R 57 , R 58 , R 60 , R 61 , and R 64  are as defined in connection with the term “optionally substituted alkyl” and R 59  is (hydroxy)alkyl or (amino)alkyl. Non-limiting exemplary optionally substituted cycloalkyl groups include 3-(4-acetylpiperazin-1-yl)cyclohexyl, 3-(3-(N-methylacetamido)pyrrolidin-1-yl)cyclohexyl, 3-morpholinocyclohexyl, and 3-(pyrimidin-5-yl)cyclohexyl. In one embodiment, the optionally substituted cycloalkyl is either unsubstituted or substituted with one, two, or three substituents, wherein each substituent is independently halo, nitro, cyano, hydroxy, amino (e.g., —NH 2 , alkylamino, dialkylamino, aralkylamino, hydroxyalkylamino, or (heterocyclo)alkylamino), heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonami do, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, —N(R 56a )C(═O)R 56b , —N(R 56c )S(═O) 2 R 56d , —C(═O)R 57 , —S(═O)R 56e , —S(═O) 2 R 58 , and —OR 59 . 
     The term “heterocyclo” as used herein by itself or as part of another group refers to saturated and partially unsaturated, e.g., containing one or two double bonds, monocyclic, bicyclic, or tricyclic groups containing three to fourteen ring members, i.e., a 3- to 14-membered heterocyclo, comprising one, two, three, or four heteroatoms. Each heteroatom is independently oxygen, sulfur, or nitrogen. Each sulfur atom is independently oxidized to give a sulfoxide, i.e., S(═O), or sulfone, i.e., S(═O) 2.    
     The term heterocyclo includes groups wherein one or more —CH 2 — groups is replaced with one or more —C(═O)— groups, including cyclic ureido groups such as imidazolidinyl-2-one, cyclic amide groups such as pyrrolidin-2-one or piperidin-2-one, and cyclic carbamate groups such as oxazolidinyl-2-one. 
     The term heterocyclo also includes groups having fused optionally substituted aryl or optionally substituted heteroaryl groups such as indoline, indolin-2-one, 2,3-dihydro-1H-pyrrolo[2,3-c]pyridine, 2,3,4,5-tetrahydro-1H-benzo[d]azepine, or 1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one. 
     In one embodiment, the heterocyclo group is a 4- to 8-membered cyclic group containing one ring and one or two oxygen atoms, e.g., tetrahydrofuran or tetrahydropyran, or one or two nitrogen atoms, e.g., pyrrolidine, piperidine, or piperazine, or one oxygen and one nitrogen atom, e.g., morpholine, and, optionally, one —CH 2 — group is replaced with one —C(═O)— group, e.g., pyrrolidin-2-one or piperazin-2-one. In another embodiment, the heterocyclo group is a 5- to 8-membered cyclic group containing one ring and one or two nitrogen atoms and, optionally, one —CH 2 — group is replaced with one —C(═O)— group. In another embodiment, the heterocyclo group is a 5- or 6-membered cyclic group containing one ring and one or two nitrogen atoms and, optionally, one —CH 2 — group is replaced with one —C(═O)— group. In another embodiment, the heterocyclo group is a 8- to12-membered cyclic group containing two rings and one or two nitrogen atoms. The heterocyclo can be linked to the rest of the molecule through any available carbon or nitrogen atom. Non-limiting exemplary heterocyclo groups include: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     The term “optionally substituted heterocyclo” as used herein by itself or part of another group refers to a heterocyclo group that is either unsubstituted or substituted with one to four substituents, wherein each substituent is independently halo, nitro, cyano, hydroxy, amino, (e.g., —NH 2 , alkylamino, dialkylamino, aralkylamino, hydroxyalkylamino, or (heterocyclo)alkylamino), heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, —N(R 56a )C(═O)R 56b , —N(R 56c )S(═O) 2 R 56d , —C(═O)R 57 , —S(═O)R 56e , —S(═O) 2 R 58 , —OR 59 , —N(R 56a )C(═N—R 60 )R 61 , —N(R 56a )C(═C—NO 2 )R 64 , —C(═N—R 60 )R 61 , or —C(═C—NO 2 )R 64 ; wherein R 56a , R 56b , R 56c , R 56d , R 56e , R 57 , R 58 , R 59 , R 60 , R 61 , and R 64  are as defined in connection with the term “optionally substituted cycloalkyl.” Substitution may occur on any available carbon or nitrogen atom of the heterocyclo group. In one embodiment, the optionally substituted heterocyclo is either unsubstituted or substituted with one to four substituents, wherein each substituent is independently halo, nitro, cyano, hydroxy, amino, (e.g., —NH 2 , alkylamino, dialkylamino, aralkylamino, hydroxy alkyl amino, or (heterocyclo)alkylamino), heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonami do, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, —N(R 56a )C(═O)R 56b , —N(R 56c )S(═O) 2 R 56d , —C(═O)R 57 , —S(═O)R 56e , —S(═O) 2 R 58 , or —OR 59 . 
     Non-limiting exemplary optionally substituted heterocyclo groups include: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     The term “aryl” as used herein by itself or as part of another group refers to an aromatic ring system having six to fourteen carbon atoms, i.e., C 6 -C 14  aryl. Non-limiting exemplary aryl groups include phenyl (abbreviated as “Ph”), naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups. In one embodiment, the aryl group is phenyl or naphthyl. In another embodiment, the aryl group is phenyl. 
     The term “optionally substituted aryl” as used herein by itself or as part of another group refers to aryl that is either unsubstituted or substituted with one to five sub stituents, wherein the substituents are each independently halo, nitro, cyano, hydroxy, amino, (e.g., —NH 2 , alkylamino, dialkylamino, aralkylamino, hydroxy alkyl amino, or (heterocyclo)alkylamino), heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonami do, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, —N(R 56a )C(═O)R 56b , —N(R 56c )S(═O) 2 R 56d , —C(═O)R 57 , —S(═O)R 56e , —S(═O) 2 R 58 , —OR 59 , —N(R 56a )C(═N—R 60 )R 61 , —N(R 56a )C(═C—NO 2 )R 64 , —C(═N—R 60 )R 61 , or —C(═C—NO 2 )R 64 ; wherein R 56a , R 56b , R 56c , R 56d , R 56e , R 57 , R 58 , R 59 , R 60 , R 61 , and R 64  are as defined in connection with the term “optionally substituted cycloalkyl.” In one embodiment, the optionally substituted aryl is either unsubstituted or substituted with one to five sub stituents, wherein the sub stituents are each independently halo, nitro, cyano, hydroxy, amino, (e.g., —NH 2 , alkylamino, dialkylamino, aralkylamino, hydroxyalkylamino, or (heterocyclo)alkylamino), heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, —N(R 56a )C(═O)R 56b , —N(R 56c )S(═O) 2 R 56d , —C(═O)R 57 , —S(═O)R 56e , —S(═O) 2 R 58 , or —OR 59 . 
     In one embodiment, the optionally substituted aryl is an optionally substituted phenyl. In another embodiment, the optionally substituted phenyl has four substituents. In another embodiment, the optionally substituted phenyl has three substituents. In another embodiment, the optionally substituted phenyl has two substituents. In another embodiment, the optionally substituted phenyl has one substituent. Non-limiting exemplary optionally substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 3-methylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl, 3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl 3,5-di-methylphenyl, 3,5-dimethoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, 3-chloro-4-fluorophenyl, and 2-phenylpropan-2-amine. The term optionally substituted aryl includes aryl groups having fused optionally substituted cycloalkyl groups and fused optionally substituted heterocyclo groups. Non-limiting examples include: 2,3-dihydro-1H-inden-1-yl, 1,2,3,4-tetrahydronaphthalen-1-yl, 1,3,4,5-tetrahydro-2H-benzo[c]azepin-2-yl, 1,2,3,4-tetrahydroisoquinolin-1-yl, and 2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl. 
     The term “heteroaryl” as used herein by itself or as part of another group refers to monocyclic and bicyclic aromatic ring systems having five to 14 fourteen ring members, i.e., a 5- to 14-membered heteroaryl, comprising one, two, three, or four heteroatoms. Each heteroatom is independently oxygen, sulfur, or nitrogen. In one embodiment, the heteroaryl has three heteroatoms. In another embodiment, the heteroaryl has two heteroatoms. In another embodiment, the heteroaryl has one heteroatom. In another embodiment, the heteroaryl is a 5- to 10-membered heteroaryl. In another embodiment, the heteroaryl has 5 ring atoms, e.g., thienyl, a 5-membered heteroaryl having four carbon atoms and one sulfur atom. In another embodiment, the heteroaryl has 6 ring atoms, e.g., pyridyl, a 6-membered heteroaryl having five carbon atoms and one nitrogen atom. Non-limiting exemplary heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, i sobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thiazolyl, isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl, and phenoxazinyl. In one embodiment, the heteroaryl is chosen from thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., 1H-pyrrol-2-yl and 1H-pyrrol-3-yl), imidazolyl (e.g., 2H-imidazol-2-yl and 2H-imidazol-4-yl), pyrazolyl (e.g., 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, and 1H-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl) and isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl). The term heteroaryl also includes N-oxides. A non-limiting exemplary N-oxide is pyridyl N-oxide. 
     The term “optionally substituted heteroaryl” as used herein by itself or as part of another group refers to a heteroaryl that is either unsubstituted or substituted with one to four substituents, wherein the substituents are independently halo, nitro, cyano, hydroxy, amino, (e.g., —NH 2 , alkylamino, dialkylamino, aralkylamino, hydroxyalkylamino, or (heterocyclo)alkylamino), heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, —N(R 56a )C(═O)R 56b , —N(R 56c )S(═O) 2 R 56d , —C(═O)R 57 , —S(═O)R 56e , —S(═O) 2 R 58 , —OR 59 , —N(R 56a )C(═N—R 60 )R 61 , —N(R 56a )C(═C—NO 2 )R 64 , —C(═N—R 60 )R 61 , or —C(═C—NO 2 )R 64 ; wherein R 56a , R 56b , R 56c , R 56d , R 56e , R 57 , R 58 , R 59 , R 60 , R 61 , and R 64  are as defined in connection with the term “optionally substituted cycloalkyl.” In one embodiment, optionally substituted heteroaryl is either unsubstituted or substituted with one to four substituents, wherein the substituents are independently halo, nitro, cyano, hydroxy, amino, (e.g., —NH 2 , alkylamino, dialkylamino, aralkylamino, hydroxyalkylamino, or (heterocyclo)alkylamino), heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, aryl sulfonyl, ureido, guanidino, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, —N(R 56a )C(═O)R 56b , —N(R 56c )S(═O) 2 R 56d , —C(═O)R 57 , —S(═O)R 56e , —S(═O) 2 R 58 , or —OR 59 . 
     In one embodiment, the optionally substituted heteroaryl has two substituents. In another embodiment, the optionally substituted heteroaryl has one substituent. Any available carbon or nitrogen atom can be substituted. 
     The term “aryloxy” as used herein by itself or as part of another group refers to an optionally substituted aryl attached to a terminal oxygen atom. A non-limiting exemplary aryloxy group is PhO—. 
     The term “heteroaryloxy” as used herein by itself or as part of another group refers to an optionally substituted heteroaryl attached to a terminal oxygen atom. A non-limiting exemplary aryloxy group is pyridyl-O—. 
     The term “aralkyloxy” as used herein by itself or as part of another group refers to an aralkyl attached to a terminal oxygen atom. A non-limiting exemplary aralkyloxy group is PhCH 2 O—. 
     The term “(cycloalkyl)oxy” as used herein by itself or as part of another group refers to a cycloalkyl group attached to a terminal oxygen atom. A non-limiting exemplary cycloalkyloxy group is: 
     
       
         
         
             
             
         
       
     
     The term “(heterocyclo)oxy” as used herein by itself or as part of another group refers to a heterocyclo group attached to a terminal oxygen atom. A non-limiting exemplary (heterocyclo)oxy group is: 
     
       
         
         
             
             
         
       
     
     The term “(cyano)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one, two, or three cyano groups. In one embodiment, the alkyl is substituted with one cyano group. In another embodiment, the alkyl is a C 1 -C 6  alkyl In another embodiment, the alkyl is a C 1 -C 4  alkyl. Non-limiting exemplary (cyano)alkyl groups include —CH 2 CH 2 CN and —CH 2 CH 2 CH 2 CN. 
     The term “(cycloalkyl)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one optionally substituted cycloalkyl group. In one embodiment, the cycloalkyl group is an optionally substituted C 3 -C 6  cycloalkyl. In another embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. Non-limiting exemplary (cycloalkyl)alkyl groups include: 
     
       
         
         
             
             
         
       
     
     The term “sulfonamido” as used herein by itself or as part of another group refers to a radical of the formula —SO 2 NR 50a R 50b , wherein R 50a  and R 50b  are each independently hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl; or R 50a  and R 50b  taken together with the nitrogen to which they are attached form a 3- to 8-membered optionally substituted heterocyclo group. Non-limiting exemplary sulfonamido groups include —SO 2 NH 2 , —SO 2 N(H)CH 3 , and —SO 2 N(H)Ph. 
     The term “alkylcarbonyl” as used herein by itself or as part of another group refers to a carbonyl group, i.e., —C(═O)—, substituted by an alkyl group. In one embodiment, the alkyl is a C 1 -C 4  alkyl. A non-limiting exemplary alkylcarbonyl group is —COCH 3 . 
     The term “arylcarbonyl” as used herein by itself or as part of another group refers to a carbonyl group, i.e., —C(═O)—, substituted by an optionally substituted aryl group. A non-limiting exemplary arylcarbonyl group is —COPh. 
     The term “alkylsulfonyl” as used herein by itself or as part of another group refers to a sulfonyl group, i.e., —SO 2 —, substituted by an alkyl group. A non-limiting exemplary alkylsulfonyl group is —SO 2 CH 3 . 
     The term “arylsulfonyl” as used herein by itself or as part of another group refers to a sulfonyl group, i.e., —SO 2 —, substituted by an optionally substituted aryl group. A non-limiting exemplary arylsulfonyl group is —SO 2 Ph. 
     The term “mercaptoalkyl” as used herein by itself or as part of another group refers to an alkyl substituted by a —SH group. 
     The term “carboxy” as used by itself or as part of another group refers to a radical of the formula —C(═O)OH. 
     The term “ureido” as used herein by itself or as part of another group refers to a radical of the formula —NR 51a —C(═O)—NR 51b R 51c , wherein R 51a  is hydrogen or alkyl; and R 51b  and R 51c  are each independently hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl, or R 51b  and R 51c  taken together with the nitrogen to which they are attached form a 4- to 8-membered optionally substituted heterocyclo group. Non-limiting exemplary ureido groups include —NH—C(C═O)—NH 2  and —NH—C(C═O)—NHCH 3 . 
     The term “guanidino” as used herein by itself or as part of another group refers to a radical of the formula —NR 52a —C(═NR 53 )—NR 52b R 52c , wherein R 52a  is hydrogen or alkyl; R 52b  and R 53c  are each independently hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl; or R 52b  and R 52c  taken together with the nitrogen to which they are attached form a 4- to 8-membered optionally substituted heterocyclo group; and R 53  is hydrogen, alkyl, cyano, alkylsulfonyl, alkylcarbonyl, carboxamido, or sulfonamido. Non-limiting exemplary guanidino groups include —NH—C(C═NH)—NH 2 , —NH—C(C═NCN)—NH 2 , and —NH—C(C═NH)—NHCH 3 . 
     The term “(heterocyclo)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one, two, or three optionally substituted heterocyclo groups. In one embodiment, the alkyl is substituted with one optionally substituted 5- to 8-membered heterocyclo group. In another embodiment, alkyl is a C 1 -C 6  alkyl. In another embodiment, alkyl is a C 1 -C 4  alkyl. The heterocyclo group can be linked to the alkyl group through a carbon or nitrogen atom. Non-limiting exemplary (heterocyclo)alkyl groups include: 
     
       
         
         
             
             
         
       
     
     The term “carbamate” as used herein by itself or as part of another group refers to a radical of the formula —NR 54a —C(═O)—OR 54b , wherein R 54a  is hydrogen or alkyl, and R 54b  is hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl. A non-limiting exemplary carbamate group is —NH—(C═O)—OtBu. 
     The term “(heteroaryl)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one or two optionally substituted heteroaryl groups. In one embodiment, the alkyl group is substituted with one optionally substituted 5- to 14-membered heteroaryl group. In another embodiment, the alkyl group is substituted with two optionally substituted 5- to 14-membered heteroaryl groups. In another embodiment, the alkyl group is substituted with one optionally substituted 5- to 9-membered heteroaryl group. In another embodiment, the alkyl group is substituted with two optionally substituted 5- to 9-membered heteroaryl groups. In another embodiment, the alkyl group is substituted with one optionally substituted 5- or 6-membered heteroaryl group. In another embodiment, the alkyl group is substituted with two optionally substituted 5- or 6-membered heteroaryl groups. In one embodiment, the alkyl group is a C 1 -C 6  alkyl. In another embodiment, the alkyl group is a C 1 -C 4  alkyl. In another embodiment, the alkyl group is a C 1  or C 2  alkyl. Non-limiting exemplary (heteroaryl)alkyl groups include: 
     
       
         
         
             
             
         
       
     
     The term “(heteroaryl)(aryl)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted heteroaryl group and one optionally substituted aryl group. In one embodiment, the heteroaryl is an optionally substituted 5- to 9-membered heteroaryl group. In another embodiment, the heteroaryl is an optionally substituted 5- or 6-membered heteroaryl group. In one embodiment, the aryl is an optionally substituted phenyl group or optionally substituted naphthyl group. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. Non-limiting exemplary (heteroaryl)(aryl)alkyl groups include: 
     
       
         
         
             
             
         
       
     
     The term “(heteroaryl)(heterocyclo)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted heteroaryl group and one optionally substituted heterocyclo group. In one embodiment, the heteroaryl is an optionally substituted 5- to 9-membered heteroaryl group. In another embodiment, the heteroaryl is an optionally substituted 5- or 6-membered heteroaryl group. In one embodiment, the heterocyclo is an optionally substituted 5- to 8-membered heterocyclo. In another embodiment, the heterocyclo is an optionally substituted 5- or 6-membered heterocyclo. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (heteroaryl)(heterocyclo)alkyl group is: 
     
       
         
         
             
             
         
       
     
     The term “(heteroaryl)(carboxamido)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted heteroaryl group and one carboxamido group. In one embodiment, the heteroaryl is an optionally substituted 5- to 9-membered heteroaryl group. In another embodiment, the heteroaryl is an optionally substituted 5- or 6-membered heteroaryl group. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1 -C 3  alkyl. Non-limiting exemplary (heteroaryl)(carboxamido)alkyl groups include: 
     
       
         
         
             
             
         
       
     
     The term “carboxamido” as used herein by itself or as part of another group refers to a radical of formula —C(═O)NR 55a R 55b , wherein R 55a  and R 55b  are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, (alkoxy)alkyl, (hydroxy)alkyl, (cyano)alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, optionally substituted heteroaryl, (aryl)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, or (heteroaryl)alkyl; or R 55a  and R 55b  taken together with the nitrogen to which they are attached from a 4- to 8-membered optionally substituted heterocyclo group. Non-limiting exemplary carboxamido groups include: morpholine-4-carbonyl, N,N-dimethylaminocarbonyl, N-(1-methylpiperidin-4-yl)aminocarbonyl, 4-methylpiperazine-1-carbonyl, N-(3-aminocyclopentyl)aminocarbonyl, N-(pyridin-3-yl)aminocarbonyl, and N-(tetrahydrofuran-3-yl)aminocarbonyl. 
     The term “(heteroaryl)(cycloalkyl)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted heteroaryl group and one optionally substituted cycloalkyl group. In one embodiment, the heteroaryl is an optionally substituted 5- to 9-membered heteroaryl group. In another embodiment, the heteroaryl is an optionally substituted 5- or 6-membered heteroaryl group. In one embodiment, the cycloalkyl is an optionally substituted C 3 -C 6  cycloalkyl. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1 -C 3  alkyl. A non-limiting exemplary (heteroaryl)(C 3 -C 6  cycloalkyl) alkyl group is: 
     
       
         
         
             
             
         
       
     
     The term “(aryl)(alkoxycarbonyl)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted aryl group and one alkoxycarbonyl group. In one embodiment, the aryl is an optionally substituted phenyl group or optionally substituted naphthyl group. In another embodiment, the aryl is an optionally substituted phenyl group. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (aryl)(alkoxycarbonyl)alkyl group is: 
     
       
         
         
             
             
         
       
     
     The term “alkoxycarbonyl” as used herein by itself or as part of another group refers to a carbonyl group, i.e., —C(═O)—, substituted by a C 1 -C 6  alkoxy group. In one embodiment, the alkoxy group is a C 1 -C 4  alkoxy. In another embodiment, the alkoxy group is a C 1 -C 3  alkoxy. Non-limiting exemplary alkoxycarbonyl groups include —CO 2 -Me and —CO 2 Et. 
     The term “(heteroaryl)(amino)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted heteroaryl group and one amino group. In one embodiment, the heteroaryl is an optionally substituted 5- to 9-membered heteroaryl group. In another embodiment, the heteroaryl is an optionally substituted 5- or 6-membered heteroaryl group. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (heteroaryl)(amino)alkyl group is: 
     
       
         
         
             
             
         
       
     
     The term “(cycloalkyl)(alkoxycarbonyl)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted cycloalkyl group and one alkoxycarbonyl group. In one embodiment, the cycloalkyl is an optionally substituted C 3 -C 6  cycloalkyl. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (cycloalkyl)(alkoxycarbonyl)alkyl group is: 
     
       
         
         
             
             
         
       
     
     The term “(heteroaryl)(alkoxycarbonyl)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted heteroaryl group and one alkoxycarbonyl group. In one embodiment, the heteroaryl is an optionally substituted 5- to 9-membered heteroaryl group. In another embodiment, the heteroaryl is an optionally substituted 5- or 6-membered heteroaryl group. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. Non-limiting exemplary (heteroaryl)(alkoxycarbonyl)alkyl groups include: 
     
       
         
         
             
             
         
       
     
     The term “(heterocyclo)(cycloalkyl)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted heterocyclo group and one optionally substituted cycloalkyl group. In one embodiment, the heterocyclo is an optionally substituted 5- to 8-membered heterocyclo. In another embodiment, the heterocyclo is an optionally substituted 5- or 6-membered heterocyclo. In one embodiment, the cycloalkyl is an optionally substituted C 3 -C 6  cycloalkyl. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (heterocyclo)(cycloalkyl)alkyl group is: 
     
       
         
         
             
             
         
       
     
     The term “(aryl)(cycloalkyl)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted aryl group and one optionally substituted cycloalkyl group. In one embodiment, the aryl is an optionally substituted phenyl group or optionally substituted naphthyl group. In another embodiment, the aryl is an optionally substituted phenyl group. In one embodiment, the cycloalkyl is an optionally substituted C 3 -C 6  cycloalkyl. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (aryl)(cycloalkyl)alkyl group is: 
     
       
         
         
             
             
         
       
     
     The terms “aralkyl” or “(aryl)alkyl” as used herein by themselves or as part of another group refers to an alkyl substituted with one, two, or three optionally substituted aryl groups. In one embodiment, the alkyl is substituted with one optionally substituted aryl group. In another embodiment, the alkyl is substituted with two optionally substituted aryl groups. In one embodiment, the aryl is an optionally substituted phenyl or optionally substituted naphthyl. In another embodiment, the aryl is an optionally substituted phenyl. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. Non-limiting exemplary (aryl)alkyl groups include benzyl, phenethyl, —CHPh 2 , and —CH(4-F-Ph) 2 . 
     The term “(aryl)(hydroxy)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one optionally substituted aryl group and one hydroxyl group. In one embodiment, the aryl is an optionally substituted phenyl group or optionally substituted naphthyl group. In another embodiment, the aryl is an optionally substituted phenyl group. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. Non-limiting exemplary (aryl)(hydroxy)alkyl groups include: 
     
       
         
         
             
             
         
       
     
     The term “(cycloalkyl)(hydroxy)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one optionally substituted cycloalkyl group and one hydroxyl group. In one embodiment, the cycloalkyl group is an optionally substituted C 3 -C 6  cycloalkyl group. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (cycloalkyl)(hydroxy)alkyl group is: 
     
       
         
         
             
             
         
       
     
     The term “(alkoxycarbonyl)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one or two alkoxycarbonyl groups. In one embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (alkoxycarbonyl)alkyl groups is: 
     
       
         
         
             
             
         
       
     
     The term “(aryl)(haloalkyl)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one optionally substituted aryl group and one haloalkyl group. In one embodiment, the aryl is an optionally substituted group or optionally substituted naphthyl. In another embodiment, the aryl is an optionally substituted phenyl. In one embodiment, the haloalkyl is a C 1 -C 4  haloalkyl. In one embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (aryl)(haloalkyl)alkyl groups is: 
     
       
         
         
             
             
         
       
     
     The term “(cycloalkyl)(haloalkyl)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one optionally substituted cycloalkyl group and one haloalkyl group. In one embodiment, the cycloalkyl is an optionally substituted C 3 -C 6  cycloalkyl. In one embodiment, the haloalkyl is a C 1 -C 4  haloalkyl. In one embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (cycloalkyl)(haloalkyl) alkyl groups is: 
     
       
         
         
             
             
         
       
     
     The term “(hydroxy)(haloalkyl)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one hydroxy group and one haloalkyl group. In one embodiment, the haloalkyl is a C 1 -C 4  haloalkyl. In one embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (hydroxy)(haloalkyl)alkyl groups is: 
     
       
         
         
             
             
         
       
     
     The term “(alkoxycarbonyl)(haloalkyl)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one alkoxycarbonyl group and one haloalkyl group. In one embodiment, the haloalkyl is a C 1 -C 4  haloalkyl. In one embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (alkoxycarbonyl)(haloalkyl)alkyl groups is: 
     
       
         
         
             
             
         
       
     
     The term “(carboxamido)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with a carboxamido group. In one embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. Non-limiting exemplary (carboxamido)alkyl groups include —CH 2 C(═O)NH 2 , —C(H)(CH 3 )C(═O)NH 2 , —CH 2 C(═O)N(H)CH 3 , and —CH 2 C(═O)N(CH 3 ) 2 . 
     The term “(carboxy)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with —C(═O)OH. In one embodiment, the alkyl is a C 1 -C 4  alkyl. In another embodiment, the alkyl is a C 1  or C 2  alkyl. A non-limiting exemplary (carboxy)alkyl group is —CH 2 CO 2 H. 
     The term “(amino)(hydroxy)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one hydroxy group and one amino group. In one embodiment, the alkyl is a C 1 -C 4  alkyl. A non-limiting exemplary “(amino)(hydroxy)alkyl group is: 
     
       
         
         
             
             
         
       
     
     The term “(amino)(aryl)alkyl” as used herein by itself or as part of another group refers to an alkyl group substituted with one amino group and one optionally substituted aryl group. In one embodiment, the amino group is —NH 2 , alkylamino, or dialkylamino. In one embodiment, the aryl group is an optionally substituted phenyl. In one embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. Non-limiting exemplary (amino)(aryl)alkyl groups include: 
     
       
         
         
             
             
         
       
     
     The term “amino” as used by itself or as part of another group refers to a radical of the formula —NR 55a R 55b , wherein R 55a  and R 55b  are independently hydrogen, optionally substituted alkyl, haloalkyl, (hydroxy)alkyl, (alkoxy)alkyl, (amino)alkyl, heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, optionally substituted heteroaryl, (aryl)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, or (heteroaryl)alkyl. 
     In one embodiment, the amino is —NH 2 . 
     In another embodiment, the amino is an “alkylamino,” i.e., an amino group wherein R 55a  is C 1-6  alkyl and R 55b  is hydrogen. In one embodiment, R 55a  is C 1 -C 4  alkyl. Non-limiting exemplary alkylamino groups include —N(H)CH 3  and —N(H)CH 2 CH 3 . 
     In another embodiment, the amino is a “dialkylamino,” i.e., an amino group wherein R 55a  and R 55b  are each independently C 1-6  alkyl. In one embodiment, R 55a  and R 55b  are each independently C 1 -C 4  alkyl. Non-limiting exemplary dialkylamino groups include —N(CH 3 ) 2  and —N(CH 3 )CH 2 CH(CH 3 ) 2 . 
     In another embodiment, the amino is a “hydroxyalkylamino,” i.e., an amino group wherein R 55a  is (hydroxyl)alkyl and R 55b  is hydrogen or C 1 -C 4  alkyl. 
     In another embodiment, the amino is a “cycloalkylamino,” i.e., an amino group wherein R 55a  is optionally substituted cycloalkyl and R 55b  is hydrogen or C 1 -C 4  alkyl. 
     In another embodiment, the amino is a “aralkylamino,” i.e., an amino group wherein R 55a  is aralkyl and R 55b  is hydrogen or C 1 -C 4  alkyl. Non-limiting exemplary aralkylamino groups include —N(H)CH 2 Ph, —N(H)CHPh 2 , and —N(CH 3 )CH 2 Ph. 
     In another embodiment, the amino is a “(cycloalkyl)alkylamino,” i.e., an amino group whereinR 55a  is (cycloalkyl)alkyl and R 55b  is hydrogen or C 1 -C 4  alkyl. Non-limiting exemplary (cycloalkyl)alkylamino groups include: 
     
       
         
         
             
             
         
       
     
     In another embodiment, the amino is a “(heterocyclo)alkylamino,” i.e., an amino group wherein R 55a  is (heterocyclo)alkyl and R 55b  is hydrogen or C 1 -C 4  alkyl. Non-limiting exemplary (heterocyclo)alkylamino groups include: 
     
       
         
         
             
             
         
       
     
     The term “(amino)alkyl” as used herein by itself or as part of another group refers to an alkyl substituted with one amino group. In one embodiment, the amino group is —NH 2 . In one embodiment, the amino group is an alkylamino. In another embodiment, the amino group is a dialkylamino. In another embodiment, the alkyl is a C 1 -C 6  alkyl. In another embodiment, the alkyl is a C 1 -C 4  alkyl. Non-limiting exemplary (amino)alkyl groups include —CH 2 NH 2 , CH 2 CH 2 N(H)CH 3 , —CH 2 CH 2 N(CH 3 ) 2 , CH 2 N(H)cyclopropyl, —CH 2 N(H)cyclobutyl, and —CH 2 N(H)cyclohexyl, and —CH 2 CH 2 CH 2 N(H)CH 2 Ph and —CH 2 CH 2 CH 2 N(H)CH 2 (4-CF 3 -Ph). 
     The present disclosure encompasses any of the Compounds of the Disclosure being isotopically-labelled (i.e., radiolabeled) by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as  2 H (or deuterium (D)),  3 H,  11 C,  13 C,  14 C,  15 N,  18 O,  17 O,  31 P,  32 P,  35 S,  18 F, and  36 Cl, respectively, e.g.,  3 H,  11 C, and  14 C. In one embodiment, provided is a composition wherein substantially all of the atoms at a position within the Compound of the Disclosure are replaced by an atom having a different atomic mass or mass number. In another embodiment, provided is a composition wherein a portion of the atoms at a position within the Compound of the disclosure are replaced, i.e., the Compound of the Disclosure is enriched at a position with an atom having a different atomic mass or mass number.” Isotopically-labelled Compounds of the Disclosure can be prepared by methods known in the art. 
     Compounds of the Disclosure may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. The present disclosure encompasses the use of all such possible forms, as well as their racemic and resolved forms and mixtures thereof. The individual enantiomers can be separated according to methods known in the art in view of the present disclosure. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers. All tautomers are also encompassed by the present disclosure. 
     As used herein, the term “stereoisomers” is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers). 
     The term “chiral center” or “asymmetric carbon atom” refers to a carbon atom to which four different groups are attached. 
     The terms “enantiomer” and “enantiomeric” refer to a molecule that cannot be superimposed on its mirror image and hence is optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image compound rotates the plane of polarized light in the opposite direction. 
     The term “racemic” refers to a mixture of equal parts of enantiomers and which mixture is optically inactive. In one embodiment, Compounds of the Disclosure are racemic. 
     The term “absolute configuration” refers to the spatial arrangement of the atoms of a chiral molecular entity (or group) and its stereochemical description, e.g., R or S. 
     The stereochemical terms and conventions used in the specification are meant to be consistent with those described in  Pure  &amp;  Appl. Chem  68:2193 (1996), unless otherwise indicated. 
     The term “enantiomeric excess” or “ee” refers to a measure for how much of one enantiomer is present compared to the other. For a mixture of R and S enantiomers, the percent enantiomeric excess is defined as |R−S|*100, where R and S are the respective mole or weight fractions of enantiomers in a mixture such that R+S=1. With knowledge of the optical rotation of a chiral substance, the percent enantiomeric excess is defined as ([α] obs /[α] max )*100, where [α] obs  is the optical rotation of the mixture of enantiomers and [α] max  is the optical rotation of the pure enantiomer. Determination of enantiomeric excess is possible using a variety of analytical techniques, including NMR spectroscopy, chiral column chromatography or optical polarimetry. 
     In one embodiment, Compounds of the Disclosure having one or more chiral centers are enantiomerically enriched, e.g., the ee is about 5% or more. In another embodiment, the ee is about 10%. In another embodiment, the ee is about 20%. In another embodiment, the ee is about 30%. In another embodiment, the ee is about 40%. In another embodiment, the ee is about 50%. In another embodiment, the ee is about 60%. In another embodiment, the ee is about 70%. In another embodiment, the ee is about 80%. In another embodiment, the ee is about 85%. In another embodiment, the ee is about 90%. In another embodiment, the ee is about 91%. In another embodiment, the ee is about 92%. In another embodiment, the ee is about 93%. In another embodiment, the ee is about 94%. In another embodiment, the ee is about 95%. In another embodiment, the ee is about 96%. In another embodiment, the ee is about 97%. In another embodiment, the ee is about 98%. In another embodiment, the ee is about 99%. 
     The terms “a” and “an” refer to one or more. 
     The term “about,” as used herein, includes the recited number ±10%. Thus, “about 10” means 9 to 11. 
     The terms “treat,” “treating,” “treatment,” and the like as used herein refer to eliminating, reducing, or ameliorating a disease or condition, and/or symptoms associated therewith. Although not precluded, treating a disease or condition does not require that the disease, condition, or symptoms associated therewith be completely eliminated. As used herein, the terms “treat,” “treating,” “treatment,” and the like may include “prophylactic treatment,” which refers to reducing the probability of redeveloping a disease or condition, or of a recurrence of a previously-controlled disease or condition, in a subject who does not have, but is at risk of or is susceptible to, redeveloping a disease or condition or a recurrence of the disease or condition. The term “treat” and synonyms contemplate administering a therapeutically effective amount of a Compound of the Disclosure to an individual in need of such treatment. 
     Within the meaning of the disclosure, “treatment” also includes relapse prophylaxis or phase prophylaxis, as well as the treatment of acute or chronic signs, symptoms and/or malfunctions. The treatment can be orientated symptomatically, for example, to suppress symptoms. It can be effected over a short period, be oriented over a medium term, or can be a long-term treatment, for example within the context of a maintenance therapy. 
     The term “therapeutically effective amount” or “effective dose” as used herein refers to an amount of the active ingredient(s) that is(are) sufficient, when administered by a method of the disclosure, to efficaciously deliver the active ingredient(s) for the treatment of condition or disease of interest to an individual in need thereof. In the case of a cancer or other proliferation disorder, the therapeutically effective amount of the agent may reduce (i.e., retard to some extent and preferably stop) unwanted cellular proliferation; reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., retard to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., retard to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; modulate protein methylation in the target cells; and/or relieve, to some extent, one or more of the symptoms associated with the cancer. To the extent the administered compound or composition prevents growth and/or kills existing cancer cells, it may be cytostatic and/or cytotoxic. 
     The term “container” means any receptacle and closure therefore suitable for storing, shipping, dispensing, and/or handling a pharmaceutical product. 
     The term “insert” means information accompanying a pharmaceutical product that provides a description of how to administer the product, along with the safety and efficacy data required to allow the physician, pharmacist, and patient to make an informed decision regarding use of the product. The package insert generally is regarded as the “label” for a pharmaceutical product. 
     The term “disease” or “condition” or “disorder” denotes disturbances and/or anomalies that as a rule are regarded as being pathological conditions or functions, and that can manifest themselves in the form of particular signs, symptoms, and/or malfunctions. Compounds of the Disclosure inhibit SETD2 protein and can be used in treating diseases and conditions such as proliferative diseases, wherein inhibition of SETD2 protein provides a benefit. See, e.g., U.S. Provisional Appl. No. 62/545,353. 
     In some embodiments, the Compounds of the Disclosure can be used to treat a “SETD2 protein mediated disorder” A SETD2 protein mediated disorder is any pathological condition in which a SETD2 protein is known to play a role. In some embodiments, a SETD2 mediated disorder is a proliferative disease. 
     In some embodiments inhibiting SETD2 protein is the inhibition of the activity of one or more activities of SETD2 protein. In some embodiments, the activity of the SETD2 protein is the ability of the SETD2 protein to transfer a methyl group to a target protein, e.g., histone. It should be appreciated that the activity of SETD2 may be inhibited in vitro or in vivo. Exemplary levels of inhibition of the activity of SETD2 include at least 5% inhibition at least 10% inhibition, at least 20% inhibition, at least 30% inhibition, at least 40% inhibition, at least 50% inhibition, at least 60% inhibition, at least 70% inhibition, at least 80% inhibition, at least 90% inhibition, and up to about 100% inhibition. 
     The term “biological sample” as used herein refers any tissue or fluid from a subject that is suitable for detecting chromosomal translocations. Examples of useful biological samples include, but are not limited to, biopsied tissues and/or cells, e.g., solid tumor, lymph gland, inflamed tissue, tissue and/or cells involved in a condition or disease, blood, plasma, serous fluid, cerebrospinal fluid, saliva, urine, lymph, cerebral spinal fluid, and the like. Other suitable biological samples will be familiar to those of ordinary skill in the relevant arts. A biological sample can be analyzed for chromosomal translocations using any technique known in the art. Such techniques include, but are not limited to, polymerase chain reaction (PCR) methodology, reverse transcription-polymerase chain reaction (RT-PCR) methodology, or cytoplasmic light chain immunofluorescence combined with fluorescence in situ hybridization (cIg-FISH). A biological sample can be obtained using techniques that are well within the scope of ordinary knowledge of a clinical practioner. In one embodiment of the disclosure, the biological sample comprises blood cells. 
     The phrase “in combination” as used in connection with the administration of a Compound of the Disclosure and a Second Therapeutic Agent to a subject means that the Compound of the Disclosure and the Second Therapeutic Agent can be administered to the subject together, e.g., as part of a single pharmaceutical composition or formulation, or separately, e.g., as part of two or more separate pharmaceutical compositions or formulations. The phrase “in combination” as used in connection with the administration of a Compound of the Disclosure and a Second Therapeutic Agent to a subject is thus intended to embrace administration of a Compound of the Disclosure and a Second Therapeutic Agent in a sequential manner, wherein the Compound of the Disclosure and the Second Therapeutic Agent are administered to the subject at a different time, as well as administration concurrently, or in a substantially simultaneous manner. Simultaneous administration can be accomplished, for example, by administering to the subject a single capsule having a fixed ratio of each of the Compound of the Disclosure and the Second Therapeutic Agent or in multiple, single capsules for each of the Compound of the Disclosure and the Second Therapeutic Agent. Sequential or substantially simultaneous administration of the Compound of the Disclosure and the Second Therapeutic Agent agent can be accomplished by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The Compound of the Disclosure and the Second Therapeutic Agent can be administered by the same route or by different routes. For example, the Second Therapeutic Agent of the combination may be administered by intravenous injection while the Compound of the Disclosure of the combination may be administered orally. Alternatively, for example, both the Compound of the Disclosure and the Second Therapeutic Agent may be administered orally or both the Compound of the Disclosure and the Second Therapeutic Agent may be administered by intravenous injection. The Compound of the Disclosure and the Second Therapeutic Agent may also be administered in alternation. In one embodiment, the Compound of the Disclosure and the Second Therapeutic Agent are administered to a subject separately, e.g., as part of two or more separate pharmaceutical compositions or formulations. 
     General Synthesis of Compounds 
     Compounds of the Disclosure are prepared using methods disclosed in PCT/US2019/046569, or by the illustrative methods shown in the General Schemes below. In the General Schemes, R 1d , R 2b , R 2d , R 2e , A 1 , A 2 , R 11a , R 14a , R 14b , R 19 , R 20 , G, Z 4 , and q are as defined in connection with Formulae II, III, IV, V, or VI, unless otherwise indicated. In any of the General Schemes, suitable protecting groups can be employed in the synthesis, for example, when Z is (amino)alkyl or any other group that may group that may require protection, or when R 8  is amino, (amino)alkyl, or any other group that may require protection. (See, Wuts, P. G. M.; Greene, T. W., “Greene&#39;s Protective Groups in Organic Synthesis”, 4th Ed., J. Wiley &amp; Sons, NY, 2007) unless otherwise indicated. 
     In General Scheme 1, the aryl hydrazine of Formula (1) is reacted with ethyl 2-oxopropanoate to give a compound of Formula (2). In step 2, the compound of Formula (2) is converted to the indole of Formula (3) under acidic conditions. In step 3, the compound of Formula (3) is hydrolyzed to give the indole-2-carboxylic acid of Formula (4). In step 4, a compound of Formula (4) is reacted with G 1 NH 2  under standard coupling conditions to give a compound of Formula II. 
     
       
         
         
             
             
         
       
     
     In General Scheme 2, a compound of Formula (5) is reacted with R 2b —H wherein R 2b  is a heterocyclo, e.g., R 2b —H is piperidine, or an amine, e.g., R 2b —H is dimethyl amine, to give a compound of Formula (6). The nitro group of the compound of Formula (6) is reduced to give a compound of Formula (7). In step 3, the compound of Formula (7) is reacted with a compound of Formula (4), see General Scheme 1, under standard coupling conditions to give a compound of Formula III, wherein A 1  and A 2  are CH and R 2b  is an optionally substituted heterocyclo or an amino group. 
     
       
         
         
             
             
         
       
     
     In General Scheme 3, a compound of Formula (8) is reacted with R 2b —H wherein R 2b  is a heterocyclo, e.g., R 2b —H is piperidine, or an amine, e.g., R 2b —H is dimethyl amine, to give a compound of Formula (9). In step 2, the compound of Formula (9) is reacted with a compound of Formula (10) to give a compound of Formula III, wherein A 1  and/or A 2  are N and R 2b  is an optionally substituted heterocyclo or an amino group. 
     
       
         
         
             
             
         
       
     
     In General Scheme 4, a compound of Formula (11) is reacted with R 11a —H, wherein R 11a  is a heterocyclo, e.g., R 11a —H is piperidine, to give a compound of Formula (12). In step 2, the Cbz group is removed to give a compound of Formula (13). The compound of Formula (13) is coupled with a compound of Formula (4) to give a compound of Formula IV, wherein R 11a  is optionally substituted heterocyclo and Z 5  is —CH 2 —. 
     
       
         
         
             
             
         
       
     
     In step 1 of General Scheme 5, a nitrile of Formula (14) is reacted with a Grignard reagent (R 14a —MgBr) and the resulting product is reduced to give a compound of Formula (15). The compound of Formula (15) is coupled with a compound of Formula (4) to give a compound of Formula V, wherein p is 0. 
     
       
         
         
             
             
         
       
     
     In General Scheme 6, an aldehyde of Formula (16) is reacted with an ester of Formula (17) to give a compound of Formula (18). In step 2, the compound of Formula (18) hydrolyzed to give a compound of Formula (19). In step 3, the compound of Formula (19) is converted to the isocyanate of Formula (20). The compound of Formula (20) is reacted with benzyl alcohol to give a compound of Formula (21). Hydrogenation of a compound of Formula (21) and removal of the Cbz groups gives an amine of Formula (23). Coupling a compound of Formula (23) with a compound of Formula (4) gives a compound of Formula V, wherein p is 1. 
     
       
         
         
             
             
         
       
     
     In General Scheme 7, the nitrile of Formula (24) is reduced to give an amine of Formula (25). The compound of Formula (25) is coupled with a compound of Formula (4) to give a compound of Formula VI. 
     
       
         
         
             
             
         
       
     
     EXAMPLES 
     Example 1 
     Synthesis of N-((1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1H-indole-2-carboxamide (Cpd. No. 15) 
     Step 1. Synthesis of ethyl (2E)-2-[2-(5-fluoro-2-methylphenyl)hydrazin-1-ylidene]propanoate 
     
       
         
         
             
             
         
       
     
     Into a 1000-mL round-bottom flask, was placed a solution of (5-fluoro-2-methylphenyl)hydrazine hydrochloride (100 g, 572.73 mmol, 1.00 equiv) in ethanol (400 mL), ethyl 2-oxopropanoate (66 g, 1.20 equiv), sulfuric acid (10 mL). The resulting solution was stirred for 2 h at 25° C. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The solids were collected by filtration. This resulted in 120 g (yield=88%) of ethyl (2E)-2-[2-(5-fluoro-2-methylphenyl) hydrazin-1-ylidene]propanoate as a yellow solid. LCMS (Method A: ESI): RT=1.399 min, m/z=239.0 [M+H] + .  1 H NMR (400 MHz, DMSO-d 6 ) δ 11.96 (d, J=2.0 Hz, 1H), 7.15 (m, 2H), 6.62 (m, 1H), 4.25 (q, J=7.1 Hz, 2H), 2.12 (d, J=9.3 Hz, 6H), 1.29 (t, J=7.1 Hz, 3H) ppm. 
     Step 2. Synthesis of ethyl 4-fluoro-7-methyl-1H-indole-2-carboxylate 
     
       
         
         
             
             
         
       
     
     Into a 1000-mL round-bottom flask, was placed a solution of ethyl (2E)-2-[2-(5-fluoro-2-methylphenyl)hydrazin-1-ylidene]propanoate (40 g, 167.89 mmol, 1.00 equiv) in Toluene (400 mL), 4-methylbenzene-1-sulfonic acid (50 g, 290.36 mmol, 1.70 equiv). The resulting solution was stirred for 18 h at 100° C. The reaction progress was monitored by LCMS. The resulting solution was concentrated under vacuum, and the residue was dissolved by 100 ml of ethyl acetate. The resulting mixture was washed with 3×200 mL of saturated aqueous NaHCO 3 . The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:5). The resulting mixture was concentrated under vacuum. The solid was purified by recrystalization from ethanol. This resulted in 9.0 g (yield=24%) of ethyl 4-fluoro-7-methyl-1H-indole-2-carboxylate as a yellow solid. LCMS (Method A, ESI): RT=1.354 min,: m/z=222.0 [M+H] + .  1 H NMR (400 MHz, DMSO-d 6 ) δ 12.07 (s, 1H), 7.17 (d, J=2.1 Hz, 1H), 7.00 (m, 1H), 6.77 (m, 7.8 Hz, 1H), 4.36 (q, J=7.1 Hz, 2H), 2.49 (d, J=1.0 Hz, 3H), 1.35 (t, J=7.1 Hz, 3H) ppm. 
     Step 3. Synthesis of 4-fluoro-7-methyl-1H-indole-2-carboxylic acid 
     
       
         
         
             
             
         
       
     
     Into a 500-mL round-bottom flask, was placed a solution of ethyl 4-fluoro-7-methyl-1H-indole-2-carboxylate (9.1 g, 41.13 mmol, 1.00 equiv) in tetrahydrofuran (150 mL), sodium hydroxide (8 g, 200.00 mmol, 5.00 equiv), water (50 mL), methanol (2 mL). The resulting solution was stirred for 6 h at 25° C. The resulting mixture was concentrated under vacuum. The residue was diluted with water 50 ml, then adjusted to pH 5 with hydrogen chloride (3.0 mol/L). The resulting solution was extracted with 3×50 mL of ethyl acetate. The solid was collected by filtration. This resulted in 8.0 (yield=81%) g of 4-fluoro-7-methyl-1H-indole-2-carboxylic acid as a brown solid. LCMS (Method C, ESI): RT=0.989 min, m/z=192.0 [M-H] + .  1 H NMR (300 MHz, DMSO-d 6 ) δ 13.10 (s, 1H), 11.94 (s, 1H), 7.09 (d, J=2.1 Hz, 1H), 6.96 (m, 1H), 6.73 (m, 1H), 2.46 (d, J=1.1 Hz, 3H) ppm. 
     Step 4. Synthesis of tert-butyl N-[3-(4-acetylpiperazin-1-yl)cyclohexyl]carbamate 
     
       
         
         
             
             
         
       
     
     Into a 100-mL round-bottom flask, was placed tert-butyl N-(3-oxocyclohexyl)carbamate (800 mg, 3.75 mmol, 1.00 equiv), 1-(piperazin-1-yl)ethan-1-one (800 mg, 6.24 mmol, 1.66 equiv), methanol (10 mL), Pd/C (0.2 g), and to the above mixture, hydrogen was introduced. The resulting solution was stirred for 2 h at 25° C. The reaction progress was monitored by LCMS. The solids were filtered out. The resulting mixture was concentrated under vacuum. The crude product (900 mg) was purified by Flash-Prep-HPLC with the following conditions: Column, C18 silica gel; mobile phase ; Detector, UV 254/220 nm. This resulted in 700 mg (yield=57%) of tert butyl N-[3-(4-acetylpiperazin-1-yl)cyclohexyl] carbamate as colorless oil. LCMS (Method A, ESI): RT=1.361 min, m/z=325.9 [M+H] + . 
     Step 5. Synthesis of 1-[4-(3-aminocyclohexyl)piperazin-1-yl]ethan-1-one 
     
       
         
         
             
             
         
       
     
     Into a 100-mL round-bottom flask, was placed tert-butyl N-[3-(4-acetylpiperazin-1-yl)cyclohexyl]carbamate (700 mg, 2.15 mmol, 1.00 equiv), dichloromethane (3 mL), trifluoroacetic acid (2 mL) was added by dropwise. The resulting solution was stirred for 2 h at 25° C. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. This resulted in 700 mg of 1-[4-(3-aminocyclohexyl)piperazin-1-yl]ethan-1-one as a brown oil. LCMS (Method A, ES): RT=0.647 min , m/z=225.95 [M+H] + . 
     Step 6. Synthesis of N-[(1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl]-4-fluoro-7-methyl-1H-indole-2-carboxamide (as the TFA salt) 
     
       
         
         
             
             
         
       
     
     Into a 100-mL round-bottom flask, was placed 4-fluoro-7-methyl-1H-indole-2-carboxylic acid (100 mg, 0.52 mmol, 1.00 equiv), 1-[4-(3-aminocyclohexyl)piperazin-1-yl]ethan-1-one (110 mg, 0.49 mmol, 0.94 equiv), N,N-dimethylformamide (4 mL), DIEA (200 mg, 1.55 mmol, 2.99 equiv), HATU (260 mg, 0.68 mmol, 1.32 equiv) was added batchwise. The resulting solution was stirred for 2 h at 25° C. The reaction progress was monitored by LCMS, and the reaction solution was quenched by 10 ml of water. The resulting solution was extracted with 3×15 ml of ethyl acetate and the organic layers combined and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:1). The crude product was purified by Chiral-Prep-HPLC with the following conditions: Column, (R,R)-WHELK-014.6*50 mm, 3.5 μm: 1-78220-30056749; mobile phase, Hexane (0.1%DEA):EtOH=85:15; Detector, UV 254 nm/220 nm. The product thus obtained was further purified by Prep-HPLC with the following conditions: Column,)(Bridge Prep Phenyl OBD Column, 5 μm, 19*150 mm; mobile phase, Water with 10 mmol TFA and MeCN (20.0% MeCN up to 30.0% in 10 min, up to 95.0% in 1 min, hold 95.0% in 1 min, down to 20.0% in 2 min); Detector, UV 254/220 nm. This resulted in 30.5 mg (yield=11%) of N-[(1R,3S)-3-(4-acetylpiperazin-1-yl)cyclohexyl]-4-fluoro-7-methyl-1H-indole-2-carboxamide trifluoroacetic acid salt as a white solid. LCMS (Method B, ES): RT=1.138 min, m/z=401.0 [M−TFA] + .  1 H NMR (300 MHz, Methanol-d4) δ 7.18 (s, 1H), 6.94-6.92 (m, 1H), 6.64-6.62 (m, 1H), 4.03-3.88 (m, 1H), 3.57-3.55 (m, 4H), 2.65 (t, J=16.4 Hz, 5H), 2.48 (t, J=1.0 Hz, 3H), 2.23 (d, J=12.0 Hz, 1H), 2.09 (s, 3H), 1.93 (d, J=12.2 Hz, 3H), 1.53-1.18 (m, 4H) ppm. 
     Example 2 
     Combination Studies 
     Multiple myeloma (MM) and mantle cell lymphoma (MCL) Cell line cultures in log-linear growth rate were treated with combinations of Cpd. No. 15 and combination partners according to a co-treatment model. Assay-ready plates were prepared by dispensing the compounds with the HP-D300 nanoliter dispenser (Tecan, Mannedorf, Switzerland) onto 384-well white opaque plates (CulturPlate-384, White Opaque 384-well Microplate, Sterile and Tissue Culture Treated) to achieve either 2-fold or 3-fold serial dilutions in a concentration range bracketed around the IC 50  of Cpd. No. 15 and the combination partner. Concentrations were matrixed in an 8×9 array (8 concentrations of Cpd. No. 15 and 9 concentrations of its combination partner). Each combination was tested in quadruplicate wells. The final concentration of DMSO (vehicle) in the assay was 0.1% v/v. Fifty microliters of cell line suspension were directly dispensed to the assay-ready plates with an automated multichannel dispenser on to 384-well assay-ready plates. Assay plates were incubated for seven days in a humidified atmosphere of 5% CO 2  at 37° C. Quantification of the effect of single agents or combinations on cell viability was performed through measurement of cellular adenosine triphosphate (ATP) using a CellTiter-Glo® (Promega, Madison, Wis.) Luminescent Cell Viability Assay. Luminescence was detected using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, Calif.). Concentration response plots were generated in GraphPad Prism version 7.0 for Windows, GraphPad Software, (La Jolla, Calif.) and curves fitted to a four-parameter logistic model with variable slope. Percent of inhibition was calculated at each treatment concentration. Quantification of synergy was performed using the Loewe Additivity model and by calculating the Loewe Volume (VLoewe) with the CHALICE software (Horizon Discovery, Cambridge, UK) (Lehar 2007) (VLoewe&gt;1: synergy, between 1 and −1: additivity, and &lt;−1: antagonistic; if neither of the agents or the combination reached 50 percent inhibition of prolferationit is deemed as “No Effect.” See Loewe,  Arzneimittelforschung  3(6): 285-290 (1953) and Lehar et al.,  Mol Syst Biol  3:80 (2007). The cell lines used in these studies were purchased from commercial suppliers. For example, NCI-H929, MM1. S, MINO, REC1, MAVER1, Z138, JEKO1, JVM2, and RPMI-8226 cell lines were purchased from the American Type Culture Collection (ATCC, Manassas Va.); KMS-11, KMS34, and KMS-28-BM were purchased from the Japanese Collection of Research Bioresourres (JCRB, Osaka, Japan); and L-363 and GRANTA519 were purchased from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures. 
     The results of these combinations are summarized in Tables A and B (multiple myeloma cell lines), and Tables C and D (mantle cell lymphoma cell lines). 
     By way of example,  FIG.  3    shows the synergistic anti-proliferative activity of Cpd. No. 15 combined with pomalidomide in KMS-11 cells in a 7-day co-treatment study.  FIG.  4    shows the Loewe Model analysis of the Cpd. No. 15/pomalidomide combination studies in KMS-11 cells. 
     Diffuse large B-cell lymphoma cells were seeded into flasks and pre-treated with several concentrations of Cpd. No. 15 or DMSO. Cells were then split adjusted to initial density, replated and co-treated Cpd. No. 15 and a second agent of interest using the HP D300 digital dispenser (Tecan Group, Mannedorf, Switzerland) in tissue culture treated solid white 384-well plates for additional 3 days. Both agents were serially diluted and combined in a matrix format with constant ratios diagonally across the plate with a final DMSO content of 0.11% (v/v). After 3 days cotreatment, cell viability was measured via ATP content using CellTiter-Glo® (Promega, Madison, Wis.) and luminescence was detected using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, Calif.). 
     Example 3 
     Combination Studies 
     Diffuse large B-cell lymphoma (DLBCL) cell line cultures in log-linear growth rate were treated with combinations of Cpd. No. 15 and combination partners according to a pre-treatment model. Cells were seeded first into 8 flasks and pre-treated with 7 different concentrations of Cpd. No. 15 (concentrations were bracketed around the IC 50  of Cpd. No. 15 in a 3-fold dilution range) and DMSO for four days. On Day 4, assay-ready plates were prepared by dispensing the compounds with the HP-D300 nanoliter dispenser (Tecan, Mannedorf, Switzerland) onto 384-well white opaque plates (CulturPlate-384, White Opaque 384-well Microplate, Sterile and Tissue Culture Treated) to achieve 3-fold serial dilutions in a concentration range bracketed around the IC50 of the combination partner. Cells were harvested from each flask and re-seeded onto the corresponding 384-well plate with the same concentration of Cpd. No. 15. and 9 concentrations of its combination partner in triplicate wells. The final concentration of DMSO (vehicle) in the assay was 0.1% v/v. Fifty microliters of cell line(s) suspension were directly dispensed to the assay-ready plates with an automated multichannel dispenser on to 384-well assay-ready plates. Assay plates were incubated for three days in a humidified atmosphere of 5% CO2 at 37° C. Quantification of the effect of single agents or combinations on cell viability was performed through measurement of cellular adenosine triphosphate (ATP) using CellTiter-Glo® (Promega, Madison, Wis.). Luminescence was detected using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, Calif.). Concentration response plots were generated in GraphPad Prism version 8.0 for Windows, GraphPad Software, (La Jolla, Calif.) and curves fitted to a four-parameter logistic model with variable slope. Percent of inhibition was calculated at each treatment concentration. Quantification of synergy was performed using the Loewe Additivity model and by calculating the Loewe Volume (VLoewe) with the CHALICE software (Horizon Discovery, Cambridge, UK) (Lehar 2007) (VLoewe&gt;1: synergy, between 1 and −1: additivity, and &lt;−1: antagonistic; if neither of the agents or the combination reached 50 percent inhibition it is deemed as no effect. See Loewe,  Arzneimittelforschung  3(6): 285-290 (1953) and Lehar et al.,  Mol Syst Biol  3:80 (2007). SUDHL6 and SUDHL2 cell lines were purchased from the American Type Culture Collection (ATCC, Manassas Va.). WSUDLCL2 was purchased from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures and KARPAS422 was purchased from Sigma Aldrich (St. Louis, Mo.). The results of these combinations are summarized in Table E (diffuse large B-cell lymphoma cell lines). 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE A 
               
               
                   
               
               
                   
                   
                 NCI-H929 
                 KMS-11 
                 KMS-28-BM 
                 RPMI-8226 
               
               
                 Combination 
                   
                 Cat. No. 
                 Cat. No. 
                 Cat. No. 
                 Cat. No. 
               
               
                 Partner 
                 Drug Class 
                 CRL-9068 
                 JCRB1179 
                 JCRB1192 
                 CCL-155 
               
               
                   
               
             
            
               
                 Dexamethasone 
                 Glucocorticoid 
                 Synergy 
                 Synergy 
                 Additivity 
                 Synergy 
               
               
                   
                 receptor agonist 
               
               
                 Pomalidomide 
                 Immunomodulatory 
                 Synergy 
                 Synergy 
                 Additivity 
                 Synergy 
               
               
                 Lenalidomide 
                 drug 
                 Not Tested 
                 Synergy 
                 No Effect 
                 Synergy 
               
               
                 Bortezomib 
                 Proteasome 
                 Additivity 
                 Additivity 
                 Additivity 
                 Additivity 
               
               
                   
                 inhibitor 
               
               
                 Venetoclax 
                 Bcl-2 inhibitor 
                 Synergy 
                 Synergy 
                 Additivity 
                 Additivity 
               
               
                 CC-122 
                 Pleiotropic 
                 Synergy 
                 Synergy 
                 Additivity 
                 Additivity 
               
               
                   
                 pathway modulator 
               
               
                 Selinexor 
                 Selective inhibitor 
                 Synergy 
                 Additivity 
                 Additivity 
                 Additivity 
               
               
                   
                 of nuclear export 
               
               
                   
                 (SINE) or XPO1 
               
               
                   
                 inhibitor 
               
               
                 Panobinostat 
                 Histone deacetylase 
                 Synergy 
                 Additivity 
                 Additivity 
                 Additivity 
               
               
                   
                 inhibitor 
               
               
                 Tazemetostat 
                 EZH2 inhibitor 
                 Not Tested 
                 Not Tested 
                 Not Tested 
                 Additivity 
               
               
                 EPZ-11989 
                   
                 No Effect 
                 Additivity 
                 Additivity 
                 Not Tested 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
             
               
                 TABLE B 
               
               
                   
               
               
                   
                   
                 KMS34 
                 L363 
                 MM1.S 
               
               
                 Combination 
                   
                 Cat. No. 
                 Cat. No. 
                 Cat. No. 
               
               
                 Partner 
                 Drug Class 
                 CCL-155 
                 JCRB1195 
                 CRL-2974 
               
               
                   
               
             
            
               
                 Dexamethasone 
                 Glucocorticoid 
                 Synergy 
                 Synergy 
                 Additivity 
               
               
                   
                 receptor agonist 
               
               
                 Pomalidomide 
                 Immunomodulatory 
                 Synergy 
                 Additivity 
                 Additivity 
               
               
                 Lenalidomide 
                 drug 
                 Synergy 
                 Additivity 
                 Additivity 
               
               
                 Bortezomib 
                 Proteasome 
                 Additivity 
                 Additivity 
                 Additivity 
               
               
                   
                 inhibitor 
               
               
                 Venetoclax 
                 Bcl-2 inhibitor 
                 Additivity 
                 Additivity 
                 Additivity 
               
               
                 CC-122 
                 Pleiotropic 
                 Synergy 
                 Additivity 
                 Additivity 
               
               
                   
                 pathway modulator 
               
               
                 Selinexor 
                 Selective inhibitor 
                 Synergy 
                 Additivity 
                 Additivity 
               
               
                   
                 of nuclear export 
               
               
                   
                 (SINE) or XPO1 
               
               
                   
                 inhibitor 
               
               
                 Panobinostat 
                 Histone deacetylase 
                 Synergy 
                 Additivity 
                 Additivity 
               
               
                   
                 inhibitor 
               
               
                 Tazemetostat 
                 EZH2 inhibitor 
                 Synergy 
                 Synergy 
                 Synergy 
               
               
                 EPZ-11989 
                   
                 Not tested 
                 Not tested 
                 Not tested 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE C 
               
               
                   
               
               
                   
                   
                 MINO 
                 REC1 
                 MAVER1 
                 Z138 
               
               
                 Combination 
                   
                 Cat. No. 
                 Cat. No. 
                 Cat. No. 
                 Cat. No. 
               
               
                 Partner 
                 Drug Class 
                 CRL-3000 
                 CRL-3004 
                 CRL-3008 
                 CRL-3001 
               
               
                   
               
             
            
               
                 Prednisolone 
                 Glucocorticoid 
                 Additivity 
                 Synergy 
                 Synergy 
                 Additivity 
               
               
                   
                 receptor agonist 
               
               
                 Lenalidomide 
                 Immunomodulatory 
                 Additivity 
                 Additivity 
                 Synergy 
                 Synergy 
               
               
                   
                 drug 
               
               
                 Bortezomib 
                 Proteasome 
                 Additivity 
                 Additivity 
                 Additivity 
                 Additivity 
               
               
                   
                 inhibitor 
               
               
                 Venetoclax 
                 Bcl-2 inhibitor 
                 Additivity 
                 Additivity 
                 Synergy 
                 Synergy 
               
               
                 Tazemetostat 
                 EZH2 inhibitor 
                 No Effect 
                 Additivity 
                 Additivity 
                 No Effect 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
             
               
                 TABLE D 
               
               
                   
               
               
                   
                   
                 JEKO1 
                 JVM2 
                 GRANTA519 
               
               
                 Combination 
                   
                 Cat. No. 
                 Cat. No. 
                 Cat. No. 
               
               
                 Partner 
                 Drug Class 
                 CRL-3006 
                 CRL-3002 
                 ACC 342 
               
               
                   
               
             
            
               
                 Prednisolone 
                 Glucocorticoid 
                 Additivity 
                 Additivity 
                 Synergy 
               
               
                   
                 receptor agonist 
               
               
                 Lenalidomide 
                 Immunomodulatory 
                 Synergy 
                 Additivity 
                 Additivity 
               
               
                   
                 drug 
               
               
                 Bortezomib 
                 Proteasome 
                 Additivity 
                 Additivity 
                 Additivity 
               
               
                   
                 inhibitor 
               
               
                 Venetoclax 
                 Bcl-2 inhibitor 
                 Additivity 
                 Synergy 
                 Synergy 
               
               
                 Tazemetostat 
                 EZH2 inhibitor 
                 No Effect 
                 Additivity 
                 No Effect 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE E 
               
               
                   
               
               
                   
                   
                   
                   
                 KARPAS422 
                   
               
               
                   
                   
                 SUDHL-6 
                 SUDHL-2 
                 Cat. No. 
                 WSUDLCL2 
               
               
                 Combination 
                   
                 Cat. No. 
                 Cat. No. 
                 06101702- 
                 Cat. No. 
               
               
                 Partner 
                 Drug Class 
                 CRL-2956 
                 CRL-2959 
                 1VL 
                 ACC 575 
               
               
                   
               
             
            
               
                 Prednisolone 
                 Glucocorticoid 
                 Synergy 
                 Synergy 
                 Additivity 
                 Antagonism 
               
               
                   
                 receptor agonist 
               
               
                 Lenalidomide 
                 Immunomodulatory 
                 No effect 
                 Additivity 
                 No effect 
                 Additivity 
               
               
                   
                 drug 
               
               
                 Venetoclax 
                 Bcl-2 inhibitor 
                 Synergy 
                 Synergy 
                 No effect 
                 Synergy 
               
               
                 Tazemetostat 
                 EZH2 inhibitor 
                 No effect 
                 Additivity 
                 No effect 
                 Additivity 
               
               
                   
               
            
           
         
       
     
     Example 4 
     Combination Studies 
     Long Term KMS-11 Proliferation Assay: Cells in log-linear growth rate were treated with Cpd. No. 15 (at 500 nM) and combination partners Tazemetostat (at 100 nM) and/or Lenalidomide (at 1000 nM)) over a total period of 14 days. Concentrations used were bracketed around the IC 50  values on day 14 for each of these agents. On day 0, exponentially growing cells were dispensed, in six replicate wells, into three 96-well plates. Cell cultures were incubated in the presence of DMSO, single agents and double or triple combinations of the above mentioned agents agents. for four and seven days in a humidified atmosphere of 5% CO 2  at 37° C. These plates were developed on days 0, 4, 7 and quantification of the effect of single agents and combinations on cell viability was performed through measurement of cellular adenosine triphosphate (ATP) using CellTiter-Glo® (Promega, Madison, Wis.). Luminescence was detected using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, Calif.). Additionally, on day 0, cells in log-linear growth rate were also seeded into three 6 well plates and treated with DMSO, single agents and double or triple combinations with the respective agents. These 6 well plates incubated for seven days in a humidified atmosphere of 5% CO 2  at 37° C. On day 7, cells from each treatment were trysinized, counted, and split back to the original plating density into three 96 well plates, in six replicate wells, to be analyzed on days 7, 11, and 14. These re-plated cells were and subjected to the same treatment as in Day 0. These plates were then developed on days 7, 11, and 14 using CellTiter-Glo® (Promega, Madison, Wis.). Luminescence was detected using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, Calif.). Cell viability vs time plot (with cell number split corrected) was generated in GraphPad Prism version 8.0 for Windows, GraphPad Software(La Jolla, Calif.). Statistical analysis done using one-way ANOVA with Tukey&#39;s Multiple Comparisons (****p&lt;0.0001) for triple combination compared to each of the doublets. The results of the Long Term KMS-11 Proliferation Assay are presented in  FIG.  1    and  FIG.  2   . 
     Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the invention or any embodiment thereof. 
     Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims. 
     All patents, patent applications, e.g., PCT/US2019/046569, and publications cited herein are fully incorporated by reference herein in their entirety.